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SUMMARY 
 
Paraxonase-1 (PON1) is a hydrolase expressed mainly in liver and secreted into the 
blood, where it associates with high-density lipoprotein (HDL). Thanks to its anti-
oxidant and anti-inflammatory properties PON1 contributes to protective, anti-
atherogenic function of HDL. Decreased levels of serum PON1 activity have been 
found in several pathological conditions such as type 1 and type 2 diabetes, 
metabolic syndrome, coronary artery disease and age-related macular 
degeneration (AMD). The PON1 gene contains a number of functional single 
nucleotide polymorphisms (SNPs) in both the coding and upstream regulatory 
regions, which affect either the level or the substrate specificity of PON1. These 
SNPs have been found to be associated with several diseases.  
To expand the knowledge on effects of PON1 gene on AMD, we studied 
association of SNPs and haplotypes within the upstream regulatory region of PON1 
with neovascular AMD in the Swiss population. Four SNPs (rs705379, rs705381, 
rs854573, rs757158) and two haplotypes (TGGCCTC and CGATGCT) were 
significantly associated with the disease. Protective and risk haplotypes within the    
5’ untranslated region of PON1 differently affected luciferase reporter activity in 
vitro, suggesting that their regulatory function might play a role in AMD.  
Genetic and biochemical analyses indicate involvement of PON1 in the 
pathophysiology of AMD. However, the function of PON1 in the eye and how it 
might affect eye pathology had not been addressed up to now. In the present study 
we used Pon1–/– mice to investigate the role of PON1 in the retina and retinal 
pigment epithelium (RPE). We demonstrated that PON1 is not essential for normal 
development, function, defense against light damage and aging of the mouse retina. 
Reduced levels of lysophosphatidylcholines in eyes of Pon1–/– mice implicate a 
phospholipase A2 (PLA2)-like enzymatic activity of PON1 to be involved in the 
modulation of the phospholipid content of retina and RPE.  
Studies presented in this thesis together with previous reports on the role of 
PON1 in atherosclerosis suggest that PON1 may be involved in AMD as a 
modulatory protein. The interplay with additional genetic and environmental 
factors could influence its contribution to disease development and/or progression. 
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ZUSAMMENFASSUNG 
 
Paraoxonase-1 (PON1) ist eine vornehmlich von Leberzellen produzierte 
Hydrolase,  die sekretiert wird und mit HDL (Lipoprotein hoher Dichte) im Blut 
assoziiert. Dank seiner anti-oxidativen und anti-inflammatorischen Aktivität trägt 
PON1 zur protektiven Wirkung von HDL gegen Arteriosklerose bei. In mehreren 
Krankheiten, wie zum Beispiel Diabetes (Typ 1 und Typ 2), dem metabolischen 
Syndrom, der koronaren Herzkrankheit und der altersabhängigen Makula-
degeneration (AMD), wurde eine reduzierte Aktivität von PON1 im Serum von 
Patienten festgestellt. Sowohl in der kodierenden Sequenz als auch in den 5’ regula-
torischen Regionen des PON1 Gens entdeckte man eine Reihe von funktionellen 
Einzelnukleotid-Polymorphismen (SNPs), die entweder die Menge von PON1 oder 
dessen Substratspezifität beeinflussen. Es wurde gezeigt, dass diese SNPs mit 
verschiedenen Krankheiten assoziiert sind. 
Um die Verbindung von PON1 mit AMD besser zu verstehen, haben wir den 
Einfluss von SNPs und Haplotypen in der 5’ regulatorischen Region von PON1 auf 
die neovaskuläre Form von AMD in der Schweizer Bevölkerung untersucht. Wir 
konnten zeigen, dass vier SNPs (rs705379, rs705381, rs854573, rs757158) und 
zwei Haplotypen (TGGCCTC und CGATGCT) signifikant mit der Krankheit assoziiert 
sind. Protektions- und Risiko-Haplotypen beeinflussten die Luziferase Reporter-
aktivität in in vitro Versuchen unterschiedlich. Dies deutet darauf hin, dass diese 
regulatorischen Sequenzen eine Rolle bei der Pathogenese von AMD spielen 
könnten. 
Obwohl genetische und biochemische Analysen auf eine Rolle von PON1 in 
AMD hindeuten, wurde die physiologische Funktion von PON1 im Auge noch nicht 
erforscht. Auch ist bislang nicht bekannt, wie PON1 Augenpathologien beeinflussen 
könnte. Mit Hilfe von Pon1 knockout Mäusen haben wir deshalb die Rolle von PON1 
in der Netzhaut und im retinalen Pigmentepithel (RPE) untersucht. Wir konnten 
zeigen, dass PON1 weder für die normale Netzhautentwicklung, noch für die 
Netzhautfunktion, den Schutz gegen Lichtschäden oder das normale Altern 
essentiell ist. Jedoch deuten die reduzierten Mengen von Lysophosphatidylcholinen 
in den Augen von Pon1–/– Mäusen auf eine Phospholipase A2 (PLA2)-ähnliche 
Aktivität von PON1 hin. Diese könnte den Gehalt von Phospholipiden in der 
Netzhaut und dem RPE beeinflussen. 
Zusammen mit bereits publizierten Daten lassen die Resultate dieser 
Doktorarbeit vermuten, dass PON1 als modulatorisches Protein bei der 
Pathogenese von AMD eine Rolle spielt. Ausserdem könnte das Zusammenspiel von 
genetischen und umweltbedingten Faktoren die Wirkung von PON1 auf die 
Krankheitsentwicklung und/oder Progression zusätzlich beeinflussen.    
  
 
 5 
 
CONTENTS 
 
SUMMARY…………………………….…………………………………………………………………………… 1 
ZUSAMMENFASSUNG………………………………………………………………………………………… 3 
CONTENTS ……………………………………………………………………………………………………….. 5 
I. INTRODUCTION ............................................................................................................................ 7 
1.1 The role of retina and retinal pigment epithelium in vision ................... 7 
    1.1.1  Retina ................................................................................................................................... 8 
      1.1.1.1   Phototransduction and visual pathways.................................................................... 8 
      1.1.1.2   Human retinal topography .............................................................................................. 9 
    1.1.2  Retinal pigment epithelium (RPE) ......................................................................... 12 
      1.1.2.1   Function of RPE ................................................................................................................... 12 
      1.1.2.2   Retinoid metabolism ......................................................................................................... 14 
      1.1.2.3   RPE cell cultures ................................................................................................................. 16 
1.2 Molecular mechanisms of age-related macular degeneration ............. 18 
    1.2.1 Aging of RPE and Bruch’s membrane ................................................................... 19 
    1.2.2 Oxidative stress ............................................................................................................. 20 
    1.2.3 Central role of the immune response ................................................................... 21 
    1.2.4 Genetic susceptibility to AMD .................................................................................. 23 
    1.2.5 Animal models in AMD research ............................................................................ 24 
1.3  Paraoxonase-1 ....................................................................................................... 27 
         1.3.1   Paraoxonase family ...................................................................................................... 27 
    1.3.2 Regulation of PON1 gene expression .................................................................... 28 
    1.3.3 PON1 enzymatic activities......................................................................................... 29 
    1.3.4 Polymorphic forms of PON1 ..................................................................................... 30 
    1.3.5 Anti-oxidant and anti-inflammatory properties of PON1 ............................. 31 
    1.3.6 Implications for involvement of PON1 in AMD ................................................. 31 
II. SPECIFIC AIMS ............................................................................................................................ 33 
III.   RESULTS and DISCUSSION ..................................................................................................... 35 
3.1  The role of upstream regulatory SNPs of PON1 in AMD .......................... 35 
        3.1.2   PON1 5’UTR haplotypes regulate gene expression in Caco-2 cells ............ 49 
3.2 The contribution of SNPs and private mutations in PON1 gene to 
coronary artery disease (CAD) ........................................................................ 52 
 
CONTENTS 
6 
 
3.3 Function of PON1 in the mouse retina .......................................................... 58 
3.3.1   Lack of paraoxonase-1 alters phospholipid composition but not  
morphology and function of the mouse retina .............................................................. 58 
    3.3.2 Revealing the role of PON1 in RPE cell cultures in vitro ............................... 95 
IV.   CONCLUDING DISCUSSION ..................................................................................................105 
V. REFERENCES .............................................................................................................................109 
ABBREVIATIONS ..............................................................................................................................125 
CURRICULUM VITAE …..…………………………………………………………………………………… 129 
ACKNOWLEDGEMENTS ………………………………………………………………………………… 133 
 
 
 
 
 7 
 
I. INTRODUCTION 
 
 
1.1 The role of retina and retinal pigment epithelium in vision 
 
The visual system is the part of the nervous system allowing organisms to see, 
meaning to detect and interpret the information from visible light to build a 
representation of the surrounding environment. Visual perception involves not 
only the eye but also various brain structures. The eye is the primary sensory organ 
for vision, responsible for collecting the light, focusing it and generating first neural 
signals of the visual pathway. Light must pass through the transparent media and 
structures of the eye: the tear film, the cornea, the anterior chamber, the lens, and 
the posterior chamber-vitreous, to be finally projected upside-down and 
backwards on to the retina (Prasad and Galetta, 2011) (Fig. 1). In the retina the 
light is converted by photoreceptors into an electrochemical signal that is further 
relayed by neurons to the cerebral cortex of the brain. The cortex combines 
received signals. Ultimately, these initial pieces of information are being integrated 
and serve to define the borders of objects and create an image (Masland and 
Martin, 2007). 
 
 
 
Figure 1. Sagittal section of the adult human eye. 
Adapted from http://smsm2a2012.weebly.com/reading-site.html 
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1.1.1  Retina 
The neurosensory retina consists of three major cell layers through which the 
signal in response to light is transduced vertically: photoreceptors connected to 
bipolar cells, further interacting with the ganglion cells. Additionally, horizontal 
and amacrine cells form lateral connections at the photoreceptor-bipolar cell 
synapses, and at the bipolar cell-ganglion cell synapses respectively (Fig. 2). 
 
1.1.1.1 Phototransduction and visual pathways 
Photon absorption and its conversion into an electrochemical signal (phototrans-
duction) take place in the photoreceptor outer segments (POS). The POS are built of 
hundreds of membranous discs stacks. These membranous structures are rich in 
proteins involved in the phototransduction, most importantly the photopigment 
 
Figure 2. Human retinal architecture. 
Left panel: schematic diagram of the retina with an emphasis on the sensory photo-
receptors (rods and cones), the ganglion cells and the interneurons (horizontal, bipolar and 
amacrine cells) connecting photoreceptors with ganglion cells. Right panel: light micro-
photograph of a vertical section through the central human retina. Three layers of nerve 
cell bodies: outer nuclear layer (ONL) containing cell bodies of rods and cones, inner 
nuclear layer (INL) containing cell bodies of the bipolar, horizontal and amacrine cells, and 
the ganglion cell layer (GCL) are separated by the outer and the inner plexiform layers 
(OPL and INL), where synaptic contacts occur. PIS, photoreceptor inner segments; POS 
photoreceptor outer segments; RPE, retinal pigment epithelium. 
Adapted from http://webvision.med.utah.edu/book/part-i-foundations/simple-anatomy-
of-the-retina/ 
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composed of a membrane protein, opsin, and a chromophore molecule, the 11-cis-
retinal. Absorption of the photon by the chromophore causes its conformation 
change from 11-cis-retinal to all-trans-retinal, and subsequent release from the 
protein moiety. The unbound opsin stimulates another membrane complex, 
transducin, by replacing guanosine diphosphate (GDP) with guanosine 
triphosphate (GTP). Active -transducin-GTP interacts with phosphodiesterase 
(PDE), leading to hydrolysis of the cytosolic second messenger, cyclic guanosine 
monophosphate (cGMP) (Palczewski, 2012). A lowered cGMP level causes closing 
of membrane sodium channels, decreases the inward sodium current, and results 
in the membrane hyperpolarization, followed by the reduction in neurotransmitter 
(glutamate) release from the photoreceptor into the synapse. Glutamate is a 
signalling molecule recognized by bipolar cells. Various bipolar cells have different 
types of the glutamate receptors needed for tuning the response to photoreceptor 
input. The so-called ON bipolar cells, triggering the ON pathway, possess inhibitory 
glutamate receptors, preventing the cells from firing when exposed to the 
neurotransmitter (response to the darkness). In light, when there is glutamate 
shortage in the photoreceptor-bipolar cell synapses, the ON bipolar cells are no 
longer inhibited but instead release glutamate at their synapses in the inner 
plexiform layer, and thus stimulate the ON ganglion cells. This pathway enables 
detecting light images against a dark background. Another type of bipolar cells, the 
OFF bipolar cells, have excitatory glutamate receptors, activating the OFF ganglion 
cells upon the glutamate binding. The OFF pathway is functioning in darkness, and 
is shut down by the light, making visible the dark areas on light background. The 
electrochemical signals received by the ganglion cells travel within the axons in the 
nerve fiber layer (the innermost retinal layer) to the optic nerve, and further to the 
primary visual cortex of the brain (Kolb, 2003). 
 
1.1.1.2 Human retinal topography 
Humans, like other primates, possess a so-called duplex retina, consisting of two 
main photoreceptor classes: cones and rods (Fig. 3). The general mechanism of 
phototransduction described in the previous section applies to both types of 
photoreceptors, because both use photopigments composed of the 11-cis-retinal 
chromophore and an opsin protein. Nevertheless, distinct structural and biochemi-
cal characteristics of the protein moiety, as well as the specific anatomical and 
physiological features of the cones and rods determine their specialized tasks 
(Kolb, 2003). Despite the much higher proportion of rods in the adult human retina 
(4.6 million cones versus 92 million rods) (Curcio et al., 1990), under most 
conditions our vision is mediated by cones, which operate over an enormous range 
INTRODUCTION 
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of intensities and wavelengths. There are three kinds of cones in humans, each 
containing a different type of opsin enabling optimal response to particular wave-
lengths of light: S-cones (short-wavelength, absorb blue light), M-cones (middle-
wavelength, absorb green light), and L-cones (long-wavelength, absorb red light). 
In contrast, rod photoreceptors possess only one type of the photopigment 
(rhodopsin, absorbs green-blue light), hence they cannot discriminate colors. More 
importantly, they have a sensitivity that is over a thousand times higher than the 
one in cones and therefore can perform well in dim light (scotopic vision). 
 
Figure 3. Photoreceptors: rods and cones. 
(A) Schematic representation of the anatomy of rod (left) and cone (right) photoreceptor 
cells. (B) Human photoreceptor absorption spectra. Maximum absorption for each photo-
receptor type was set to 100%. S, S-cones; M, M-cones; L, L-cones.  
A: Adapted from http://www.studyblue.com/notes/note/n/lecture-5/deck/5665773 
B: Adapted from http://askabiologist.asu.edu/rods-and-cones 
 
The distribution of cones and rods within the human retina is highly skewed 
(Fig. 4A). While rods dominate in the peripheral retina in a 20:1 ratio, the central 
retinal region called fovea is a rod-free zone characterized by a high density of 
cones, nearly 15-fold higher than in the periphery (Curcio et al., 1990). The fovea 
lies at the center of macula, an area located temporal to the optic nerve, appearing 
on the fundus image as an oval-shaped highly pigmented yellow spot, histologically 
distinguished by having more than one layer of ganglion cell nuclei (Fig. 4B). 
Anatomical differences between the peripheral and the foveal region of the retina 
concern not only the photoreceptor layer. In contrast to the retinal periphery, 
delete 
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Figure 4. Characterization of the human fovea. 
(A) Distribution of rods and cones in the human retina. Cones are concentrated in the 
fovea, which is free of rods. (B) Histology of the human retina in the foveal region. CH, 
choroid; RPE, retinal pigment epithelium; PIS, photoreceptor inner segments; POS, 
photoreceptor outer segments; ONL, outer nuclear layer; OPL, outer plexiform layer; INL, 
inner nuclear layer; GCL, ganglion cell layer. 
A: Adapted from http://hyperphysics.phy-astr.gsu.edu/hbase/vision/rodcone.html 
B: Adapted from http://webvision.med.utah.edu/book/part-xii-cell-biology-of-retinal-
degenerations/age-related-macular-degeneration-amd/ 
INTRODUCTION 
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where a bipolar cell summates the inputs from multiple photoreceptor cells, in the 
fovea each bipolar cell receives input from a single cone (Prasad and Galetta, 2011).  
Additionally, the fovea shows high concentration of so-called midget ganglion cells, 
having spectrally-opponent small receptive field, specialized for high spatial acuity, 
color vision, and fine stereopsis. The peripheral retina, on the contrary, has equal 
contribution of the midget and parasol ganglion cells. The parasol ganglion cells 
have a larger receptive field, spatially opponent concentric organization allowing 
edge detection, but they lack spectrally opponent organization, therefore are color-
insensitive. In summary, the fovea is specialized for high visual acuity, color vision 
and depth perception, whereas the periphery of the retina accounts for low spatial 
resolution, motion detection and crude stereopsis (Prasad and Galetta, 2011).  
 
1.1.2  Retinal pigment epithelium (RPE) 
Retinal pigment epithelium (RPE) is the outermost retinal layer. Unlike the 
neuroretina described in the previous sections, RPE is composed of epithelial cells, 
not of neurons. RPE is not directly involved in the phototransduction, but it is vital 
to support the architecture and function of the adjacent photoreceptor nerve cells, 
therefore it is essential for vision. In the next section diverse features and tasks of 
RPE will be presented. Renewal of the chromophore 11-cis-retinal, one of the 
fundamental functions of RPE, will be discussed in a separate section (1.1.2.2, 
“Retinoid metabolism”).  
 
1.1.2.1 Function of RPE 
The RPE is a single layer of cuboidal, polygonal, post-mitotic differentiated 
epithelial cells, densely packed with pigmented granules (melanosomes). Thanks to 
its pigmentation, RPE acts as a neutral density filter that absorbs any intraocular 
light passing through the photoreceptor layer. This reduces backscatter of light and 
therefore maintains high-fidelity acuity (Boulton and Dayhaw-Barker, 2001). The 
RPE monolayer forms the outer blood-retinal barrier (BRB), which separates the 
neuroretina from the choroid, and controls the passage of molecules and cells into 
and from the retina. To fulfil this role the RPE cells are joined by several junctional 
complexes: tight, adherens and gap junctions, which interact together to regulate 
the apical-basal polarity and transepithelial transport, as well as the cell size, shape 
and proliferation (Rizzolo et al., 2011). The RPE polarity concerns both its anatomy 
(structure) and physiology (function). The apical RPE surface is facing the 
photoreceptor cells. It contains two types of microvilli: long, thin microvilli (5-7m) 
that increase the surface available for transepithelial transport; and specialized 
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shorter microvilli that form photoreceptor sheaths responsible for phagocytosis of 
the photoreceptor outer segments (Fig. 5). The basolateral surface of the RPE is 
directed toward the choriocapillaris (CC) and stays in contact with an extracellular 
matrix called Bruch’s membrane (BrM). This side of the RPE contains numerous 
invaginations which, similarly to their apical counterparts, maximise the surface for 
the exchange of metabolites and ions (Boulton and Dayhaw-Barker, 2001). The 
architectural RPE polarity is accompanied by the asymmetric distribution of the 
channels and transporters throughout the apical and basal membrane. As a result, 
RPE can control the pH and ion concentrations in the subretinal space (matrix 
between the POS and RPE), thus sustain the photoreceptor excitability. 
Additionally, the RPE polarity allows directed transport of nutrients from the 
choriocapillaris to the retina and of the metabolic end-products in the opposite 
direction (Strauss, 2005).  
 
Figure 5. Ultrastructure of the RPE. 
Electron micrograph of the retinal pigment epithelium in contact with the photoreceptor 
cells. RPE microvilli extending from the apical surface participate in transepithelial 
transport and phagocytosis of the photoreceptor outer segments. Phagosomes and 
elongated melanin granules are localized apically. Presence of tight junctions (black arrow) 
establishes polarity of RPE cells. 
Adopted from http://www.oculist.net/downaton502/prof/ebook/duanes/pages/v7/v7c021.html 
The above mentioned POS phagocytosis by the RPE is critical for photo-
receptor survival. Both, rods and cones are extensively exposed to light and to high 
oxygen levels. Their outer segments are particularly susceptible to oxidative 
damage, as they contain highly reactive retinoids and polyunsaturated fatty acids. 
Importantly, the rods and cones as terminally differentiated post-mitotic cells, do 
INTRODUCTION 
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not divide. Therefore, they have developed a unique mechanism of renewing POS 
by shedding outer segments tips, further phagocytosed by the RPE. The 
phagocytosed material is being processed by a combination of over 40 lysosomal 
enzymes. The end-products of degradation are either recycled back to the photo-
receptors or removed from the retina via the choroidal capillaries. In mammals it 
takes around 10 days for the rod outer segments to be fully recycled (Boulton and 
Dayhaw-Barker, 2001).  
The posterior part of the eye displays an immune-privileged characteristic, 
primarily attributed to the RPE. The RPE dampens an immune response in the 
subretinal space by limiting lymphatic drainage into the retina (as a BRB). Further-
more, the RPE secretes various soluble immunosuppressive factors (transforming 
growth factor-, somatostatin, thrombospondin, pigment epithelial derived factor 
(PEDF), prostaglandin E2), and expresses cell membrane bound, anti-inflammatory 
molecules, such as FasL (CD95L) (Zamiri et al., 2007). The unique immunological 
properties of the RPE and the subretinal space have only recently been appreciated, 
but are gaining more interest in the context of therapeutic retinal transplantations 
and the indicated immunologic etiology of some forms of age-related macular 
degeneration (AMD). 
 
1.1.2.2 Retinoid metabolism 
The key molecule of phototransduction, the chromophore 11-cis-retinal, originates 
from its precursors vitamin A (all-trans-retinol, ROL) and provitamin A (,-
carotene), which cannot be synthesised by animals, but must be delivered through 
the diet. Dietary carotenoids are absorbed in the intestine, metabolized to retinyl 
esters (REs), packed into chylomicrons (lipoprotein particles), and in this form 
secreted into the lymph. Most of these circulating REs (~70%) are cleared and 
stored by the liver. Hepatocytes can secret retinoids into the blood as a complex 
with serum retinol-binding protein (RBP). The ROL-RBP is taken up by the RPE 
cells via the retinoid transporter STRA6, ROL is estrified to the REs, and further 
converted to the chromophore to maintain the vision. Additionally, the all-trans-
retinal (RAL) released from the opsin after the photon absorption needs to be 
recycled back to the 11-cis-retinal (von Lintig, 2012). The chain of metabolic 
changes to which retinoids are cyclically subjected in order to regenerate the 
chromophore is known as the retinoid cycle or the visual cycle. This process takes 
place in two cellular systems, photoreceptors and the RPE, and involves sets of 
enzymes depicted and described in figure 6. Recent studies provide evidence for an 
alternative cone-specific visual cycle that occurs in Müller cells (von Lintig, 2012). 
bbb 
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Fig.6. Visual cycle. 
Phototransduction starts in the disc membranes of rod outer segments (ROS). Absorption 
of a photon of light by rhodopsin causes photoisomerization of 11-cis-retinal to all-trans-
retinal (RAL) and its eventual release from the opsin into the disc lumen. ABCA4 (ATP-
binding cassette transporter) transfers RAL to the cytosol, where it is reduced to all-
trans-retinol (ROL) in a reaction catalyzed by retinol dehydrogenases (RDHs). ROL is 
then translocated to the RPE with the involvement of two retinoid-binding proteins: 
interphotoreceptor retinoid binding protein (IRBP), which binds retinoids in the extra-
cellular space, and cellular retinol binding protein (CRBP), located within RPE cells. 
Inside the RPE the ROL is estrified to all-trans-retinyl esters (REs) by the lecithin:retinol 
acyltransferase, LRAT, which is crucial both for the clearance of ROL from ROS and for 
the uptake of ROL from the blood. In the next step, all-trans-REs undergo reaction of 
isomerization catalyzed by the RPE65 (retinal pigment epithelium 65kDa) protein. The 
product of this reaction, 11-cis-retinol, enters the final step of the visual cycle, in which it 
is oxidized to 11-cis-retinal, bound by cellular retinaldehyde binding protein (CRALBP) 
and further transported back to the ROS to be built into the photopigment molecules. In 
red boxes are depicted diverse retinopathies related to the defects in individual enzymes 
of the retinoid cycle: Stargardt disease, age-related macular degeneration (AMD), Leber 
congenital amaurosis (LCA), retinitis pigmentosa (RP), and fundus albipuncatus. 
Adapted from Kiser et al., 2012.  
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Disrupting any of the enzymatic steps of chromophore regeneration severely 
affects visual performance and eventually leads to various forms of retinal 
degeneration (Kiser et al., 2012). Independently of those pathologies, under normal 
physiological conditions RAL present at high concentrations in the POS can form 
adducts with primary amino groups of cellular lipids, proteins, and ribonucleotides. 
An example of such by-product of the retinoid cycle is bisretinoid A2E, arisen from 
the reaction of two RAL molecules with the membrane lipid phosphatidylethanol-
amine. Ocular accumulation of A2E as a component of lipofuscin has been 
implicated in the pathology of AMD (Sparrow and Boulton, 2005; Sparrow et al., 
2000; Zhou et al., 2006). 
 
1.1.2.3 RPE cell cultures 
In vitro cell culture is a powerful tool for studying biology and biochemistry of RPE 
monolayer that offers several advantages over the in vivo situation: examining pure 
RPE devoid of other retinal cells, finer control of the physical and chemical 
environment in which cells are cultivated, accessibility for administration of 
exogenous compounds, expansion of experimental material by proliferation and 
subculture. To be a useful in vitro experimental system, cultured RPE cells on the 
one hand have to proliferate, and on the other hand have to resemble their in vivo 
counterpart. Both these requirements can be achieved by applying specially 
formulated culturing media. It was observed that epithelial cells tend to lose some 
differentiated functions under conditions encouraging proliferations, therefore 
numerous groups reported usage of two distinct medium formulations in order to 
either stimulate proliferation or the differentiated state of RPE cells in vitro, where 
reduction of serum and calcium concentration synergistically increased 
proliferation rate (Hu, 2000; Pfeffer, 1991). 
The fact that RPE cells lose their specialized properties after multiple 
passages promotes utilization of primary cultures in RPE research. Primary RPE 
cultures from various species have been shown to retain many normal 
physiological functions, including the ability to transport retinoids (Pfeffer et al., 
1986), and phagocytosis of rod outer segments (Bosch et al., 1993). Despite their 
undeniable advantages, primary cultures may exhibit physiological differences 
caused by variability between the donor tissues and introduced during the isolation 
procedure. Therefore, each individual cell line needs to be continually monitored 
for the desired physiological, morphological and molecular features to verify its 
usefulness and to ensure controlled, reproducible experimental conditions (Pfeffer, 
1991). The proper evaluation of primary RPE cultures includes examination of RPE 
cell morphology: polygonal shape, pigmentation, presence of apical microvilli and 
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junctional complexes. Additionally, it is important to test for the secretion of the 
components of cellular matrix, like collagen (types I, III, IV, V), laminin, fibronectin, 
and heparin sulphate proteoglycan, which are produced by all epithelia. 
Immunofluorescence can also serve to detect sub-apical actin ring, characterizing 
differentiated epithelia, or apical distribution of Na+, K+-ATPase, distinguishing RPE 
among other epithelia. To truly mimic the native tissue, in vitro RPE cultures should 
express enzymes metabolising visual chromophore, as RPE65, CRALBP, and RDH5 
(Pfeffer, 1991). 
Limited proliferation, substantial heterogeneity and related necessity for 
laborious, thorough characterization of primary RPE cultures caused the need for 
establishing RPE cell lines. ARPE19 is a commercially available, in research most 
widely used human RPE cell line, which arose spontaneously under selective 
trypsinization of a primary RPE culture derived from a 19-years old male donor 
(Dunn et al., 1996). When cultured to post-confluent densities, ARPE19 cells 
developed morphology and biochemical features of differentiated RPE, such as 
expression of CRALBP and RPE65 mRNA (Dunn et al., 1996), therefore they might 
be a useful tool to study retinoid metabolism or the regulation of RPE-specific gene 
expression. Importantly, original ARPE19 cultures displayed pronounced 
heterogeneity in any RPE-specific property that has been tested, which was 
reflected in a low transepithelial resistance. This feature may limit application of 
ARPE19 cell line in more complex studies, such as polarized secretion of proteins. 
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1.2 Molecular mechanisms of age-related macular degeneration 
Age-related macular degeneration (AMD) is a progressive complex disease that 
affects the central retina (macula) in people at age of 50 years and more (Jager et 
al., 2008). It is the most common cause of blindness and visual disability among the 
elderly in the developed countries. The clinical hallmark of AMD is accumulation of 
focal, acellular deposits that form at the interface between the RPE and BrM, called 
drusen. Advanced AMD occurs in two forms: geographic atrophy, GA (non-
neovascular, dry, non-exudative), and choroidal neovascularization, CNV (neovas-
cular, wet, exudative) (Fig. 7). GA is a clinical manifestation of progressive RPE cell 
death. Patients with GA develop gradual central vision loss, usually over the course 
of months to years. CNV is characterized by the growth of abnormal blood vessels 
from the choroid through BrM and the RPE. This process is accompanied by 
increased vascular permeability and fragility. Its extension may lead to subretinal 
haemorrhage, exudative retinal detachment, or scar formation, and can result in 
sudden, profound vision loss. CNV that accounts for only 10% of all AMD cases is 
responsible for approximately 75% of severe central vision loss in AMD (Klein et 
al., 1997).  
 
Age is the major risk factor for AMD. Because the population of the 
industrialized world is rapidly aging, the overall prevalence of advanced AMD is 
projected to increase more than 50% by the year 2020 (Friedman, 2004). The 
magnitude of this problem has driven enormous amount of studies to elucidate the 
 
Figure 7. Fundus images. 
Fundus photography presents an image of the interior surface of the eye, including the 
retina, optic disc, macula, and the retinal periphery. It is used in ophthalmology for 
diagnosis of a disease (combined with retinal angiography), and for monitoring the 
progression of a disease. (A) A fundus image of the normal retina. Macula is visible in the 
center of the retina as a highly pigmented spot (arrow). (B) A fundus image of the retina 
with geographic atrophy (arrowheads). Black arrowheads indicate drusen. (C) A fundus 
image of the retina with neovascular AMD shows subretinal haemorrhage (arrow), 
choroidal neovascularization (white arrowheads), and numerous drusen (black arrow-
heads). Adopted from http://www.thelondonproject.org/OurVision/TheDisease/?id=74 
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molecular mechanisms of the disease that would eventually provide prevention 
and therapy. How do “normal aging” processes contribute to the pathology? Which 
genetic, molecular and/or environmental factors shift the balance toward 
developing AMD? How to use this information for the early diagnosis? How to 
target the early-onset molecular changes to prevent AMD? Which factors accelerate 
progression of the disease and how to counteract them? These are the main 
questions that over 13’000 published studies have tried to solve to date, and the 
research effort is continuously growing (Fig. 8). 
 
1.2.1 Aging of RPE and Bruch’s membrane 
Aging is a naturally occurring process accompanied by substantial anatomical and 
physiological changes in the organism. It may take place without direct clinical 
consequences. It is clear however, that age-related, non-pathogenic changes may 
compromise the overall fitness of the cells and tissues, predisposing them to a 
pathogenic state. In the eye, progression of aging may be slow enough so that no 
loss of function is experienced. Nevertheless, senescence of the RPE and BrM are 
known to underlie the development and progression of AMD. Human RPE cells, 
which are a post-mitotic, non-regenerating system, undergo structural changes 
with increasing age that result in loss of cell shape, multilayered organization, and 
atrophy, hyper- and hypopigmentation (Curcio et al., 2000). Additionally, due to the 
 
Figure 8. Number of publications on AMD available in PubMed database. 
Graph was generated based on the PubMed search (http://www.ncbi.nlm.nih.gov/ 
pubmed) using a query: (((amd[Title/Abstract]) OR age-related macular degenera-
tion[Title/Abstract]) OR geographic atrophy[Title/Abstract]) OR choroidal neovasculari-
zation[Title/Abstract].  13586 hits were found, February 2014. 
INTRODUCTION 
20 
 
increasing metabolic insufficiency they accumulate non-degraded material 
originating from phagocytosed POS in form of lipid/protein aggregates (lipofuscin 
granules) (Wing et al., 1978). The indigestible molecules can be exported 
basolaterally, where they accumulate in BrM or diffuse to the bloodstream 
(Kinnunen et al., 2012). Otherwise, compromised lysosomal, proteasomal, and 
autophagosomal clearance may cause increased RPE cell damage eventually 
leading to cell death (Sparrow and Boulton, 2005). A2E has been long considered to 
be the main bisretinoid component of the RPE lipofuscin responsible for induction 
of the RPE apoptosis, and thus contributing to the development of AMD (Sparrow et 
al., 2000; Sparrow et al., 2003). Interestingly, the recent study by Ablonczy and 
colleagues (Ablonczy et al., 2013) that demonstrated lack of correlation between 
the A2E and lipofuscin distribution in the human RPE, with predominantly 
peripheral accumulation of A2E, has challenged the pre-existing dogma and 
revealed the need to revise the role of bisretinoid A2E in human retinal 
degeneration. 
BrM, just as RPE, undergoes significant changes throughout human life. Most 
prominently, BrM thickness increases in a linear manner with age, being in the 
eighth decade of life more than twice as thick as in the first decade (Ramrattan et 
al., 1994). BrM thickening involves structural changes: elevated accumulation of 
lipids and advanced glycation end products (AGEs), collagen cross-linking, larger 
proteoglycans size, increased calcification, iron and zinc deposition. These age-
related features of BrM impair protein turnover, decrease BrM elasticity, induce 
formation of a lipid wall, and as a result compromise fluid and macromolecule 
exchange between the choroid and RPE. Structurally and functionally altered BrM 
does not provide sufficient metabolic support for the RPE and promotes drusen 
formation, a feature of AMD (Booij et al., 2010). 
 
1.2.2 Oxidative stress 
Cumulative oxidative damage contributes to aging (Adelman et al., 1988). The 
retina, on the other hand, through its daily exposure to visible light, high oxygen 
consumption, and enrichment in docosahexaenoate, the most oxidizable 
polyunsaturated fatty acid (PUFA) in humans, offers a high oxidative stress 
environment (Fliesler and Anderson, 1983). It is not surprising therefore, that 
oxidative stress has been long suspected to play a role in the pathogenesis of AMD 
(Beatty et al., 2000). Convincing evidence in favour of this hypothesis came from 
epidemiological studies showing that smoking significantly increases the risk of 
AMD, whereas carotenoids and antioxidant vitamins may retard progression of the 
disease (Snodderly, 1995). By now numerous studies have explored the 
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mechanism, how oxidative modifications of diverse classes of molecules can act 
detrimentally to the POS, RPE and BrM. In particular, bisretinoid A2E has been 
shown to carry out its cytotoxic action via blue light and oxygen mediated 
mechanism (Sparrow et al., 2000; Sparrow et al., 2003). Already mentioned PUFAs, 
representing 50% of the lipids in POS membranes, can easily generate lipid 
peroxides that have the potential to oxidize, thus damage further molecules. 
Docosahexaenoate-derived oxidative modifications of proteins (i.e., CEP-protein 
adducts) have been found at higher concentrations in AMD drusen compared to 
drusen derived from healthy aged individuals, which implicates their involvement 
in the “pathological aging” (Crabb et al., 2002). Similarly, AMD drusen contain 
protein modifications generated from lipoxidation and glyoxidation (AGEs). By 
cross-linking common drusen proteins (TIMP3 and vitronectin) and structural 
proteins in BrM, AGEs prevent normal protein turnover, accelerate drusen 
formation and promote progression of AMD (Crabb et al., 2002; Glenn et al., 2009; 
Handa et al., 1999; Yamada et al., 2006). 
 
1.2.3 Central role of the immune response 
In the late 1990-ties and at the beginning of the XXI century a number of immuno-
histochemical studies has consistently identified various plasma proteins in drusen, 
including acute phase reactants: amyloid P component, complement C5,   1-anti-
trypsin, and proteins mediating immune response, such as vitronectin, activated 
complement components (Fig. 9) and apolipoprotein E (Mullins et al., 2000). These 
findings together with the fact that immune and inflammatory response appeared 
to play a role in formation of other pathologic, age-related deposits, led to a concept 
that similar mechanism may be involved in the development and/or regression of 
drusen (Johnson et al., 2000). Nevertheless, at that stage of research on AMD and 
understanding its pathogenesis, there was no general consensus regarding the 
origin of drusen, and the importance of the immune pathways in drusen formation. 
The last 15 years of research have been constantly delivering strong evidence 
positioning immunological responses in the center of the AMD etiology. A strong 
line of evidence in favour of this hypothesis came from genetic analyses revealing 
that sequence variants in complement-related genes have large contribution to the 
AMD heritability (Klein et al., 2005) (more detailed information in section 1.2.4, 
“Genetic susceptibility to AMD”). Additionally, in a recent study at the systems-level 
involving comparative transcriptome profiling combined with interactome 
analysis, Newman and colleagues showed that cell-mediated immune response is a 
common feature of all examined AMD phenotypes, whereas apoptosis and 
angiogenesis related genes are overrepresented in GA and CNV, respectively 
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(Newman et al., 2012). Similarly, a comparative quantitative proteomics analysis of 
AMD and control BrM/choroid samples revealed elevated levels of complement 
proteins, various damage-associated molecular patterns (DAMPs), and other 
immune system stimulators at all stages of AMD, again demonstrating a central role 
of the immunity (Yuan et al., 2010). Latest findings have established pattern 
recognition receptors (PRRs), which are part of the innate immune response, as key 
sensors recognizing various DAMPs and controlling further molecular pathways, 
including vascular growth and RPE cell survival. Specifically, activation of NLRP3 
inflammasome by CEP-protein adducts and C1Q drusen component was shown to 
be protective against CNV, whereas priming of this PRR by Alu RNA was 
demonstrated to induce RPE cell degeneration, and thus to contribute to the 
pathogenesis of GA (Doyle et al., 2012; Tarallo et al., 2012). Toll-like receptors 
(TLRs) are other “immune-hubs” known to control both angiogenesis and develop-
ment of geographic atrophy in response to oxidative stress or siRNA (Kleinman et 
al., 2008; West et al., 2010; Yang et al., 2008).  
Taken together, a model is supported where aging, environmental and 
genetic factors accelerate the onset and progression of cell-based immunological 
events, leading to chronic local inflammation and promoting atrophic and/or 
neovascular changes characteristic of advanced AMD. Furthermore, these findings 
suggest key components of the immune system to be promising targets for 
therapeutic intervention at all stages of the disease.   
 
Figure 9. Drusen. 
Left panel: Histology of a human retina with a druse localized between the retinal 
pigment epithelium (RPE) and the Bruch’s membrane. Right panel: Drusen from a human 
donor eye with AMD immunofluorescently labelled with an antibody directed against 
terminal complement complex C5b-9 (green fluorescence) illustrate involvement of 
immune-mediated processes in AMD. Nuclei are stained with DAPI visible in blue. INL, 
inner nuclear layer; ONL, outer nuclear layer; PIS, photoreceptor inner segments; POS 
photoreceptor outer segments; CC, choriocapillaris; CH, choroid.  
Adapted from http://webeye.ophth.uiowa.edu/mullinslab/ 
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1.2.4 Genetic susceptibility to AMD 
It is now beyond the question that genes play a significant etiological role in AMD. 
Some of the early suggestions of genetic predisposition originated from familial 
aggregation studies. For example, a high concordance of clinical features was 
observed in monozygotic twins (Hammond et al., 2002). Additionally, first-degree 
relatives of affected probands displayed higher incidence of AMD in comparison to 
controls, with siblings of affected individuals having a three to six-fold increase in 
disease risk (Klaver et al., 1998; Seddon et al., 1997). These initial indications 
established the need for further characterization of the genetic component of AMD. 
To date various classical genetic analyses and novel state-of-the art genotyping and 
sequencing techniques were utilized for this purpose. In particular, genome-wide 
linkage analysis of large families led to the discovery of the major AMD-
susceptibility loci on chromosome 1 (1q31) and on chromosome 10 (10q26), which 
was replicated in several independent studies, and further validated through a 
meta-analysis of whole genome scans (Abecasis et al., 2004; Barral et al., 2006; 
Fisher et al., 2005; Iyengar et al., 2004; Klein et al., 1998; Majewski et al., 2003; 
Seddon et al., 2003; Weeks et al., 2004). Testing of these two AMD-susceptibility 
loci in a single nucleotide polymorphism (SNP)-association studies on case-control 
populations identified specific genetic variants associated with AMD, among them 
the p.Tyr402His polymorphism in the complement factor H (CFH) gene (Edwards 
et al., 2005). Subsequent analysis of the complement pathway identified SNPs 
conferring risk/protection for AMD in other complement genes: complement factor 
C2, CFB, C3, and CFI, supporting a critical role for complement regulation in the 
pathology of AMD (Fagerness et al., 2009; Gold et al., 2006; Maller et al., 2007; 
Spencer et al., 2007; Yates et al., 2007). While the pathogenicity of variants in the 
complement genes has been well characterized, the functional pathway involving 
the 10q26 locus has not yet been understood (Swaroop et al., 2007).  
Advances in genotyping technology enabled high-throughput genome-wide 
association scans (GWAS) for AMD on large cohorts, aiming to explain the 
unrevealed heritability of AMD. In 2010 two large consortia of researchers 
conducted two independent GWASs with subsequent replication of risk factor 
findings. These studies identified several new genes associated with advanced AMD 
such as LIPC (hepatic lipase), CEPT (cholesterylester transfer protein), LPL 
(lipoprotein lipase), and ABCA1 (ATP-binding cassette, sub-family A, member 1). 
Interestingly, these genes encode proteins involved in high-density lipoprotein 
(HDL) and cholesterol metabolism, pathways that were previously indicated in 
drusenogenesis (Chen et al., 2010; Curcio et al., 2005; Li et al., 2005; Neale et al., 
2010). 
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For complete benefit from the genetic studies, discovery of direct casual 
mechanisms for particular genes and their protein products are essential. Recently, 
a couple of studies have beautifully explained the molecular consequence of single 
nucleotide variants, previously shown to be associated with risk to develop AMD. 
Weissman and colleagues demonstrated that malondialdehyde (MDA), a common 
lipid peroxidation product present at elevated concentrations in plasma of AMD 
patients, directly interacts with CFH (Baskol et al., 2006; Weismann et al., 2011). 
Moreover, the CFH p.His402 variant conferring high risk of AMD markedly reduces 
ability of CFH to bind MDA, which shifts the active-inactive complement balance 
toward the active state and promotes chronic inflammation. Another study 
provided insights into the pathogenicity of the highly penetrant risk variant 
p.Gly119Arg in CFI, a complement factor which similarly to CFH can inactivate the 
alternative pathway of the complement system (van de Ven et al., 2013). The 
Gly119Arg substitution resulted in a lower factor I proteolytic activity, and led to 
defects in the morphology of hyaloids vessels in the developing retina of zebrafish. 
A further recent finding showed that the rare allele in complement component C3 
posing risk of AMD that encodes p.Lys155Gln amino acid exchange results in 
resistance to proteolytic inactivation by CFH and CFI (Seddon et al., 2013). All risk 
alleles in the complement system investigated to date share common molecular 
mechanism, namely they lead to an excessive alternative pathway activation, which 
may eventually cause RPE cell death. 
 
1.2.5 Animal models in AMD research 
Expanded understanding of the mechanisms of human disease leading to the 
formulation of efficient and safe therapeutic strategies would not be feasible 
without employing appropriate animal models. The animal models are particularly 
useful due to their relatively unlimited supply, ease of manipulation, and closely 
controlled experimental conditions. A perfect model organism should display high 
similarity to humans in terms of genetics, anatomy, and physiology. Considering 
AMD, one could propose the primates as a preferable model organism, because they 
are the only mammals possessing a macula. Despite this obvious anatomical 
prerequisite, other factors like the slow course of disease, limited supply of 
animals, economic constrains, and ethical challenges in generating genetically 
modified monkeys restrict their utilization in AMD research (Ramkumar et al., 
2010). 
Since 1924 when the first inherited retinal degeneration has been identified 
in mice, these rodents have become the main model organism to study retinal 
degeneration, and helped to discover genes causing retinal dystrophies in humans 
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(Hafezi et al., 2000; Keeler, 1924). The mouse retina closely resembles that of the 
human nasal and peripheral retina, thus is well suitable to model defects in these 
parts of the retina. AMD, however is a disease affecting the macula, a functional 
area that is not distinguishable in mouse. As nocturnal animals, mice have rod-
dominated retinas with rods comprising 97% of photoreceptor cells and 3% of 
cones spread through the retina (Carter-Dawson and LaVail, 1979). Furthermore, 
murine Burch’s membrane structure, its age-related changes, and RPE lipofuscin 
metabolism differ from the one present in humans (Mishima and Hasebe, 1978). 
Despite those differences in the retinal anatomy and physiology, there are 
numerous mouse models showing partial features of AMD like drusenoid lesions, 
sub-RPE basal deposits, Bruch’s membrane thickening, A2E accumulation, RPE 
atrophy, choroidal neovascularization, and electroretinogram (ERG) abnormalities 
(Ramkumar et al., 2010). Most murine models for dry AMD are genetically 
engineered mice with modified genes that either are causative for the juvenile 
macular dystrophies in humans or have been implicated in the pathogenesis of 
AMD. These models include Abca4–/– (Stargardt disease) (Mata et al., 2001; Weng et 
al., 1999) and transgenic ELOVL4 mice (Stargardt-3 dominant inherited disease) 
(Vasireddy et al., 2009), as well as models targeting the immune pathway such as 
Cfh–/–, Ccl2–/–, Ccr2–/–, Cx3cr1–/–, Ccr2–/–/cx3cr1–/– mice (Ambati et al., 2003; Coffey 
et al., 2007; Combadiere et al., 2007; Combadiere et al., 2013; Luhmann et al., 
2013a; Luhmann et al., 2013b; Tuo et al., 2007); oxidative stress associated genes 
like in Sod1–/–, Sod2–/– and Nrf2–/– knockout mice (Imamura et al., 2006; Justilien et 
al., 2007; Zhao et al., 2011); or metabolic pathways related genes, for example in 
ApoE4 transgenic mice on high fat and high cholesterol diet (lipid metabolism) 
(Malek et al., 2005). Features of dry AMD were also observed in CEP-immunized 
wild type mice (C57BL/6J) and in a few natural mouse strains such as “age-related 
retinal degeneration” mouse (arrd2) and the Senescence-Accelerated Mouse (SAM) 
(Chang et al., 2008; Hollyfield et al., 2010; Majji et al., 2000; Takeda et al., 1994). In 
some of the above-mentioned models dry AMD-like changes are accompanied by 
CNV (ApoE4 transgenic mouse, SAM). The best-established model for wet AMD, 
however, is a laser-induced CNV (Bora et al., 2003). 
An alternative in vivo model system to investigate photoreceptor and RPE 
cell death involves exposure to the high intensities of white fluorescent light or blue 
light (light damage, LD) (Grimm and Reme, 2013; Wenzel et al., 2005). This 
experimental model provides an opportunity to explore the light-induced 
cytotoxity as a mechanism contributing to AMD pathology (Sparrow and Boulton, 
2005; Sparrow et al., 2000). Light exposure was shown to cause RPE damage and 
altered Bruch’s membrane structure in the golden hamster (Thumann et al., 1999). 
Photoreceptor apoptosis, followed by RPE cell death upon light illumination was 
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observed in rats (Hafezi et al., 1997). On the contrary, mouse RPE stayed preserved 
after LD (Reme et al., 2000), it displayed, however, several dysfunctionalities, like 
tight and adherent junctions disassembly, increased permeability and abnormal 
polarity of VEGF (vascular endothelial growth factor) secretion (Cachafeiro et al., 
2013). Additionally, activation of proinflammatory signalling followed by the 
macrophage infiltration into the subretinal space was observed (Joly et al., 2009). 
These molecular events, known to play a role in inflammatory angiogenesis which 
contributes to AMD, could be further studied using the light damage model in mice. 
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1.3  Paraoxonase-1 
1.3.1 Paraoxonase family 
Paraoxonase-1 (PON1) is the best studied member of the paraoxonase (PON) gene 
family composed of 3 genes: PON1, PON2 and PON3 aligned next to each other on 
the evolutionary conserved region on chromosome 7 in human and on chromo-
some 6 in mouse (Humbert et al., 1993; Sorenson et al., 1995). The human paraoxo-
nases share approximately 70% identity at the nucleotide level and 65% identity at 
the amino acid level (Primo-Parmo et al., 1996). Based on the structural homology, 
PON2 appears to be the oldest member of the family, followed by PON3 and more 
recently by PON1 (Draganov and La Du, 2004). All three PON proteins are 
lactonases with antioxidant properties, which differ in their site of synthesis and in 
the mechanisms of action (Draganov et al., 2000; Rosenblat et al., 2003). While 
PON2 is commonly expressed in various organs/cell types, the PON1 and PON3 
production is limited almost exclusively to the liver (Ng et al., 2005) (Fig. 10). 
Additionally, the PON1 and PON3 proteins have signal sequences that route them 
for secretion. Both PON1 and PON3 are being secreted to the blood where they bind 
HDL, enabling its transport and protecting it from oxidation (Draganov et al., 2000; 
Mackness, 1989). PON2 on the contrary, is an intracellular protein important in 
protecting endoplasmic reticulum (ER) and mitochondria from reactive oxygen 
species (ROS) mediated damage (Altenhofer et al., 2010; Horke et al., 2007). 
 
Figure 10. Tissue distribution of the human PON transcripts.  
Northern blot analysis of human tissue containing 2 g of mRNA per lane. Sm, small. 
Adapted from Ng et al., 2005. 
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1.3.2 Regulation of PON1 gene expression 
The human PON1 gene (ID: 5444) extends over approximately 26 kb at 7q21.3 and 
consists of 9 exons and 8 introns (Fig. 11). Mouse Pon1 (ID: 18979) located at 
chromosome 6 displays the same gene structure as its human ortholog (Sorenson 
et al., 1995). Transcription of PON1 can be initiated from the multiple transcription 
start sites located within the TATA-less promoter (Gouedard et al., 2003). 
Peroxisome proliferator-activated receptor gamma (PPAR) and the aryl 
hydrocarbon receptor (AhR) are two ligand-activated transcription factors that 
have been shown to regulate PON1 expression. Statins, pharmacological 
compounds widely used for the treatment of hyperlipidemia, up-regulate PON1 
expression via activation of PPAR that results in higher serum PON1 activity in 
hypercholesterolemic patients (Tomas et al., 2000). Similarly, plant-derived 
polyphenols increase PON1 expression upon binding to PPAR in human hepato-
cytes in vitro (Khateeb et al., 2010). Resveratrol, a natural phenol, and aspirin have 
been shown to induce PON1 expression through an AhR-mediated mechanism in 
human liver cell lines (Gouedard et al., 2004a; Jaichander et al., 2008).  
 
Five single nucleotide polymorphisms (SNPs) have been identified in the 
first 1000 bases upstream of the PON1 coding region at positions -107/-108, -126,  
-160/-162, -824/-832, and -907/-909 (Brophy et al., 2001a; Leviev and James, 
2000; Suehiro et al., 2000). Several of these SNPs -107, -162 and -909 exerted 
functional effects on PON1 expression in vitro (Brophy et al., 2001a), whereas the    
-909 polymorphism appeared to have little or no effect on PON1 levels in human 
plasma (Brophy et al., 2001b). The -107 polymorphism, which displayed a 
dominant effect on expression of PON1 gene both in vitro and in vivo (Brophy et al., 
2001a; Brophy et al., 2001b), lies within the consensus sequence of the binding site 
for the transcription factor Sp1, and affects interaction between this factor and 
 
Figure 11. Schematic representation of the human PON1 gene. 
Single nucleotide polymorphisms within upstream regulatory region of PON1 gene and 
missense SNPs in exon 3 and exon 6 are indicated: rs757158, C(-1740)T; rs854573,           
T(-1075)C; rs854572, C(-908)G; rs854571, C(-831)T; rs705381, G(-162)A; rs705380,               
G(-126)C; rs705379, T(-107)C; rs854560, p.L55M; rs662, p.Q192R. UUR, upstream 
untranscribed region; UTR, untranslated region; ex, exon. 
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PON1 promoter (Deakin et al., 2003). The -107 variant was found to be associated 
with increased risk of coronary artery disease and AMD (James et al., 2000; Oczos 
et al., 2013). 
Four SNPs and variant poly(A) signal sequences have been identified in the 
3’UTR of PON1 transcript (Brophy et al., 2001b). To date no experimental evidence 
has clarified whether they affect the addition of the poly(A) tail or otherwise alter 
the stability of the PON1 mRNA. 
 
1.3.3 PON1 enzymatic activities 
Human paraoxonase-1 (PON1) is a serum glycosylated protein consisting of 355 
amino acids with a molecular mass of approximately 45kDa (Draganov et al., 2005; 
Hassett et al., 1991). Mouse Pon1 cDNA encodes a 355-amino acid long protein, that 
shares 83% identity with the human PON1 amino acid sequence (Primo-Parmo et 
al., 1996). Human PON1 forms a six-bladed beta-propeller structure containing two 
Ca(2+) ions necessary for the protein stability, as shown in figure 12 (Erdos et al., 
1959; Harel et al., 2004).  
 
Figure 12. 3D model of the structure of human PON1. 
(A) A view of the 6-bladed -propeller from the top. Shown are N- and C-termini, the six 
blades (labelled 1-6) each of which is comprised of 4 -strands (labelled A-D) and the two 
calcium atoms in the central tunnel of the propeller (red and green spheres). (B) A side 
view of the propeller. The top calcium ion (green sphere) is a key part of the enzyme’s 
active site. Three helices at the top (H1-H3) comprise an active site lid. Helix H1 contains 
N-terminal hydrophobic signal sequences that is retained after PON1 secretion. Helixes H1 
and H2 are believed to participate in the binding of PON1 to HDL.  
Adapted from Harel et al., 2004. 
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The name “paraoxonase” indicates hydrolyzing activity (E.C. 3.1.8.1) toward 
paraoxon, the active metabolite of the organophosphorous insecticide, parathione 
(Aldridge, 1953). PON1 can hydrolyze a broad range of molecules: toxic 
metabolites of a number of other insecticides (phosphotriesterase activity), as well 
as aromatic esters (arylesterase activity) and aromatic or long-chain aliphatic 
lactones (lactonase activity) (Billecke et al., 2000). Despite the long list of various 
PON1 substrates that have been identified, its “major” physiological function and 
the endogenous substrates remain uncertain (La Du et al., 1999; Teiber et al., 
2007). The fact that other members of the PON family lack, or have very limited 
paraoxonase and arylesterase activity implies that the name “paraoxonases” is 
purely historical, and suggests the lactonase activity to be the one, for which the 
PONs may have evolved. Comprehensive structure-reactivity studies with PON1 
and PON1 variants generated from directed evolution have supported this 
hypothesis (Khersonsky and Tawfik, 2005, 2006). Furthermore, Dragnov and 
colleagues have characterized PONs enzymatic activities in detail and proposed 
lactone and hydroxy acid derivatives of polyunsaturated fatty acids (PUFAs) as the 
endogenous substrates (Draganov et al., 2005). Homocystein thiolactones, the toxic 
homocystein metabolites involved in the pathogenesis of the cardiovascular 
disease in humans, are another group of lactones that have been described as likely 
natural PON1 substrates (Jakubowski et al., 2001). 
 
1.3.4 Polymorphic forms of PON1 
The PON1 activity polymorphisms have been subject of numerous studies for more 
than 20 years before Humbert and colleagues found the actual genetic determinant 
of those variants (Geldmacher-von Mallinckrodt, 1973; Humbert et al., 1993). The 
two known PON1 allozymes differ in paraoxonase activity, originating from the 
amino acid exchange at position 192 (p.Q192R). In addition to the amino acid 
substitution at position 192, a large interindividual variability in the amount of 
serum PON1 contributes to the reported differences in paraoxonase activity 
(Furlong et al., 1988; Playfer et al., 1976). Currently it is known that the level of 
PON1 in serum is determined by the genetic variants (leucine to metionine 
substitution at codon 55 (p.L55M); and T(-107)C polymorphisms), as well as 
disease state, dietary, life-style, and environmental factors (Costa et al., 2003; 
Leviev and James, 2000).   
The two common coding PON1 polymorphisms: p.L55M (rs854560), 
p.Q192R (rs662) have been investigated for genetic association with a number of 
pathophysiological conditions, including atherosclerosis, hyperlipidemia, coronary 
artery disease (CAD), stroke, type 2 diabetes, Parkinson`s disease, Alzheimer`s 
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disease, and AMD; frequently giving contradictory results (Baird et al., 2004; 
Esfandiary et al., 2005; Ikeda et al., 2001; Ng et al., 2005; Pauer et al., 2010). Never-
theless, independent of PON1 genotype, low serum PON1 activity levels have been 
implicated in hyperlipidemia, type I diabetes, CAD, chronic renal failure, metabolic 
syndrome, rheumatoid arthritis, thyroid dysfunction, uremia, and AMD (Ates et al., 
2009; Baskol et al., 2006; Ng et al., 2005). The inconsistence between various 
genetic and physiological studies led to the suggestion, that PON1 status (activity 
and level) may be more important in determining the PON1 involvement in disease 
than paraoxonase genetic polymorphisms (Brophy et al., 2000; Jarvik et al., 2003; 
Jarvik et al., 2000; Mackness et al., 2001; Richter and Furlong, 1999). 
 
1.3.5 Anti-oxidant and anti-inflammatory properties of PON1 
In 1991 Mackness and colleagues discovered that PON1 purified from human HDL 
may be responsible for destroying pro-inflammatory oxidized lipids present in 
oxidized low-density lipoprotein (oxLDL), and thus may act anti-atherogenic 
(Mackness et al., 1991). This study has stimulated further investigations, which 
provided further evidence that PON1 protects vascular tissue from oxidative 
damage (Aviram et al., 1998; Mackness et al., 1993; Watson et al., 1995). Additional 
confirmation of the in vitro findings came from characterization of mice lacking 
PON1 (Pon1–/–) (Shih et al., 1998). Relative to their control littermates, HDL from 
PON1-deficient mice was more susceptible to oxidation and was unable to prevent 
LDL from oxidation in a co-cultured cell model of the artery wall. On the contrary, 
HDL isolated from transgenic mice overexpressing human or mouse PON1 
exhibited enhanced ability to protect LDL against oxidation, further confirming 
anti-oxidant function of PON1 (Oda et al., 2002; Tward et al., 2002). 
Another mechanism by which PON1 contributes to the anti-atherogenic 
properties of HDL is its anti-inflammatory activity. PON1 can decrease oxLDL-
mediated secretion of monocyte chemotactic protein-1 (MCP-1) and monocyte 
transmigration, as demonstrated by studies on PON1-knockouts (Shih et al., 1998). 
Furthermore, PON1 inhibits monocyte-to-macrophage differentiation and directly 
suppresses macrophage pro-inflammatory responses (Aharoni et al., 2013; 
Rosenblat et al., 2011). 
 
1.3.6 Implications for involvement of PON1 in AMD 
Atherosclerosis and AMD are complex diseases that share similar aetiology, 
environmental risk factors, and underlying molecular mechanisms. In particular, in 
both conditions oxidative stress and inflammation are involved in formation of 
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pathological extracellular lesions, plaques in atherosclerosis or drusen in AMD 
(Curcio et al., 2010; Curcio et al., 2011). As described above, diverse studies have 
demonstrated beneficial, anti-atherogenic function of PON1, whereas its role in 
development of drusen or other ocular changes characteristic to AMD has not been 
described to date. There exist, however, several lines of evidence for the 
involvement of PON1 in AMD. Decreased serum paraoxonase activity levels were 
found in patients with neovascular and nonexudative AMD (Ates et al., 2009). Also 
cigarette smoking, one of the strongest environmental risk factors to develop AMD, 
reduces serum PON1 activities (Isik et al., 2007; Solak et al., 2005). Furthermore, 
association between the two missense PON1 gene polymorphisms (p.L55M and 
p.Q192R) and AMD was found in Japanese and Caucasian populations (Ikeda et al., 
2001). Though, in different patient cohorts of European origin no association has 
been detected (Baird et al., 2004; Brion et al., 2011; Esfandiary et al., 2005). 
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II. SPECIFIC AIMS 
 
 
The overall goal of the thesis was to understand the role of PON1 in complex 
human diseases (age-related macular degeneration and coronary artery disease), 
as well as in development, maintenance and function of the mouse retina. 
The thesis had three specific aims: 
 
1. To determine whether SNPs in PON1 contribute to AMD. 
 
2. To determine whether SNPs and private mutations in PON1 contribute to 
coronary artery disease. 
 
3. To determine function of PON1 in the retina using Pon1–/– mice. 
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RESULTS and DISCUSSION
uals, while haplotype CGATGCT increased the risk
(OR01.55, CI01.09–2.21) for AMD. These results were
also reflected when haplotypes for the untranscribed and
the 5′untranslated regions (5′UTR) were analyzed sepa-
rately. To assess haplotype correlation with levels of gene
expression, the three SNPs within the 5′UTR were tested
in a luciferase reporter assay. In retinal pigment
epithelium-derived ARPE19 cells, we were able to mea-
sure significant differences in reporter levels, while this
was not observed in kidney-derived HEK293 cells. The
presence of the risk allele A (SNP rs705381) caused an
increase in luciferase activity of approximately twofold.
Our data support the view that inflammatory reactions
mediated through anti-oxidative activity may be relevant
to neovascular age-related macular degeneration.
Keywords Paraoxonase 1 . Gene regulation . SNP
association . Age-related macular degeneration (AMD)
Introduction
Age-related macular degeneration (AMD) is a pro-
gressive degenerative disease, which in its advanced
stages leads to severe visual impairment. It is the
major cause of loss of vision in elderly patients in
developed countries (Deangelis et al. 2011). Advanced
stages of AMD manifest either as atrophic changes in
the macula (dry/atrophic/nonexudative AMD) or as cho-
roidal neovascularization (wet/neovascular/exudative
AMD). Although the neovascular AMD represents only
10–20 % of all AMD cases, it accounts for the vast
majority of cases with severe and rapid vision loss
(~90 %) (Jager et al. 2008).
The etiologic complexity of AMD arises from an
interplay of genetic and environmental factors. Recent
progress in AMD genetics has established several impor-
tant risk loci, among them the complement factor
H (CFH) on chromosome 1 (1q31) (Edwards et al.
2005; Hageman et al. 2005, 2006; Hughes et al. 2006;
Klein et al. 2005; Li et al. 2006) and the age-related
maculopathy susceptibility 2 (ARMS2/HTRA1) on chro-
mosome 10 (10q26) (Dewan et al. 2006; Jakobsdottir
et al. 2005; Rivera et al. 2005; Schmidt et al. 2006;
Tanimoto et al. 2007; Weger et al. 2007; Yang et al.
2006). Both loci combined are thought to account for
more than 50 % of AMD cases (Edwards et al. 2005;
Klein et al. 2005; Maller et al. 2006; Swaroop et al. 2007;
Thakkinstian et al. 2006). Their association with AMD
has been replicated across multiple ethnic groups world-
wide and further validated through a meta-analysis of
whole genome scans (Fisher et al. 2005). The discovery
of CFH as a genetic risk factor for AMD was supported
by functional studies revealing a role of the alternative
complement pathway in drusen formation (Hageman et
al. 2005). Following the discovery of genetic susceptibil-
ity loci, an impressive number of further genes has been
reported that either increase or lower the risk towards
AMDdevelopment (Katta et al. 2009). Despite the strong
associations established, it is still not possible to predict
the onset or course of AMD (Swaroop et al. 2007).
Hence, it is necessary to identify other genes involved
in the pathogenesis and understand their interactions.
To date, several additional candidate genes have been
studied for their association with AMD, including lipid
metabolism and oxidative stress genes (APOE (Baird et
al. 2004b; Pang et al. 2000),VLDLR (Conley et al. 2005;
Haines et al. 2006), LRP5 (Kloeckener-Gruissem et al.
2011), LRP6 (Haines et al. 2006), PON1 (Baird et al.
2004a; Brion et al. 2011; Esfandiary et al. 2005; Ikeda et
al. 2001; Pauer et al. 2010), LIPC (Neale et al. 2010),
and SOD2 (Gotoh et al. 2008; Kimura et al. 2000).
Discordant results across multiple studies indicate the
existence of additional factors that influence the devel-
opment of AMD in different populations.
Oxidative stress is implicated in the development of
AMD (AREDS 2001; Beatty et al. 2000; Khandhadia
and Lotery 2010); thus, identification of enzymes con-
ferring antioxidant protection is of interest. During the
last decade, paraoxonase 1 (PON1), an enzyme with
antioxidant properties, has been extensively investigated
in several disorders, including age-related pathologies
such as hyperlipidemia, atherosclerosis, coronary artery
disease, metabolic syndrome, type 2 diabetes, as well
as Alzheimer's disease (Androutsopoulos et al. 2011;
Mackness et al. 1998b, c; Paragh et al. 1998; Senti et
al. 2003). PON1 is a protein mainly synthesized in the
liver, and most studies have focused their analysis on
this fact. The enzyme is secreted into the blood where it
binds high-density lipoprotein (HDL) (Aviram 2004).
One of the functions of PON1 is to protect low-density
lipoprotein (LDL) from oxidative damage and to inacti-
vate oxidized LDL by hydrolyzing its oxidized phos-
pholipids (Deakin and James 2004).
PON1 serum concentration and activity are highly
variable across the general population (Deakin and
James 2004). This variability is attributed to environmen-
tal factors, such as smoking, diet, alcohol consumption,
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but also to the genetic polymorphisms in the PON1 gene.
There are two annotatedmissense SNPswithin thePON1
coding region: p.L55M (rs854560), where the major
allele L leads to elevated PON1 protein levels, and
p.Q192R (rs662), affecting substrate specificity as well
as enzyme activity (Garin et al. 1997; Humbert et al.
1993). These two missense polymorphisms affect also
the ability of HDL to protect LDL from oxidative mod-
ifications, with MM/QQ genotype being most effective
(Mackness et al. 1998a). The level of PON1 concentra-
tion in serum is also affected by sequence variants within
the promoter of the PON1 gene. In particular, the C allele
at position −107 (SNP rs705379) yields the highest level
of PON1 in the serum among all alleles that have been
investigated so far (Leviev and James 2000).
The antioxidant properties of PON1 stimulated re-
search for association of DNA sequence variants within
the PON1 coding region and AMD (Baird et al. 2004a;
Brion et al. 2011; Esfandiary et al. 2005; Ikeda et al.
2001; Pauer et al. 2010). Much focus has been on
studying the effects of the two above-mentioned poly-
morphisms, p.L55M and p.Q192R. In a Japanese AMD
patient cohort, the 55L and the 192R variants were
found more frequently (Ikeda et al. 2001), while in one
Caucasian cohort, the 55Q variant was associated with
the disease (Pauer et al. 2010). This association could
not be confirmed in further three Caucasian patient
groups suggesting the influence of other factors as well
(Baird et al. 2004a; Brion et al. 2011; Esfandiary et al.
2005). No information has been published on associa-
tions of sequence variants within upstream regulatory
regions of the gene and diseases. It was our goal to
expand the knowledge of effects of PON1 gene sequen-
ces beyond protein isoforms and to investigate the in-
fluence of the upstream regulatory regions on AMD.We
report here the identification of protective and risk hap-
lotypes with effects on gene expression, which displays
cell-type specificity.
Materials and methods
Patients
Patients with neovascular AMD were diagnosed at the
Department of Ophthalmology at the University
Hospital Zurich. Inclusion criteria regarding age,
visual acuity, and lesion type (minimally classic, pre-
dominantly classic, and occult) were based on the
MARINA (Rosenfeld et al. 2006) and ANCHOR
(Brown et al. 2006) trials. The patients were given a
full explanation of the nature and purpose of the study.
The study was conducted according to the Declaration
of Helsinki and was approved by the local ethics
committee. Clinical and demographic description as
well as the analysis of several common AMD risk
factors of this patient cohort has been published pre-
viously (Kloeckener-Gruissem et al. 2011). Data from
305 neovascular AMD patients are reported in the
current study. The average age of the patients was
79.41 years (±6.97); female to male ratio, 1.95. All
were of European descent, living in Switzerland. DNA
of 288 individuals representing the general population
was used as the control group (Moskvina et al. 2005).
These individuals were not age-matched and did not
undergo clinical assessment for the present study. They
were of European descent, living in Switzerland. The
female/male ratio was 2.1.
Genotyping
Venous blood was collected in EDTA tubes, and ge-
nomic DNA was extracted as described (Kloeckener-
Gruissem et al. 2011). DNA concentration was adjusted
to 10 ng/μl. SNP genotyping was performed either by
DNA sequencing (primer 1 CCTCCCCGACTGGAC-
TAGG and primer 2 AGGGAGTGAGGAGGAC-
GAAG were used for genotyping SNPs rs705379,
rs705380, and rs705381; primer 3 CCAAAAGCCTT-
GAGAAGGAA and primer 4 TGCTCTAGGTGATG-
CATGTGwere used for genotyping SNPs rs854571 and
rs854572) or by TaqMan technology (SNPs rs854571,
rs854573, and rs757158), using ABI chemistry (Ap-
plied Biosystems, Inc. [ABI], Rotkreuz, Switzerland).
Sequencing primers were designed by Primer3 (v. 0.4.0;
http://frodo.wi.mit.edu/primer3, provided in the public
domain by Massachusetts Institute of Technology,
Cambridge, MA) and synthesized by Microsynth
(http://www.microsynth.ch; Balgach, Switzerland).
Annealing temperatures varied between 54 and 60 °C.
For PCR, 50-ng genomic DNA and primers were cycled
35 times, each cycle lasting 1 min. For TaqMan assay,
probes from ABI were used. Genotype calling was
performed on SDS2.2 software, ABI. The allele
calling of SNP assay was verified by DNA
sequencing analysis for 10 % of all samples,
yielding 100 % concordance. In addition, genotyping
of 10 % of all samples was repeated for each SNP.
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Selection of SNPs and haplotype analysis
Seven SNPs, namely rs705379, rs705380, rs705381,
rs854571, rs854572, rs854573, and rs757158 (Fig. 1
and Table 1), within PON1 gene (NG_008779.1) were
chosen for association studies based on the linkage dis-
equilibrium (LD) data in the HapMap Caucasion (CEU)
population panel, using a tagging criteria of R2>0.8.
Since there is no LD information available for SNPs in
the 5′UTR (rs705379, rs705380, and rs705381), we in-
cluded them in the analysis.
Individual haplotypes and their estimated population
frequencies were inferred using PHASE program,
v2.1.1 (http://stephenslab.uchicago.edu/software.html),
with all parameters set at the default values (Stephens
and Donnelly 2003; Stephens et al. 2001).
In silico analysis of 5′UTR variants on RNA folding
Putative RNA folding structures were predicted
using the Mfold online software with standard settings
(http://mfold.rna.albany.edu/?q0mfold/RNA-Folding-
Form) (Zuker 2003). RNA structures were predicted
for the PON1 transcript (transcript: PON1-001
ENST00000222381) containing eight possible combina-
tions of alleles at the SNPs within 5′UTR.
Cloning
A 400-bp fragment of PON1 exon 1 containing the 5′
UTR was PCR-amplified (primer 1 and primer 2) and
cloned into the intermediate pJET1.2/blunt cloning vec-
tor using the CloneJET PCR Cloning Kit (Fermentas
International Inc, Glen Burnie, MD, USA). Fragments
containing four of the eight possible haplotypes were
obtained directly through PCR from patients' genomic
DNA (CCA, CGA, CGG, and TGG; SNPs' order from
left to right, rs705379, rs705380, and rs705381). DNA
fragments containing the other four haplotypes were
obtained by site-directed mutagenesis with the primer
extension approach. For all substitutions, primer 1
and primer 2 served as outside flanking primers. Each
mutation was obtained using additional pairs of inside
primers (sequences are written from 5′to 3′) as primer 5
CCGACCCGGCGGGGAGGGGTGGGGCGG
GCC with primer 6 GCAGCGCCGATTGGCCC
GCCCCACCCCTCCC, primer 7 GGGGCTGA
CCGCAAGCCGCGCCTTCTGTGC with primer
8 GACCAGGTGCACAGAAGGCGCGGCT
TGCGG, primer 9 GGGGCTGACCGCAAGC
CACGCCTTCTGTGC with primer 10 GACCAGGTG
CACAGAAGGCGTGGCTTGCGGTC, and primer 11
TGGTCGGCCCAGCTAGCTGCCGACCCGGCGGG
with primer 12 CCACCCCTCCCCGCCGGGTCGG
CAGCTAGC. Subsequently, the PON1 fragments repre-
senting each of the haplotype were cloned into pGL3-
Control vector (Promega, Madison, WI, USA). In the
first step, PCR reaction was performed to create aHindIII
restriction site upstream of the three 5′UTR SNPs using
primer 2 and primer 13 TATAAGCTTGTTGGAAG
GAGCAAAATG. In the second step, 238-bp fragments
spanning from the constructed HindIII site to the trans-
lational start codon ATG (NcoI site) were cloned into the
pGL3-Control vector using HindIII and NcoI restriction
enzymes (Fermentas). DNA sequences of all constructs
were verified by Sanger sequencing.
Expression studies
HEK293 cells were seeded on 24-well plates (105cells/
well) in 1 ml DMEM, 10 % FBS, and 1 % penicillin/
streptomycin and incubated under standard conditions
(37 °C, 5 % CO2). After 24 h, cells were transfected
using 1.5-μl branched polyethylenimine, PEI (1 μg/μl),
600-ng pFirefly construct, and 15-ng pRenilla construct
per well. Twenty-four hours later, the cells were har-
vested, and luciferase activities were analyzed using
Dual-Glo Luciferase Assay System according to the
protocol provided by Promega and measured on a Bio-
Tek Synergy microplate reader (BioTek Instruments,
Fig. 1 Schematic representation of the PON1 gene. Positions of
SNPs that were analyzed in this study are printed in bold. They
map to the upstream untranscribed region (UUR) and the 5′un-
translated region (5′UTR). SNPs in exon 3 (Ex3), exon 6 (Ex6),
and exon 9 (Ex9), investigated by other groups, are printed in
italics (Baird et al. 2004a; Brion et al. 2011; Esfandiary et al. 2005;
Ikeda et al. 2001; Pauer et al. 2010)
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Winooski, VT, USA). Data were normalized for trans-
fection efficiency by Renilla luciferase activity. The ex-
periment was performed three times with three replicates
each. ARPE19 cells (ATCC, Manassas, VA, USA) were
seeded on 24-well plates (8×104cells/well) in 1 ml
DMEM, 10 % FBS, 1 % penicillin/streptomycin, and
7.5 % Na2CO3 and cultured under standard conditions
(37 °C, 5 % CO2). Twenty-four hours later, transfection
was performed; for each well, 0.75-μl X-tremeGENE
9 transfection reagent (Roche Diagnostics, Indianapolis,
IN, USA), 250-ng pFirefly construct, and 6.25-ng pRe-
nilla construct were used. Luciferase activities were
measured and analyzed 24 h after transfection as
described above. The experiment was repeated four
times. Three of these repeats included three technical
replicates while one of them included eight.
Statistical analysis
Pairwise LD analysis was performed on phased haplo-
type data generated from the control group according to
the following formulas: R20D2/(pA1pA2pB1pB2 ), where
D0pA1B1pA2B2−pA1B2pA2B1; D′0D/Dmax, with Dmax0
min(pA1pB2, pA2pB1) if D>0 and Dmax0min(−pA1pB1, -
pA2pB2) ifD<0 (Mueller 2004). For association studies,
odds ratios and significance were calculated using 2×2
contingency table provided on an open access Internet
portal (http://faculty.vassar.edu/lowry/odds2x2.html).
Odds ratios were displayed with 95 % confidence inter-
vals and Chi-square and P values according to Pearson.
Statistical significance was assumed at P<0.05. For
expression studies, eight technical replicas were mea-
sured and averages with confidence intervals at 95 %
were computed. Fold-change differences were deter-
mined after normalizing the data to those obtained for
the TCG haplotype. This haplotype was chosen because
it yielded the lowest luciferase activity in the ARPE19
cell line. The Shapiro–Wilk test was applied to assess
normal distribution of the data. For statistical analysis,
the two-tailed t test was used.
Results
Linkage disequilibrium revealed two DNA blocks
within the upstream regulatory region of PON1
Linkage disequilibrium data are crucial for the design of
association studies. If two SNPs share high linkage
disequilibrium, with R2>0.8 one of them can be used
as tagged SNP. The region of PON1 investigated in our
study contains seven annotated SNPs (Fig. 1 and
Table 1). LD data on the HapMap website are available
only for four of them (rs854571, rs854572, rs854573,
and rs757158). To complete this information, we per-
formed LD analysis on phased genotype data of the
control individuals (Table 2). Our analysis confirms
already annotated data in a larger group of individuals
(haplotype number n0500 in our study, n0224 in Hap-
Map) and also provides pairwise R2 and D′ values for
SNPs which are not included in HapMap. Among the
seven analyzed SNPs, six belong to one haplotype block
Table 1 Allele frequencies of SNPs in the upstream regulatory region of PON1
Marker Major/minor allele Position Region MAF P value OR CI (95 %)
HapMap AMD (n0305) Controls (n0288)
rs705379 T/C −107 5′UTR 0.425 0.517 0.440 0.0099 1.36 1.08–1.73
rs705380 G/C −126 5′UTR 0.042 0.056 0.044 0.3566 1.29 0.75–2.21
rs705381 G/A −162 5′UTR 0.167 0.253 0.199 0.0295 1.37 1.03–1.81
rs854571 C/T −831 UUR 0.302 0.284 0.257 0.3009 1.14 0.89–1.49
rs854572 C/G −908 UUR 0.425 0.471 0.419 0.0759 1.23 0.98–1.56
rs854573 T/C −1075 UUR 0.230 0.255 0.194 0.0121 1.42 1.08–1.88
rs757158 C/T −1740 UUR 0.376 0.444 0.380 0.0256 1.30 1.03–1.64
Comparison between patients with neovascular AMD (n0305) and control individuals (n0288). Three SNPs map to the 5′untranslated
region while four of the SNPs lie within the upstream untranscribed region (Fig. 1). Minor allele frequencies for a Caucasian population
were taken from the HapMap website (http://www.hapmap.org) and were calculated for our patient (AMD) and control groups.
Statistical analyses are displayed as odds ratios (OR) with confidence intervals (CI) and P values, with α00.05
5′UTR 5′untranslated region, UUR upstream untranscribed region, MAF minor allele frequencies
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as they revealed high pairwise D′ values (rs705379,
rs705380, rs705381, rs854571, rs854572, and
rs854573). SNP rs757158 belongs to a separate haplo-
type block (Fig. 2). Among the analyzed SNPs, only
two pairs (rs705381 with rs854573, and rs854572 with
rs757158) fulfill tagging criteria of R2>0.8 (Table S1).
Association studies showed risk and protection
potential for AMD
Genotypes of seven SNPs within regulatory, non-coding
regions of the PON1 locus were determined from 305
patients with neovascular AMD and compared to those
from 288 control individuals (Table 1). The patients'
AMD phenotype has been reported in detail previously
(Kloeckener-Gruissem et al. 2011). Three SNPs within
the 5′UTR and four SNPs within the upstream untran-
scribed region (UUR) (Fig. 1) were genotyped and
analyzed. Note that as the transcriptional promoter re-
gion has not been defined experimentally, we chose to
name this region “UUR”, rather than “promoter region”.
Statistically significant association was found at two
SNP loci within the 5′UTR and two within the UUR:
rs705379 (OR01.36, CI01.08–1.73, P00.0099),
rs705381 (OR01.37, CI01.03–1.81, P00.0295),
rs854573 (OR01.42, CI01.08–1.88, P00.0121), and
rs757158 (OR01.30, CI01.03–1.64, P00.0256)
(Table 1).
To strengthen the significance of the association, we
included analyses of haplotypes. For the seven SNP
haplotypes (rs705379 at −107, rs705380 at −126 and
rs705381 at −162, rs854571 at −831, rs854572 at −908,
rs854573 at −1075, and rs757158 at −1740), PHASE
predicted 18 different combinations. Haplotypes with
fewer than five counts in PHASE (11 haplotypes) were
not taken into account for statistical analyses. The haplo-
type TGGCCTC, comprising exclusively major alleles,
was more frequently found in the control group, suggest-
ing a protective function (OR00.76, CI00.60–0.97, P0
0.0293), whereas the haplotype CGATGCT was more
frequent in AMDpatients (OR01.55, CI01.09–2.21,P0
0.0141), posing a risk for the disease (Table 2). Similar
results were found when SNPs from the 5′UTR and the
upstream untranscribed region (UUR) were analyzed
separately. The PHASE program revealed the presence
of four possible haplotypes for SNPs in the 5′UTR (TGG,
CGG, CGA, CCA; order of SNPs from left to right,
rs705379 at −107, rs705380 at −126, and rs705381 at
−162). Carriers of the haplotype TGG, representing the
major alleles within a population, were more frequently
found in the control group compared to the patient group,
and, hence, this haplotype confers a protection against
AMD (OR00.72, CI00.57–0.91,P00.0063), while con-
versely the haplotype CGA indicates a risk for AMD
(OR01.35, CI00.99–1.85, P00.0564) (Table 3). For the
four SNPs in the UUR, PHASE predicted seven different
haplotypes. Three haplotypes showed statistically signif-
icant differences between patient and control group
Table 2 Haplotype analysis for all seven SNPs
Haplotype AMD
(n0556)
n (%)
Controls
(n0500)
n (%)
P value OR CI (95 %)
TGGCCTC 264 (47.5) 271 (54.2) 0.0293 0.76 0.60–0.97
CGGCGTT 100 (18.0) 74 (14.8) 0.1637 1.26 0.91–1.75
CGATGCT 94 (16.9) 58 (11.6) 0.0141 1.55 1.09–2.21
CCATGCT 25 (4.5) 22 (4.4) 0.9203 1.02 0.57–1.84
CGGCCTC 26 (4.7) 18 (3.6) 0.3833 1.31 0.71–2.43
CGGTGTT 17 (3.1) 25 (5.0) 0.1069 0.60 0.32–1.12
CGATGCC 12 (2.2) 14 (2.8) 0.5023 0.77 0.35–1.67
SNP order for each haplotype, from left to right is as follows: -107,
-126, -162, -831, -908, -1075, and −1740. Haplotype counts (n)
and percentages (%) are given. Haplotypes with less than five
counts in PHASE were not taken into account for statistical
analysis. Odds ratios (OR) with confidence intervals (CI) and P
values (alpha00.05) are shown
Fig. 2 Pairwise linkage analysis of SNPs within the PON1 5′
UTR and upstream untranscribed region. R2 and D′ values are
depicted by the grayscale color code according to the legend.
Asterisks indicate SNPs for which no data are available on the
HapMap website
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frequencies (Table 3). The haplotype TGCT (rs854571 at
−831, rs854572 at −908, rs854573 at −1075, and
rs757158 at −1740) was associated with the disease
(OR01.44, CI01.07–1.95, P00.0165), whereas the
two haplotypes CCTC and TGTT were more frequently
found in the control group (OR00.79, CI00.63–0.99,
P00.0492 and OR00.48, CI00.27–0.84, P00.0092,
respectively) (Table 3).
Sequence variants in the 5′UTR alter predicted
structure of the PON1 mRNA
It is known that SNPs within the 5′UTR of genes can
affect its mRNA folding and consequently change trans-
lational efficiency (Zuercher et al. 2010). We simulated
the influence of the 5′UTR polymorphisms on secondary
RNA structures using the web server Mfold. RNA struc-
tures of the entire PON1mRNA (5′UTR, coding sequen-
ces, and 3′UTR) were predicted (Fig. 3). The predicted
structure of the reference sequence carrying the minor
alleles at three analyzed positions (−107C, -126C, and
-162A) was not different from that containing only one
major T allele at position −107 (Fig. 3a). In contrast,
predicted folding of RNA containing the major alleles
at position −126 and −162, singly, or in combination,
assumed a strikingly different structure (Fig. 3b). Based
on these bioinformatic predictions, we hypothesized that
SNPs within the 5′UTR of PON1 may have different
effects on protein synthesis.
AMD risk haplotype altered reporter gene activity
in cell culture
To correlate our association data and the structural pre-
dictions with potential effects on gene expression, we
designed experiments to test whether different PON1 5′
UTR haplotypes influence luciferase reporter gene ex-
pression in cell culture. We generated the eight possible
haplotypes in DNA constructs, containing the PON1 5′
UTR region fused to the Luciferase coding region, both
transcribed from the SV40 promoter. Since tissue-
specific effects on gene expression are likely to occur,
we included two different cell lines in this test: the
embryonic kidney-derived cell line HEK293 and the
retinal pigment epithelium-derived cell line ARPE19.
Both cell lines were transiently transfected with the
various PON1 5′UTR haplotypes in front of the lucifer-
ase reporter. In ARPE19 cells, we found statistically
significant differences in luciferase levels (Fig. 4). To
assess contribution of each individual SNP to increased
protein expression, we performed a pairwise compari-
son of luciferase levels between haplotypes differing at
only one position (Table 4). This analysis revealed that
SNP rs705381 at position −162 is mostly responsible for
Table 3 Haplotype analysis of the upstream untranscribed and untranslated region
Region Haplotype AMD n (%) Controls n (%) P value OR CI (95 %)
5′UTRa
TGG 280 (48.4) 297 (56.7) 0.0063 0.72 0.57–0.91
CGG 150 (26.0) 121 (23.1) 0.2713 1.17 0.89–1.54
CGA 116 (20.1) 82 (15.6) 0.0564 1.35 0.99–1.85
CCA 32 (5.5) 24 (4.6) 0.4708 1.22 0.71–2.10
UURb
CCTC 308 (52.4) 320 (58.2) 0.0492 0.79 0.63–0.99
TGCT 128 (21.8) 89 (16.2) 0.0165 1.44 1.07–1.95
CGTT 109 (18.5) 87 (15.8) 0.2253 1.21 0.89–1.65
TGTT 19 (3.2) 36 (6.5) 0.0092 0.48 0.27–0.84
TGCC 19 (3.2) 17 (3.1) 0.8875 1.05 0.54–2.04
Four haplotypes in the 5′untranslated region (5'UTR) and five haplotypes in the upstream untranscribed region (UUR) were analyzed in our
patient and control population. The order of SNPs, from left to right is −107, -126, and −162 (5′UTR) and −831, -908, -1075, and −1740
(UUR). Haplotype counts (n) and percentages (%) are given. Odds ratios (OR) with confidence intervals (CI) and P values (alpha00.05) are
shown. Haplotypes with fewer than five counts in PHASE were not taken into account for statistical analysis
a AMD, n0578; controls, n0524
b AMD, n0588; controls, n0550
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the observed difference in luciferase activity. The pres-
ence of the minor allele A leads to increase in the
reporter activity up to 2.1-fold. Small contribution to
the protein expression regulation has been found for two
other SNPs (rs705379 at −107, and rs705380 at −126),
with minor allele C at position −107 and minor allele C
at position −126, causing up to 1.6- and 1.4-fold
increase in luciferase level, respectively. Interestingly,
in HEK293 cells, we did not find statistically significant
differences in luciferase activity between the different
constructs (data not shown), supporting our initial as-
sumption of cell-specific effects on gene expression.
Discussion
This is the first report to show association of SNPs in the
upstream regulatory region of PON1 with neovascular
AMD. Previous studies have investigated association
between SNPs within the PON1 coding region and
AMD (Brion et al. 2011; Baird et al. 2004a; Esfandiary
et al. 2005; Pauer et al. 2010; Ikeda et al. 2001). The
focus was on twomissense polymorphisms p.L55M and
p.Q192R. Conflicting results were obtained when com-
paring different patient cohorts; while association with
wet AMD has been found for both variants in a Japanese
population (Ikeda et al. 2001), only the p.Q192R variant
was associated in only one of the four Caucasian cohorts
(Pauer et al. 2010). Furthermore, in the Japanese study,
the arginine at position 192 of the PON1 protein has
been found more frequently in the patient group,
whereas in Caucasians, the glutamine (192Q) variant
has been associated with the disease. Possible explana-
tions encounter different allele frequencies in the differ-
ent ethnic groups but also a diverse phenotype of AMD
(Bird 2003; Oshima et al. 2001). Specifically for SNP
p.Q192R in Caucasians, the minor variant is R with a
frequency of 0.332, whereas in Japanese, the arginine is
the major variant with an allele frequency of 0.706
(HapMap). As there is no linkage disequilibrium between
p.Q192R variant and the promoter polymorphisms (Lev-
iev and James 2000) (HapMap), a direct comparison
between our data and those reported from other Cauca-
sian patient cohorts, which examined p.Q192R (Baird et
al. 2004a; Brion et al. 2011; Esfandiary et al. 2005; Pauer
et al. 2010) is not meaningful.
In contrast to p.Q192R, the variant 55L is in linkage
disequilibrium with the allele -107C (Leviev and James
2000), which is associated with AMD in our study. It has
been shown that these two alleles lead to increased levels
of PON1 in serum (Leviev and James 2000). Thus, it
may be difficult to understand how higher levels of a
protein that is known to have antioxidant properties can
be associated with AMD. For a possible explanation, we
would like to emphasize that variant p.L55M has been
reported to affect PON1 activity towards lipid peroxides,
with the LL genotype being less effective than MM at
protecting LDL against oxidation (Mackness et al.
1998a). Since alleles at position -107C and -162A are
in linkage disequilibriumwith variant 55L, they are likely
to be also associated with the less effective protection
against oxidation, thus can confer the risk for AMD and
Fig. 3 Predicted PON1
mRNA foldings. a The
structure represents folding
of the PON1 mRNA
containing the minor alleles
CCA in the 5′untranslated
region. It was indistinguish-
able from the allele combi-
nation TCA. b The structure
depicts mRNA folding in the
presence of the other six
allelic combinations: CGA,
TGA, CCG, TCG, CGG, and
TGG (SNP order from left to
right, -107,-126, and −162)
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be responsible for increased oxLDL levels (Ikeda et al.
2001) in AMD patients.
To strengthen the significance of the association found
with individual SNPs, we performed haplotype associa-
tion analysis. We discovered two seven-SNP haplotypes
associated with AMD. The most abundant haplotype
(54.2 % in controls), TGGCCTC, was more frequently
found in controls conferring a protection against AMD,
whereas haplotype CGATGCT was a risk factor. Inter-
estingly, the two haplotypes CGATGCC and CCATGCT,
each differing at only one position in comparison to
CGATGCT, appeared not to be associated with the dis-
ease. These data imply a possible interplay between the
analyzed loci and underlines the importance of haplotype
analysis to assess risk factors. Similar results were
obtained when analyzing haplotypes within the 5′UTR
and UUR separately.
It is known that sequence variants within the 5′UTR
can regulate gene expression at the level of protein
translation. We asked whether this would also apply
to the PON1 gene. To support our notion, we performed
in silico RNA folding predictions for the different
allelic combinations and found that the presence of the
major alleles for two SNPs in the 5′UTRwould lead to a
striking difference in the folding properties of the entire
PON1 transcript. Furthermore, these alleles also appear
to have an effect on reporter gene expression as mea-
sured by luciferase enzyme activity. Specifically,
in the retinal pigment epithelium-derived cell line
ARPE19, the protective TGG haplotype yielded the
lowest level of luciferase activity, while the CCA hap-
lotype resulted in the highest reported expression levels.
When comparing those haplotypes differing at only one
position, we discovered that the SNP at position −162
provided the largest contribution, with the A nucleotide
causing up to 2.1-fold increase in luciferase reporter
activity. Previous reports have shown that this allele
Fig. 4 Fold increase of
luciferase activity for the
eight PON1 5′UTR haplo-
types in ARPE19 cells. The
luciferase activity of the re-
porter construct containing
the TCG haplotype was set
to 1. SNP order in haplo-
types from left to right: -
107, -126, and −162. Error
bars show confidence inter-
vals, CI095 %. Displayed
are results from a represen-
tative experiment with eight
technical replicates
Table 4 Effects of 5′UTR haplotypes on luciferase reporter
activity
SNP Haplotypea Fold increase
in luciferase
activityb
P valuec
1 2
−107 CCA TCA 1.4 <0.001
CCG TCG 1.4 0.016
CGA TGA 1.3 0.030
CGG TGG 1.0 0.984
−126 CCA CGA 1.6 <0.001
CCG CGG 1.2 0.094
TCA TGA 1.4 <0.001
TCG TGG 0.9 0.242
−162 CCA CCG 2.1 <0.001
CGA CGG 1.6 <0.001
TCA TCG 2.0 <0.001
TGA TGG 1.2 0.030
The comparison is based on haplotypes that differ at a single
position. Displayed are results for a representative experiment
shown in Fig. 4
a SNP order in haplotype, from left to right is −107, -126,
and −162
b Fold increase in luciferase activity, haplotype 1 versus
haplotype 2
c Two-tailed t test
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caused up-regulation of transcription in cultured kidney
and liver cell lines (Brophy et al. 2001). These data,
together with our findings, indicate that the position at
−162 has regulatory function at both steps of gene ex-
pression, transcription, as well as translation. Alternative-
ly, a sole effect on transcription of the luciferase reporter
cannot be excluded. In our study, the two other investi-
gated SNPs at positions −107 and −126 caused only
minor changes in luciferase activity. In the literature, no
effect of the SNP at −126 has been reported, but the
minor allele C at position −107 has been shown to
increase transcription of a luciferase reporter gene in
HepG2 and HEK293 cells (Brophy et al. 2001). Taking
these data together, we conclude that the three SNPs
support different activities for PON1 gene expression.
It is important to note that the luciferase reporter
assays did not yield the same results in the two different
cell lines tested. As cell and tissue-specific regulation of
gene expression is a well-known phenomenon, it is not
surprising that gene expression control potential within
the 5′UTR of PON1 is manifested in ARPE19 cells, but
not in HEK293 cells. The latter cells, derived from kid-
ney, do not seem to be implicated in the AMD pathology,
while ARPE19 cells, derived from retinal pigment epi-
thelium, do (Kinnunen et al. 2012). In this context, it is
plausible that the relevant SNP at position −162 exerts a
cell type-specific effect in favor of AMD. Since Pon1 is
expressed in the retinal pigment epithelium in mice (data
not shown), further studies will provide crucial informa-
tion to clarify these assumptions.
A number of factors such as blood pressure, usage
of antihypertensive medication, blood cholesterol, or
blood levels of high-density lipoprotein were shown to
be associated with the development of neovascular
AMD (Hyman et al. 2000). As the mean age of the
population studied here is 79.5 years, it can be
expected that some of the factors (e.g., increased
arterial blood pressure) are present in the study
population—assumingly randomly distributed across
the participants. An influence of the proposed cardio-
vascular risk factors on the outcome of the treatment
of neovascular AMD using ranibizumab has not yet
been shown. Hence, it remains speculative whether or
not such risk factors may have had an impact in the
current study population and the reported outcomes.
Many open questions remain on the involvement of
PON1 in AMD pathology. As our patients were diag-
nosed with the end stage neovascular AMD, our results
cannot account for a potential role of PON1 as a trigger
for the onset of AMD or as an accelerator during the
progression of the disease, or maybe both. Our and other
previous association studies imply the involvement of
PON1 at the late stage of the disease. An alternative
mechanism may exist, where PON1 enzyme changes
are secondary to other events, present at early stages of
AMD. For example, paraoxonase activity in serum is
decreased in AMD patients. As AMD is considered to
be a chronic inflammatory disease and the PON1 tran-
scription levels in liver are known to be down-regulated
in response to infections, it seems feasible that PON1
down-regulation and decreased activity are the outcome
of primarily inflammation events. Cross talk between
PON1 levels and inflammatory response could be medi-
ated by the oxLDL, which can induce expression of
genes involved in an inflammation by stimulating various
transcription factors (Maziere and Maziere 2009). Our
results provide insights in the action of PON1, but further
investigation is required for a deeper understanding of the
contribution of PON1 in the pathology of AMD.
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SUPPLEMENTARY INFORMATION 
Supplementary Table S1. Linkage disequilibrium measurements for seven 
SNPs within the regulatory region of the PON1 gene.  
Data calculated using the control dataset (Table 2). D` is given in the upper right 
half and the R2 in the lower left half.  
 
SNP rs705379 rs705380 rs705381 rs854571 rs854572 rs854573 rs757158 
rs705379  1 1 0.90 0.91 0.93 0.93 
rs705380 0.06  1 1 1 1 0.93 
rs705381 0.33 0.19  0.93 0.93 0.94 0.693 
rs854571 0.36 0.14 0.63  1 0.99 0.79 
rs854572 0.76 0.07 0.31 0.49  1 1 
rs854573 0.28 0.19 0.88 0.71 0.36  0.73 
rs757158 0.67 0.07 0.20 0.35 0.87 0.22  
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3.1.2 PON1 5’UTR haplotypes regulate gene expression in Caco-2 cells 
 
Unpublished data 
 
Contributors 
Jadwiga Oczos1, Barbara Kloeckener-Gruissem1 and Wolfgang Berger1  
1 Institute of Medical Molecular Genetics, University of Zurich, Schwerzenbach, Switzerland 
 
Personal contribution 
Cloning, expression studies, statistical analysis 
 
PURPOSE 
Our previous study has shown that various PON1 5’UTR haplotypes exert cell-
specific regulation of gene expression in vitro (section 3.1.1 of this thesis, Oczos et 
al., 2013). To further investigate this phenomenon, we tested DNA constructs 
containing different PON1 5’UTR haplotypes in the colon epithelium-derived cell 
line, Caco-2. We chose Caco-2 cells because of their epithelial characteristics and 
since they are known to express PON1 protein (Shamir et al., 2005). 
 
METHODS 
Eight DNA constructs containing all possible haplotypes of the PON1 5’UTR cloned 
into the pFirefly vector (pGL3-Control vector; Promega, Madison, WI, USA) were 
obtained as previously reported (section 3.1.1), and used in a functional assay in 
Caco-2 cells, a colon carcinoma-derived cell line (American Type Culture Collection 
(ATCC), Manassas, VA, USA; product ATCC-HTB-37). Of note, the PON1 5’UTR 
fragment was inserted downstream of the SV40 promoter. Therefore, we assume 
that both the PON1 5’UTR and the Luciferase coding sequence were transcribed 
from the strong viral promoter and we could assay an effect of the PON1 fragment 
on mRNA folding and consequently on the protein synthesis, as measured by 
luciferase reporter activity. 
Caco-2 cells at passage 90-92 were seeded on 24-well plates (8104 
cells/well) in 1 ml DMEM, 10% FBS, and 1% penicillin/streptomycin and cultured 
at 37°C in 5% CO2 in air. Twenty-four hours later, cells were transfected using    
0.75 l X-tremeGENE9 transfection reagent (Roche Diagnostics, Indianapolis, IN, 
USA), 250 ng pFirefly construct, and 25 ng pRenilla construct per well. Forty-eight 
hours after transfection cells were harvested and luciferase activity was analyzed 
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using Dual-Glo Luciferase Assay System according to the manufacturer’s protocol 
(Promega) and measured on a BioTek Synergy microplate reader (BioTek 
Instruments, Winooski, VT, USA). Data were normalized to the Renilla luciferase 
activity. The experiment was conducted four times with four replicates each. 
 
RESULTS 
Various PON1 5’UTR haplotypes affected differently gene expression in Caco-2 cells, 
as measured by luciferase reporter activity (Fig. 13). To assess contribution of each 
individual SNP to observed alterations, we performed a pairwise comparison 
between haplotypes differing at only one position. The SNP at position -162 
appeared to be responsible for detected differences, with the A nucleotide causing 
an up to 1.6-fold increase in luciferase activity (Fig. 13 and Table 1). Effect of the 
two other polymorphisms on the gene expression was negligible and not consistent 
between repeated experiments. 
 
Figure 13. Luciferase activity for the eight PON1 5’UTR haplotypes in Caco-2 cells. 
SNP order in haplotypes from left to right: -107, -126, -162. Luciferase activity of the 
reporter construct containing the TGG haplotype was set to 1. Shown are mean values ± SD 
of N = 4. Two-tailed t test revealed highly significant differences in luciferase activity 
between haplotypes differing at SNP -162. A p-value of less than 0.05 was considered 
significant; ***p<0.001.  
 
DISCUSSION 
PON1 5’UTR haplotypes affected gene expression in Caco-2 and ARPE19 cells 
(section 3.1.1) in a similar way. In both cell lines the SNP at position -162 caused 
alterations in luciferase reporter activity. In contrast, tested PON1 haplotypes did 
not affect expression levels in HEK293 cells (section 3.1.1). Detected differences 
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between the three cell lines may be attributed to cell-specific trans-acting factors 
controlling translation (Di Liegro et al., 2014). Since both Caco-2 and ARPE19 cells 
are of epithelial origin, factors specific to epithelium might be involved. It is also 
possible that such regulatory mechanisms contribute to the previously reported 
tissue-specific differences in the expression of human PON1 (Ng et al., 2005). 
 
    
 SNP Haplotype* Fold increase  
in luciferase 
activity† 
P value‡ 
 1 2 
-107 CCA TCA 1.1 0.014 
 CCG TCG 1.1 ns 
 CGA TGA 1.2 0.001 
 CGG TGG 1.1 0.010 
-126 CCA CGA 0.9 0.018 
 CCG CGG 1.1 ns 
 TCA TGA 1.0 ns 
 TCG TGG 1.1 ns 
-162 CCA CCG 1.4 <0.001 
 CGA CGG 1.6 <0.001 
 TCA TCG 1.4 <0.001 
 TGA TGG 1.5 <0.001 
Table 1. Effects of the PON1 5’UTR haplotypes on the luciferase reporter activity in 
Caco-2 cells. 
Numerical representations of the results shown in figure 13. Compared are haplotypes 
differing at a single position: -107, -126, or -162. * SNP order in haplotypes from left to 
right:  -107, -126, -162. † Fold increase in luciferase activity of haplotype 1 versus haplo-
type 2. ‡ Two-tailed t test was used to analyze statistical significance. A p-value of less than 
0.05 was considered significant; ns, non-significant. 
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3.2 The contribution of SNPs and private mutations in PON1 
gene to coronary artery disease (CAD)  
 
Unpublished data 
 
Contributors 
Jadwiga Oczos1, Meliana Riwanto2,3, Ulf Landmesser2,3, Barbara Kloeckener-
Gruissem1 and Wolfgang Berger1  
1 Institute of Medical Molecular Genetics, University of Zurich, Schwerzenbach, Switzerland 
2 Cardiology, Cardiovascular Center, University Hospital Zurich, Zurich, Switzerland  
3 Cardiovascular Research, Institute of Physiology, University of Zurich, Zurich, Switzerland 
 
Personal contribution 
Design of the case-control study, genotyping, statistical analysis 
 
PURPOSE 
Studies on Pon1–/–, Pon1–/–/ApoE–/– and transgenic mice expressing human PON1 
have demonstrated protective, anti-atherosclerotic function of PON1 (Rozenberg et 
al., 2003; Shih et al., 1998; Shih et al., 2000; Tward et al., 2002). Additionally, lower 
serum paraoxonase activity levels have been implicated in CAD (MacKness et al., 
2000b). However, association studies between SNPs within PON1 coding sequence 
and atherosclerosis or CAD led to contradictory results (Wheeler et al., 2004). To 
clarify the interplay between PON1 genotype, serum PON1 activities and the 
disease status we performed a comprehensive study in collaboration with the 
Cardiovascular Center at the University Hospital Zurich. The project had the 
following specific aims: (i) to examine whether SNPs within the PON1 are 
associated with CAD in the Swiss population; (ii) to identify possible novel DNA 
sequence alterations in PON1 that contribute to CAD; (iii) to study correlation 
between PON1 genotypes, HDL-associated PON1 enzymatic activities and CAD 
(Besler et al., 2011). 
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METHODS 
Patients 
Patients with stable coronary artery disease (CAD) or acute coronary syndrome 
(ACS) between 40 and 70 years of age were consecutively recruited into the study 
at the University Hospital of Zurich (ethics committee approval: KEK-1471). The 
diagnosis of CAD and ACS was made according to guidelines of the American Heart 
Association (Anderson et al., 2007). Age- and sex-matched control subjects were 
enrolled by the Blood Donation Service of the University Hospital Zurich and had 
no cardiovascular risk factors or accompanying disorders. A detailed description of 
the recruitment criteria has been published previously (Besler et al., 2011).  
 
Genotyping 
Genomic DNA extraction and genotyping were performed as described in section 
3.1.1 above (Oczos et al., 2013). Additionally, the entire PON1 coding region 
including splice sites was sequenced by Sanger DNA sequencing using primer pairs 
listed in table 2.  
Exon Forward 5’ → 3’ Reverse 5’ → 3’ 
1 CCTTTCCCATGGCAATTTAC TTAACAGCCTGGACCCAACT 
2 CCTGGAAAAATTGCAGGAAA GGACAGAATTGAACAGGCACA 
3 CCAGTTTCAAGTGAGGTGTGA TTTATTTGAAAGTGGGCATGG 
4 CTGTGGTTTGGAGCAGTCAA TTGGCATGTTTTTCTGTTTTTG 
5 ATTCCATCTGCCTGACATCC CCTACTCTGGCCAAAAGGAA 
6 AGACAGTGAGGAATGCCAGTT TCTCCTGAGAATCTGAGTAAATCC 
7 GGGTTCCATTTTCCATTCCT TCTCACCCACCCCAATTAAG 
8 GACCAAGGACAAGAGGCAAC AAAACAGTAGCTGGGAATAAAGTCA 
9 GGCTTCTTATGGAGGATGACC CACTGGGTCCTCGGAATATG 
Table 2. DNA sequence of primers used for Sanger DNA sequencing. 
Sequencing primers were designed by Primer3 (v. 0.4.0; http://frodo.wi.mit.edu/primer3, 
provided in the public domain by Massachusetts Institute of Technology, Cambridge, MA), 
and synthesized by Microsynth (http://www.microsynth.ch; Balgach, Switzerland). Annea-
ling temperatures were established empirically and varied between 54 and 60°C. 
 
Design of the case-control study 
An online sample size calculator (http://sampsize.sourceforge.net/iface/s3.html) 
was used to estimate number of samples needed to collect in order to achieve 80% 
power to detect the minimum odds ratio (OR) of 2 with the error rate  = 0.05. We 
designed our study based on the power calculation for the polymorphism rs705381 
characterized by relatively low minor allele frequency (MAF = 0.167, dbSNP, 
https://www.ncbi.nlm.nih.gov/SNP/, HapMap-CEU European population) among 
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the analysed SNPs, for which collection of 193 cases and 193 controls would ensure 
desired power. The same sample size would enable detection of the minimum      
OR = 3.1 for the polymorphism rs705380 with the lowest minor allele frequency 
(MAF = 0.042), and the minimum OR = 1.8 for the rs705379 and rs854572 with the 
highest MAF = 0.425 among the analysed SNPs. 
 
Statistical analysis 
For association studies, odds ratios and significance were calculated using 22 
contingency table provided on an open access Internet portal (http://faculty. 
vassar.edu/lowry/odds2x2.html). Odds ratios are given with 95% confidence 
intervals and Chi-square and P-values according to Pearson. Statistical significance 
was assumed at p<0.05.  
 
RESULTS 
This study in collaboration with the Cardiovascular Center at the University Hospi-
tal Zurich is an ongoing project that has not come to a completion. Preliminary 
results obtained until January 2013 will be presented. 
 
Association of the PON1 SNPs with coronary artery disease 
Genotypes of 9 SNPs: 2 within the coding region (rs662, rs854560), 3 within the 
5’UTR (rs705379, rs705380, rs705381), and 4 within the UUR (rs854571, 
rs854572, rs854573, rs757158) were determined from 39 CAD patients, 31 ACS 
patients, and 24 healthy control individuals (Table 3A, B). As described in the 
methods section, we would have to examine roughly 200 samples per each group to 
achieve sufficient power to detect differences in frequencies of the analysed alleles 
between the patient and the control groups. Analysis of the current sample size has 
the power to detect an OR of 4.5 and higher, thus only a relatively strong effect size. 
Nevertheless, we compared minor allele frequencies (MAFs) in the control group 
with the MAFs in both affected groups (CAD and ACS) by means of the odds ratio. 
Results of the statistical analysis presented in table 3 show lack of association 
between the analysed alleles with either CAD or ACS. 
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Table 3. Allele frequencies of the PON1 SNPs in CAD and ACS patients. 
Analysis of the allele frequencies in CAD patients (Table 3A) and ACS patients (Table 3B) compared 
to the healthy control individuals. Two analysed SNPs lie within the coding region (Ex6, exon6; and 
Ex3, exon3), another 3 within the 5’ untranslated region (5’UTR), and additional 4 SNPs map to the 
upstream untranscribed region (UUR). Minor allele frequencies (MAF) for a Caucasian population 
were taken from the dbSNP database (https://www.ncbi.nlm.nih.gov/SNP/, HapMap-CEU European 
population), and were calculated for the control and both patient (CAD and ACS) groups. Odds ratios 
(OR) with confidence intervals (CI) and P-values ( = 0.05) revealed no association between any of 
the analysed SNPs and any of the patient groups. For the polymorphism rs705380, P-value was not 
obtained because of too few counts for the minor allele C (n<5).  
 
Marker Major/ 
minor 
allele 
Position Region MAF 
dbSNP 
MAF 
Controls 
(n=24) 
MAF 
CAD 
(n=39) 
P 
value 
OR CI 
(95%) 
rs662 A/G c.575A>G 
(p.Q192R) 
Ex6 0.332 0.295 0.250 0.75 0.79 0.34-
1.86 
rs854560 T/A c.163T>A 
(p.L55M) 
Ex3 0.375 0.370 0.448 0.54 0.72 0.33-
1.59 
rs705379 T/C -107 5’UTR 0.425 0.476 0.500 0.81 0.91 0.43-
1.93 
rs705380 G/C -126 5’UTR 0.042 0.045 0.039 — 1.15 0.19-
7.22 
rs705381 G/A -162 5’UTR 0.167 0.227 0.224 0.86 1.02 0.42-
2.48 
rs854571 C/T -831 UUR 0.302 0.300 0.231 0.38 1.43 0.64-
3.19 
rs854572 C/G -908 UUR 0.425 0.438 0.423 1.00 0.94 0.46-
1.95 
rs854573 T/C -1075 UUR 0.230 0.271 0.205 0.40 1.44 0.62-
3.34 
rs757158 C/T -1740 UUR 0.376 0.420 0.395 0.78 0.90 0.44-
1.86 
Marker Major/ 
minor 
allele 
Position Region MAF 
dbSNP 
MAF 
Controls 
(n=24) 
MAF 
ACS 
(n=31) 
P 
value 
OR CI 
(95%) 
rs662 A/G c.575A>G 
(p.Q192R) 
Ex6 0.332 0.295 0.224 0.55 0.69 0.28-
1.69 
rs854560 T/A c.163T>A 
(p.L55M) 
Ex3 0.375 0.370 0.435 0.62 0.76 0.35-
1.66 
rs705379 T/C -107 5’UTR 0.425 0.476 0.466 0.92 1.04 0.47-
2.31 
rs705380 G/C -126 5’UTR 0.042 0.045 0.083 — 0.52 0.10-
2.83 
rs705381 G/A -162 5’UTR 0.167 0.227 0.233 0.86 0.97 0.38-
2.44 
rs854571 C/T -831 UUR 0.302 0.300 0.274 0.76 1.13 0.50-
2.58 
rs854572 C/G -908 UUR 0.425 0.438 0.414 1.00 0.91 0.42-
2.00 
rs854573 T/C -1075 UUR 0.230 0.271 0.226 0.58 1.27 0.53-
3.04 
rs757158 C/T -1740 UUR 0.376 0.420 0.387 0.73 0.87 0.41-
1.86 
A 
B 
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Screening for novel DNA sequence variants in PON1 in patients with CAD 
Sequencing of the entire PON1 coding region including splice sites and 5’UTR was 
performed for 5 healthy individuals and 9 CAD patients. No unknown sequence 
variants were discovered. We confirmed several of the 18 annotated SNPs within 
the PON1 gene that map to 5’UTR, coding and intronic regions. Genotype results for 
the three polymorphisms: T(-107)C within the 5’UTR, p.L55M in exon 3 and 
p.Q192R in exon 8, which are crucial from a functional and regulatory point of view 
(Furlong et al., 1988; Leviev and James, 2000), are presented in table 4. 
 
Sample ID Status rs705379         
T(-107)C 
rs854560  
c.163T>A 
(p.L55M) 
rs662  
c.575A>G 
(p.Q192R) 
70682A Healthy CC TT (LL) AA (QQ) 
70683A Healthy CT TA (LM) AA (QQ) 
70684A Healthy CT TA (LM) AA (QQ) 
70685A Healthy CT TT (LL) AG (QR) 
70686A Healthy TT TA (LM) AA (QQ) 
70687A CAD CC TT (LL) AA (QQ) 
70688A CAD CT TA (LM) AG (QR) 
70689A CAD TT AA (MM) AA (QQ) 
70690A CAD CT TT (LL) AG (QR) 
70691A CAD CT TA (LM) AA (QQ) 
70692A CAD CT TA (LM) AA (QQ) 
70693A CAD CT TT (LL) AG (QR) 
70694A CAD CC TT (LL) AA (QQ) 
70695A CAD CT TT (LL) AA (QQ) 
Table 4. Genotyping results for selected SNPs within PON1 gene. 
For the two non-synonymous PON1 SNPs (rs854560 and rs662) both genotypes 
and corresponding amino acids are given. L, leucine; M, methionine; Q, glutamine; 
R, arginine. 
 
DISCUSSION 
The study presented here showed no association between the genotyped PON1 
SNPs and either CAD or ACS patient groups. However, since analysis was 
performed only on a relatively small sample size, which enabled detection of a large 
(OR ≥ 4.5) but not a small effect, we can only make a clear statement on the lack of 
such a strong effect. Contribution of SNPs to a complex disease could be much 
smaller, e.g. OR = 1.5, as for the association between the PON1 SNPs and AMD 
described in section 3.1.1. Therefore, we plan to analyse additional cases and 
controls. CAD and ACS patients, as well as control subjects are consecutively 
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recruited at the Cardiovascular Center, University Hospital Zurich. Additional blood 
samples are collected for DNA extraction and the following genotyping to reach the 
planned sample size of 193 controls and 193 affected individuals. 
In parallel, for a subset of subjects, from whom HDL-associated PON1 
activity will be measured, we will perform sequencing of the entire PON1 coding 
region. Correlation analysis between the biochemical and genetic data will give an 
insight into the interaction between these factors in CAD pathology.  
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3.3 Function of PON1 in the mouse retina 
 
3.3.1 Lack of paraoxonase-1 alters phospholipid composition but not 
morphology and function of the mouse retina 
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Purpose. Biochemical and genetic analyses established a contribution of lipid 
metabolism to AMD pathology. PON1 (Paraoxonase 1) encodes an anti-oxidative 
protein involved in high density lipoprotein (HDL) function and was found to be 
associated with AMD. Here we used Pon1–/– mice to study the influence of PON1 on 
retinal physiology and to reveal the potential impact of PON1 on AMD aetiology.  
 
Methods. Laser capture microdissection served to isolate single retinal layers. 
Retinal function was assessed by ERG. Retinal and RPE morphology were 
monitored by fundus imaging, fluorescein angiography, light and transmission 
electron microscopy, and immunofluorescence microscopy. Levels of mRNA and 
composition of phospholipid species were determined by real-time PCR and LC-MS, 
respectively.  
 
Results. Adult (8-week old) Pon1–/– mice displayed normal retinal function and 
morphology, but their retinas contained reduced amounts of lysophosphatidyl-
cholines (LPCs) compared to controls. Aged (12-month old) Pon1–/– animals did not 
show any morphological or molecular signs of photoreceptor or RPE degeneration, 
or of accelerated aging. Photoreceptors of Pon1–/– and control mice were similarly 
susceptible to light damage.  
 
Conclusions. PON1 is not essential for normal development, function, ageing and 
the defense against light damage of the mouse retina. Reduced levels of LPCs in 
eyes of Pon1–/– mice may reflect a decreased activity of phospholipase A2 or altered 
anti-oxidative activity in aged eyes.  
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INTRODUCTION 
Age-related macular degeneration (AMD) is the leading cause of irreversible 
blindness and visual disability in the elderly population of industrialized countries. 
Various environmental risk factors, such as advanced age, cigarette smoking, diet, 
obesity, atherosclerosis, hypertension, inflammatory disease, as well as genetic 
predisposition have been implicated in this complex disease (Guymer and Chong, 
2006; Smith et al., 2001; Swaroop et al., 2007). The epidemiological risk factors 
point towards various molecular mechanisms that might be involved in the 
aetiology of AMD. Among those, cellular and extracellular oxidative stress, along 
with chronic inflammation are best-known to play a role in disease development 
and/or progression (Ambati et al., 2013; Handa, 2012; Khandhadia and Lotery, 
2010).  
Aging, the strongest risk factor for AMD is associated with structural and 
functional changes in Bruch’s membrane and the retinal-pigment epithelium (RPE). 
Drusen, a hallmark of AMD (Booij et al., 2010) are formed between RPE and Bruch’s 
membrane and contain polymorphous material. Major components of this material 
are lipid aggregates containing numerous lipoproteins and cholesterol (Curcio et 
al., 2011; Wang et al., 2010). These results established a connection between lipid 
metabolism and AMD aetiology, which was further confirmed by genetic studies. 
Genome-wide association scans identified several genes contributing to HDL 
metabolism to be associated with AMD, among them LIPC (hepatic lipase), CEPT 
(cholesterylester transfer protein), LPL (lipoprotein lipase), and ABCA1 (ATP-
binding cassette, sub-family A1) (Chen et al., 2010; Neale et al., 2010). We and 
others have also found an association of PON1 (paraoxonase 1), a gene involved in 
HDL function, with advanced AMD in single populations (Baird et al., 2004; Ikeda et 
al., 2001; Oczos et al., 2013). 
PON1 together with PON2 and PON3 forms a family of lactonases with 
antioxidant properties, which differ in sites of synthesis and mechanisms of action 
(Draganov and La Du, 2004). PON1 is mainly expressed in liver (Ng et al., 2005) and 
encodes a secreted enzyme with a broad spectrum of functions that favor the 
involvement of PON1 in AMD pathology. In particular, PON1 present in serum HDL 
inhibits LDL oxidation, or “neutralizes” oxidized LDL by hydrolyzing lipid    
peroxides (Mackness et al., 1991; Mackness and Durrington, 1995). Additionally, 
PON1 acts in an anti-inflammatory manner by reducing monocyte chemotaxis and 
adhesion to endothelial cells (Ahmed et al., 2003), inhibiting monocyte-to-
macrophage differentiation (Rosenblat et al., 2011), and directly suppressing 
macrophage pro-inflammatory responses (Aharoni et al., 2013). The anti-oxidant as 
well as the anti-inflammatory activities of PON1 suppress the formation of 
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atherosclerotic plaques, pathological lesions that share several properties with 
drusen (Curcio et al., 2010; Tabas et al., 2007). Whereas PON2 is an ubiquitous 
intracellular protein that can protect endoplasmic reticulum and mitochondria 
against reactive oxygen species (ROS) mediated damage (Altenhofer et al., 2010; 
Horke et al., 2007), PON3 acts similarly to PON1, as it is transported by HDL and 
protects HDL from oxidation (Draganov et al., 2000). 
The genetic studies mentioned above, biochemical analyses reporting lower 
serum paraoxonase activity in patients with AMD (Baskol et al., 2006), and reports 
showing that smoking reduces PON1 activity in serum (Isik et al., 2007; Solak et al., 
2005) are indications for a potential involvement of PON1 in the pathophysiology 
of AMD. Nevertheless, the role of PON1 in the eye has not been studied. Here we 
used Pon1–/– mice to investigate the role of PON1 in the retina/RPE to elucidate its 
potential contribution to retinal lesions and eye pathology. 
 
MATERIALS AND METHODS 
 
Mice 
Animals were treated in accordance with the regulations of the Veterinary 
Authority of Zurich and with the statement of The Association for Research in Vision 
and Ophthalmology for the use of animals in research. Wild type 129S6/SvEvTac 
mice were purchased from Taconics (Eiby, Denmark). Pon1–/– mice (B6.129X1-
Pon1tm1Lus/J) (Shih et al., 1998) were purchased from Jackson Laboratory (Bar 
Harbor, ME, USA), and genotyped by PCR using the following primers: common 
forward primer 5’-CTT GTC CAT CCT CAG CTT GT-3’, wild type reverse primer      
5’-CCG ATG GTT CTT GTA AAG TGC-3’, mutant reverse primer 5’-CTT GGG TGG AGA 
GGC TAT TC-3’. Pon1–/– mice were backcrossed for 10 generations onto the 
129S6/SvEvTac background prior to analyses. All mice were kept at the animal 
facility of the University Hospital Zurich in a dark-light cycle (12 h : 12 h) with 60 
lux of light at cage level and a normal chow diet.  
 
Light exposure 
Six- to 8-week old mice were dark adapted overnight (16 h). Pupils were dilated 
with 1% cyclogyl (Alcon, Cham, Switzerland) and 5% phenylephrine (Ciba Vision, 
Niederwangen, Switzerland) 30 minutes before exposure to 17,000 lux of white 
light for 2 hours. After light exposure mice were kept in darkness until the next day 
before being returned to cyclic light. Mice were killed at different time points after 
light offset (N=3 for each group) and retinas, eyecups, or whole eyeballs were 
removed. Mice that were dark-adapted but not exposed to light served as controls. 
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Laser capture microdissection 
Eyes of 8-week old wild type and Pon1–/– mice were enucleated, immediately 
embedded in tissue freezing medium (Leica Microsystems Nussloch GmbH, 
Nussloch, Germany), and frozen in a 2-methylbutane bath cooled in liquid nitrogen. 
Retinal sections (20 m) were collected on Arcturus PEN Membrane Glass Slides 
(Applied Biosystems, Foster City, CA, USA), fixed (5 min acetone), air dried (5 min), 
and dehydrated (30 sec 100% ethanol, 5 min xylol). Retinal layers were isolated 
using an Arcturus XT Laser Capture Microdissection system (Bucher Biotec AG, 
Basel, Switzerland) and Arcturus CapSure Macro LCM Caps (Applied Biosystems). 
RNA was isolated using the Arcturus PicoPure RNA Isolation Kit (Applied 
Biosystems) according to the manufacturer’s directions, including a DNase 
treatment to remove residual genomic DNA. cDNA was synthesized using random 
hexamer primers (High-Capacity cDNA Reverse Transcription Kit; Applied 
Biosystems), and further analyzed by real-time PCR as described in section `RNA 
preparation and semi-quantitative real-time PCR`. 
 
Electroretinogram (ERG)  
Electroretinograms were recorded from both eyes simultaneously following 
published protocols (Seeliger et al., 2001; Tanimoto et al., 2009). Briefly, mice were 
dark-adapted overnight and anesthetized the next day with ketamine (66.7 mg/kg; 
Ratiopharm GmbH, Ulm, Germany) and xylazine (11.7 mg/kg; Bayer HealthCare, 
Monheim, Germany). Pupils were dilated with 1% cyclogyl and 5% phenylephrine 
30 min before performing single flash ERG recordings under dark-adapted 
(scotopic) and light adapted (photopic) conditions. Light adaptation was 
accomplished with low background illumination starting 5 min before photopic 
recordings. Single white-flash stimulus intensities ranged from –3.7 to 1.9 log 
cd*s/m2 under scotopic and from –0.6 to 2.9 log cd*s/m2 under photopic 
conditions, divided into 12 and 8 steps, respectively. Ten responses per flash 
intensity were averaged with an interstimulus interval of either 4.95 sec or 16.95 
sec (for 1.4, 1.9, 2.4, and 2.9 log cd*s/m2). 
 
Fundus imaging and fluorescein angiography 
Pupils were dilated with 1% cyclogyl and 5% phenylephrine. After 30 min mice 
were anesthetized with ketamine (66.7 mg/kg) and xylazine (11.7 mg/kg) and 
corneas were moistened with 2% methocel (OmniVision, Puchheim, Germany). 
Fundi were monitored and photographed using a mouse imaging system (Micron 
III, Phoenix Research Laboratories, Pleasanton, CA, USA). Fluorescein solution (2% 
in PBS; AK-FLUOR; Lake Forest, IL, USA) was injected intraperitoneally and eyes 
were analyzed immediately. 
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Light and transmission electron microscopy  
Eyes were enucleated and fixed in 2.5% glutaraldehyde in 0.1 M cacodylate buffer 
(pH 7.3) at 4˚C overnight. Cornea and lens were removed and eyecups cut dorso-
ventrally through the optic nerve head. Trimmed tissue was washed in cacodylate 
buffer, incubated in osmium tetroxide for 1 hour at room temperature, dehydrated, 
and embedded in Epon 812. For light microscopy (Axioplan 2, Zeiss, Feldbach, 
Switzerland) semi-thin cross sections (500 nm) were cut and counterstained with 
toluidine blue. For transmission electron microscopy (TEM), ultra-thin sections (50 
nm) were stained with uranyl acetate and lead citrate, and analyzed using a Philips 
CM100 transmission electron microscope. 
 
RPE flat mount preparation and analysis 
Unless stated otherwise, all procedures were conducted at room temperature. Eyes 
were enucleated and incubated in 2% paraformaldehyde (PFA) in 0.1 M phosphate 
buffer pH 7.4 (PB, 0.081M Na2HPO4, 0.019M NaH2PO4H2O) for 5 min. Cornea and 
lens were removed and the remaining tissue was left in PB-salt (PB containing 140 
mM NaCl and 2.7 mM KCl) for 20 min to allow the retina to separate from the 
eyecup. The retina was gently removed and the eyecup containing the RPE cut into 
a “clover-leaf” shape and post-fixed in 4% PFA in PB for 1 hour. Flatmounts were 
blocked with blocking solution (3% normal goat serum, 0.3% Triton X-100 in PBS) 
for 1 hour and incubated with the primary antibody anti--catenin (1:300 in 
blocking solution; BD Biosciences, Allschwil, Switzerland) overnight at 4°C. After 
washing 3  10 min in PBS, Cy3-conjugated anti-mouse secondary antibody (1:200 
in blocking solution; Jackson ImmunoResearch, Suffolk, UK) and Alexa Fluor 488-
phalloidin (1.3 U/ml in blocking solution; Applied Biosystems) were applied for 2 
hours. After washing, cell nuclei were stained with Hoechst (2 µg/ml in PBS; Sigma 
Aldrich, Buchs, Switzerland) for 30 min. Flatmounts were washed with PBS and 
mounted with anti-fade medium (10% Mowiol 4–88 (w/v); Calbiochem, San Diego, 
CA, USA; 25% glycerol (w/v); 0.1% 1,4-diazabicyclo[2.2.2]octane in 100 mM Tris, 
pH 8.5). RPE sheets were examined using a digitalized fluorescence microscope and 
an ApoTome module (Axioplan 2, Zeiss, Switzerland).  
Morphometric measurements including eccentricity and form factor were 
performed with CellProfiler software (Carpenter et al., 2006). Phalloidin-stained 
images (magnification: 20x) were illumination corrected and analyzed using the 
“Tissue Neighbours” pipeline with the background adaptive thresholding method. 
At least N=700 RPE cells per group were examined. RPE cells were counted in 4 
quadrants of 176.8  235.3 m (1040  1384 pixels), approximately 800-900 m 
temporal, dorsal, nasal and ventral of the optic nerve head. Three animals per 
genotype and condition were analyzed. 
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RNA preparation and semi-quantitative real-time PCR 
Retinas were removed through a slit in the cornea and placed in an Eppendorf tube. 
The rest of the eye (eyecup without lens) was isolated separately. All samples were 
immediately frozen in liquid nitrogen and stored at -80°C. Total RNA from retina 
and eyecups was prepared using the High Pure RNA Isolation Kit (Roche 
Diagnostics, Mannheim, Germany) or the RNeasy kit (Qiagen, Hilden, Germany), 
respectively. RNA isolations included a DNase treatment to digest residual genomic 
DNA. Equal amounts of RNA were reverse transcribed using oligo(dT) primer and 
M-MLV reverse transcriptase (Promega, Madison, WI, USA). Real-time PCR with 
specific primer pairs (Table 1), a polymerase ready mix (LightCycler 480 SYBR 
Green I Master Mix; Roche Diagnostics, Basel, Switzerland), and a thermocycler 
(LightCycler, Roche Diagnostics) were used to study gene expression. Three 
animals per time point were analyzed in duplicates. Signals were normalized to     
-actin and relative gene expression was calculated using the Ct method. 
 
Lipid extraction 
For most analyses, lipids were extracted from retinal and eyecup tissue together. 
We will refer to these samples as “retina/eyecup” samples from here on. In some 
instances retinas and eyecups were isolated separately and named accordingly. 
Isolated tissue samples were immediately frozen in liquid nitrogen and stored at     
-80°C. Retina/eyecup samples were homogenized in lysis buffer (PBS, 0.2% Triton 
X-100 [vol./vol.]) using a Precellys 24 tissue homogenizer (Bertin Technologies, 
Montigny-le-Bretonneux, France). The protein content was measured using the 
Bradford assay. Total lipids were extracted from aliquots of homogenized tissue 
containing 40 mg of protein. Extraction was conducted according to the Bligh and 
Dyer (Bligh and Dyer, 1959) procedure in the presence of 200 ng of the internal 
standards PG 17:0/17:0, PA 14:0/14:0, PE 14:0/14:0, PC 14:0/14:0, PC 24:0/24:0, 
LPC 17:0, SM d18:1/12:0 and Cer d18:1/17:0 (Avanti Polar Lipids, Alabaster, AL, 
USA). Samples were mixed with 375 µl of methanol/chloroform (2:1, v/v) and 
vortexed, followed by the addition of 100 ml water and 125 ml chloroform. The 
mixture was shaken for 15 minutes and centrifuged at 16100×g for 5 minutes at 
25°C. The lower phase was collected, 250 ml chloroform added, shaken for             
15 minutes and centrifuged at 16100g for 5 minutes at 25°C. All lower phases 
were combined and evaporated to dryness under a stream of nitrogen. Dried 
material was reconstituted in 200 ml of a mixture of mobile phases A (80%) and B 
(20%) (see below). 10 ml was injected into the LC-MS system for PL analysis. 
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Table 1. Primers and conditions for real-time PCR 
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Analysis of the retina/eyecup lipidome: LC-MS instrumentation and 
chromato-graphic conditions  
Analyses of six different phospholipid (PL) classes: phosphatidylcholines (PC), 
sphingomyelins (SM), phosphatidylethanolamines (PE), phosphatidylglycerols 
(PG), phosphatidic acids (PA) and ceramides/hexosylceramides (Cer/HexCer) were 
performed by utilizing liquid chromatography and mass spectrometry. Details of 
the method are described in the supplementary materials. Briefly, total lipid 
extracts were analyzed on a LC-MS system consisting of a Rheos 2200 pump (Flux 
Instruments, Reinach, Switzerland), an HTC PAL autosampler (CTC Analytics, 
Zwingen, Switzerland) and a TSQ Quantum Access triple quadrupole mass analyzer 
(Thermo Fisher Scientific, Waltham, MA, USA). Separation of lipid extracts was 
performed on a diol silica-based column (QS Uptisphere 6 OH, 150  2.1 mm, 5 m, 
Interchim, France). Mobile phase A was a mixture of hexane/isopropanol/water 
(70:30:2, v/v) with 15 mM ammonium formate. Mobile phase B was isopropanol/ 
water (50:2, v/v) with 15 mM ammonium formate.  The solvent-gradient was          
0-7 min A/B (%) 80/20, 8-10 min A/B (%) 60/40, 11-23 min A/B (%) 40/60 and 
25-30 min A/B (%) 80/20 at a flow rate of 0.35 ml/min. The column was 
maintained at 30°C. Mass spectrometry was performed in positive ionization mode 
with the following parameters: 4500 V spray voltage, skimmer voltage 2 - 14 V 
(depending on the scan mode), 250°C capillary temperature, and 10 and 6 
(arbitrary units) sheath and auxiliary N2 gas, respectively. Molecular masses 
provided by a neutral loss and precursor scan were used to selectively detect 
specific phospholipids. A neutral loss of masses m/z 115 and 189 from [M+NH4]+ 
ions were used for analysis of PA and PG lipids, respectively. A precursor ion scan 
of m/z 184 specific for phosphocholine containing lipids was used for PC, SM and 
LPC. A neutral loss scan of m/z 141 was used for PE and a precursor scanning of 
m/z 264 was applied for screening of Cer. Acquired data were analyzed using 
Xcalibur (version 2.0.6, Thermo Scientific). The structure of the head groups were 
determined from the type of MS/MS scanning. Molecular species were identified by 
using LIMSA (Haimi et al., 2006). All species were assigned to the lipid classes and 
species with a defined total number of carbon atoms and double bounds in O-linked 
fatty acids. Data were corrected for isotopic overlap. Quantification was based on 
calibration curves for seven PL standards including PC 16:0/18:2, SM d18:1/16:0, 
LPC 16:0, PE 18:0/18:0, Cer d18:1/14:0, PG 16:0/16:16 and PA 14:0/14:0. The 
calibration curves were constructed by plotting the PL/IS peak area ratios against 
the nominal concentration of the standards. The concentrations for the individual 
lipid classes were calculated from linear regressions of the calibration curves. 
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Statistical analysis 
Semi-quantitative real-time PCR and morphometric analysis of the RPE flat mounts: 
Statistical analyses were performed using Prism4 software. All data are given as 
means ± standard deviation (SD) of three animals per group. Statistical differences 
of means were calculated using 2-way ANOVA followed by a Bonferroni post-hoc 
test. A p-value of less than 0.05 was considered significant.  
Lipidomic analysis: Statistical analyses were performed using SPSS, version 19 
(SPSS Switzerland, Zurich, Switzerland). Normality of the data was determined by 
using Kolmogorov-Smirnov test. Since not all lipid species had normally distributed 
values nonparametric Mann-Whitney U test was used. The Mann-Whitney U test 
was applied for comparison between Pon1–/– and wild type mice. Bonferroni 
correction was applied to adjust the p-value for multiple comparisons (37 
statistical tests). A p-value of 0.001 or below was considered significant. Data are 
presented as median with lower and upper range values. 
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RESULTS 
Paraoxonase-1 is highly expressed in the RPE 
To evaluate the expression pattern of paraoxonases in the retina we isolated the 
retinal pigment epithelium (RPE), the outer nuclear layer (ONL), the inner nuclear 
layer (INL) and the ganglion cell layer (GCL) by laser capture microdissection and 
analyzed levels of Pon1, Pon2 and Pon3 mRNA by semi-quantitative real-time PCR 
(Fig. 1). Expression of monocarboxylate transporter, member 3 (Mct3; RPE), 
guanine nucleotide binding protein, alpha transducing activity polypeptide (Gnat1; 
ONL), visual system homeobox 2 (Vsx2; INL), and melanopsin (Opn4; GCL) were 
used as layer-specific markers and showed that cross-contamination between 
collected layers was minimal. In wild type mice, Pon1 was highest expressed in the 
RPE with 267-, 590-, and 651-fold higher levels than in ONL, INL, and GCL, 
respectively. Similarly, Pon3 was most abundant in the RPE (45-, 43-, 72-fold higher 
levels than in ONL, INL, and GCL, respectively). Pon2 content was comparable in the 
RPE and the INL, approximately 25- and 9-fold higher than in ONL and GCL, 
respectively. 
Even though Pon1–/– mice have a neomycin cassette inserted into exon 1 of 
Pon1 and do not produce a functional PON1 protein (Shih et al., 1998), the RNA 
transcript can still be detected. Interestingly, we found differential effects of the 
neomycin insertion on Pon1 expression in RPE and neuronal retina. Whereas 
expression of the disrupted Pon1 gene was 33-fold decreased in the RPE, it was   
15-fold increased in the INL and 6-fold in the GCL, indicating differential regulation 
of Pon1 expression in RPE and neuroretina. Levels of Pon2 and Pon3 transcripts 
were not significantly affected by the lack of functional PON1. 
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Figure 1. Pon1 is highly expressed in the RPE. 
Retinal pigment epithelium (RPE), outer nuclear layer (ONL), inner nuclear layer (INL) 
and ganglion cell layer (GCL) were isolated from wild type (grey bars) and Pon1–/– mice 
(black bars) using laser capture microdissection. Relative gene expression was 
determined by semi-quantitative real-time PCR in each individual layer. Values were 
normalized to -actin, and expressed relative to levels in the RPE of Pon1–/– mice, which 
were set to 1. Shown are mean values ± SD of N=3. Expression of Mct3 (marker for 
RPE), Gnat1 (marker for ONL), Vsx2 (marker for INL), and Opn4 (marker for GCL) was 
determined to monitor contamination between the isolated retinal layers. 
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Absence of PON1 does not compromise retinal function and architecture 
To evaluate whether PON1 is important for normal retinal development, ageing and 
function, we analyzed 8-week and 1-year old mice. Pon1–/– mice showed regular 
retinal architecture and no signs of RPE or photoreceptor degeneration at either 
age (Fig. 2A). Similarly, funduscopy and fluorescein angiography revealed no 
retinal or vascular defects in Pon1–/– mice (Fig. 2B). Normal scotopic and photopic 
ERGs with a- and b-wave amplitudes similar to wild types (Fig. 2C) supported the 
conclusion that Pon1–/– mice developed a normal and functional retina. 
 
Lack of PON1 does not affect RPE morphology 
Since we found high Pon1 expression in the RPE and PON1 was previously 
implicated in AMD (Baird et al., 2004; Baskol et al., 2006; Ikeda et al., 2001; Oczos 
et al., 2013), a disease strongly affecting RPE and Bruch’s membrane, we examined 
these structures in young and old mice. Transmission electron microscopy did not 
detect any obvious differences in the ultrastructure of RPE and Bruch’s membrane 
between Pon1–/– and wild type mice at any age (Fig. 3A). Also, RPE microvilli and 
basal infoldings appeared normal and no AMD-like features such as Bruch’s 
membrane thickening or sub-RPE deposits (Ramkumar et al., 2010) were present 
in any of the analyzed animals up to one year of age.  
To analyze RPE cell morphology on a larger scale, we prepared RPE flat 
mounts. The RPE monolayer is normally formed by a relatively uniform array of 
polygonal cells containing one to two centrally positioned nuclei. The regular shape 
is maintained by adherens and tight junctions, as well as by the actin-myosin 
cytoskeleton, whose components may serve as markers of epithelial integrity. We 
monitored the RPE cell boundaries by immunofluorescent staining for -catenin 
(adherens junctions) and phalloidin (F-actin) and did not observe any abnormal-
lities in mice lacking PON1 up to one year of age (Fig. 3B). This was further 
supported by morphometric analyses, which were used to quantitatively assess 
RPE cell shape. The eccentricity (ECC) and form factor (FF) are two measures of 
distortion from a circular shape, whose values vary between 0 and 1, with ECC=0 
and FF=1 for a perfect circle. These factors did not differ significantly between cells 
in the RPE of Pon1–/– and age-matched wild type mice (Fig. 3C).    
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Figure 2. Lack of PON1 does not compromise retinal architecture and function 
(A) Retinal morphology of Pon1–/– and control mice (WT) at 8 weeks and 1 year of age. Shown are represen-
tative sections of N=3. RPE, retinal pigment epithelium; POS, photoreceptor outer segments; PIS, photore-
ceptor inner segments; ONL, outer nuclear layer; INL, inner nuclear layer. Scale bar: 50 m. (B) Funduscopy 
(top panels) and fluorescein angiography (bottom panels) of WT and Pon1–/– mice at 8 weeks of age. Shown 
are representative images of N=3. (C) Scotopic and photopic electroretinograms from WT and Pon1–/– mice 
at 8 weeks of age. Top panels: representative traces from individual mice. Bottom panels: scotopic a- and b-
wave amplitudes, as well as photopic b-wave amplitudes as a function of light intensity. N=3. 
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Figure 3. Lack of PON1 does not affect RPE morphology  
The RPE was analyzed in Pon1–/– and control (WT) mice at 8 weeks (8w) and 1 year (1y) 
of age. (A) Transmission electron micrographs of the RPE and adjacent tissues. Shown are 
representative sections of N=3 for each panel. N, nucleus; BrM, Bruch’s membrane;            
BI, basal infoldings; MV, apical microvilli; M, melanosomes. Scale bar: 2 m. (B) RPE flat 
mounts immunostained for -catenin (red) and phalloidin (green). Nuclear staining 
(Hoechst) is visible in blue. Shown are representative microphotographs of N=3 for each 
panel. Scale bar: 50 m. (C) Morphometric analysis of RPE cells. Shown are mean values   
± SD of at least N=700 RPE cells examined per group. Two-way ANOVA revealed no 
significant differences in RPE cell shape between WT and Pon1–/– mice at 8w and 1y of age 
(p>0.05).  
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Gene expression in Pon1–/– mice 
To reveal whether the lack of PON1 influences expression of related genes or of 
genes encoding known PON1 interaction partners, we analyzed gene expression in 
retina and eyecup at 8 weeks and 1 year of age. Similar to the LCM data (Fig. 1), 
expression of Pon1 was lower in the neuronal retina compared to that in the eyecup 
(Fig. 4). Cross-contamination between RPE and neuronal retina was minimal as 
shown by the relative expression of Mct3 (RPE) and Gnat1 (retina) in both isolated 
compartments (Supplementary Table 1).  
In accordance with the LCM experiment, we found significant up-regulation of 
Pon1 mRNA expression in the retina of 8 week old Pon1–/– mice and down-
regulation in the eyecup. Since lack of the anti-oxidative PON1 protein may 
influence the oxidative balance in a tissue, expression of other anti-oxidative genes 
may be affected. However, both other members of the paraoxonase family (Pon2 
and Pon3), the two superoxide dismutases (Sod1 and Sod2), as well as heme 
oxygenase 1 (Hmox1) were similarly expressed in control and Pon1–/– mice (Fig. 4). 
Remarkably, we detected an age-related moderate decrease in the expression of 
Sod1, Sod2, Pon3 (retina and eyecup), Pon2 (retina), Pon1 and Hmox1 (eyecup) 
independently of the Pon1 genotype (Fig. 4 and Supplementary Table 1). 
Previous studies showed that the role of PON1 in HDL transport and function 
involves interaction with partner proteins, such as scavenger receptor class B 
(SCARB1, also known as SR-BI) and ATP-binding cassette transporter (ABCA1). 
Whereas SCARB1 facilitates acquisition of PON1 secreted from hepatocytes (James 
et al., 2010), interaction between PON1 and ABCA1 transporter enhances HDL-
mediated cholesterol efflux from macrophages (Rosenblat et al., 2005). Both 
SCARB1 and ABCA1 were previously shown to be involved in lipid efflux and 
reverse cholesterol transport in retina and RPE (Duncan et al., 2009), and this 
function might depend on interaction with PON1. Nevertheless, expression of 
Scarb1 was similar in control and Pon1–/– mice at either age.  The expression of 
Abca1 was also similar in old control and knockout mice, whereas expression in 
young Pon1–/– mice was variable in different sets of animals (see also Fig. 5), 
suggesting the influence of other, yet unknown factors. Further studies are 
required to investigate a potential functional connection between Pon1 and Abca1 
in the retina. 
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Figure 4. Expression of PON1-related genes 
Expression of genes related to PON1 function was determined by semi-quantitative real-time 
PCR in retinas (upper panels) and eyecups (lower panels) of wild type (white bars) and           
Pon1–/– mice (black bars) at 8 weeks (8w) and 1 year (1y) of age as indicated. Shown are mean 
values ± SD of N=3. Values were normalized to -actin, and levels in WT mice at 8w were set 
to 1. Two-way ANOVA with Bonferroni post-hoc analysis was used to test statistical signifi-
cance. A p-value of less than 0.05 was considered significant; **p<0.01; ***p<0.001. Shown are 
statistics for the comparison of expression levels in wt and Pon1–/– mice at 8w or 1y of age. 
See supplementary Table 1 for statistical analysis of age-dependent expression in wt and 
Pon1–/– mice. 
 
Alterations of phospholipid composition in retina/eyecup of Pon1–/– mice 
The retina contains very high levels of polyunsaturated fatty acids (PUFAs). The 
majority of retinal PUFAs is esterified to phospholipids (PLs), which build up the 
membranous disks of photoreceptor outer segments (Giusto et al., 2000). Due to 
their molecular structure and constant exposure to a photo-oxidative environment 
(Handa, 2012; Khandhadia and Lotery, 2010), retinal PLs are particularly prone to 
oxidative modifications. Based on the fact that PON1 can reduce lipid peroxidation 
in LDL and cell membranes (Ahmed et al., 2003; Mackness et al., 1991), we 
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hypothesized that PON1 might have a similar effect on retinal PLs, and thus affect 
their composition. To test this assumption, we employed a combination of liquid 
chromatography (LC) and mass spectrometry (MS) for the identification and 
quantification of retina/eyecup PLs from wild type and Pon1–/– mice.  
The overall phospholipid profile was similar in the retina/eyecup samples of 
wt and Pon1–/– mice at the age of 8 weeks. The most abundant PLs were 
phosphatidylcholines (PC) and phosphatidylethanolamines (PE) (Table 2). The 
most abundant PE species was PE 40:6, which possibly contained polyunsaturated 
C22:6n-3 docosahexaenoic (DHA) fatty acid at the sn-1 or sn-2 position. PC 40:6 was 
the third most abundant PC species after PC 32:0 and PC 34:1. Interestingly, highly 
unsaturated PC 44:12 and PE 44:12 species were identified in both mouse strains. 
They probably represent PC and PE lipids that were esterified with two molecules 
of DHA at the sn-1 and sn-2 position. The third abundant lipid class was 
sphingomyelin (SM). Among lysophosphatidylcholines (LPC), the most abundant 
species contained a DHA fatty acid (LPC 22:6). Ceramides/hexosylceramides 
(Cer/HexCer), phosphatidylglycerols (PG) and phosphatidic acids (PA) were found 
at very low concentrations, therefore we report only total concentrations of these 
three lipid classes. 
The major difference between 8-week old Pon1–/– and wt mice was seen for 
total LPC (p=0.001) and in particular for LPC 22:6 species (p=0.001), which were 
detected at significantly reduced levels in Pon1–/– mice (Table 2). These differences 
remained significant after Bonferroni correction for multiple testing. Analysis of 
PLs in wild type retinas and eyecups, which were isolated separately, revealed that 
LPC 22:6 was the most abundant LPC species in the retina, whereas it was almost 
absent in the eyecup (data not shown). Some polyunsaturated and mono-
unsaturated PCs as well as polyunsaturated PEs were also decreased in Pon1–/– 
mice (p<0.05). However, these differences missed significance after Bonferroni 
correction (Table 2). Other PL species were also not significantly different in      
Pon1–/– as compared to controls.  
Since aging is a major risk factor for the development of AMD, and lipid 
metabolism is known to be involved in the etiology of this disease, we characte-
rized the PL profiles of 1-year old wild type and Pon1–/– mice. In contrast to young 
adults at 8 weeks of age, levels of total LPC and LPC 22:6 species in 1-year old mice 
did not differ between the two mice strains (Table 3). Interestingly, age-related 
changes in the PLs profiles showed different trends in wild type and Pon1–/– mice. 
While control animals showed a trend for decreased levels of total LPC and LPC 
22:6 with age, Pon1–/– mice revealed almost no age-related changes in the content 
of those PLs (Table 3). 
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Table 2. Phospholipid species in the retina/eyecup samples from control (WT) and 
Pon1–/– mice at 8 weeks (8w) of age (page 77). 
Phospholipid (PL) analysis was performed by LC-MS. Content of PL classes and species is 
shown as nmol of PL per one mg of retina and eyecup proteins. Total phospholipids 
represent sum of molecular species of a given class and are presented for 
ceramides/hexosylceramides (Cer/HexCer), phosphatidylglycerols (PG) and phospho-
tungstic acids (PA).  Species pattern is displayed for phosphatidylcholines (PC), 
phosphatidylethanolamines (PE), sphingomyelins (SM) and lysophosphatidylcholines 
(LPC). Data values are displayed as median with range. N=10 for both genotypes. Statistical 
significance was determined by the Man-Whitney U test. After Bonferroni correction a p-
value of 0.001 corresponds to a significance level of 0.05. Statistically significant results are 
indicated in bold. An assignment of PL species includes number of carbon atoms and 
double bounds in both acyl chains (for example, PC 34:1 consist of 34 carbon atoms and 
one double bond and can correspond to the following species PC 16:0/18:1 or PC 
18:0/16:1, etc.). Sphingomyelin assignment comprises the number of carbon atoms and 
double bonds in both sphingoid base and in N-linked fatty acid.  
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Table 2. Phospholipid species in the retina/eyecup samples from control (WT) and 
Pon1–/– mice at 8 weeks (8w) of age. 
 
 
 
PLs 
Content of PL in nmol / mg of retina and eyecup proteins 
Mann-Whitney 
Test, p values 
 
WT 8w  
vs Pon1–/– 8w 
WT 8w 
Median(min;max) 
Pon1–/– 8w 
Median(min;max) 
Total PC 143.5(92;170.5) 120.5(54.1;140.3) 0.023 
Total SM 20(7.2;26.8) 17(7.2;23.7) 0.174 
Total LPC 5.2(2.1;5.9) 2.5(1.2;4.1) 0.001 
Total PE 26.5(16.2;29.8) 21.9(11.4;24.6) 0.013 
Total Cer/HexCer 5.6(2.7;7.6) 6.1(2.6;9.4) 0.545 
Total PG 1.2(0.2;1.9) 0.9(0.3;1.5) 0.253 
Total PA 2.8(2.3;3.1) 2.9(2.5;3.2) 0.326 
PC 32:0 27.3(15.5;31.5) 23.3(10.9;27.7) 0.070 
PC 32:1 2.7(2.1;3.5) 2.1(1.1;2.6) 0.010 
PC 34:0 6.4(3.7;8) 5.9(3;7.6) 0.257 
PC 34:1 27.8(18.8;33.4) 23.4(10.9;28.9) 0.016 
PC 34:2 4.7(3;5.9) 4.2(1.7;4.6) 0.096 
PC 36:1 14.1(8;16.2) 11.1(5.3;13.3) 0.019 
PC 36:2 5.6(4.3;7.2) 4.7(2.2;5.8) 0.023 
PC 36:3 1.5(1;2) 1.3(0.4;1.7) 0.070 
PC 36:4 6.4(4.1;7.2) 5.4(2.6;6.3) 0.059 
PC 38:4 7.9(4.7;10.4) 6.6(2.8;8.3) 0.013 
PC 38:5 2.5(1.6;2.8) 2.4(0.9;2.9) 0.450 
PC 38:6 12.1(7.6;15.1) 9.5(4;12.3) 0.013 
PC 40:5 1.7(0.7;2.3) 1.3(0.8;1.9) 0.023 
PC 40:6 17.7(12.2;20.4) 13.7(5.7;15.6) 0.004 
PC 40:7 1.4(1.2;2.4) 1.1(0.5;1.5) 0.008 
PC 44:12 4.9(3.7;8.3) 3.9(1.4;5.7) 0.016 
SM34:1 5.8(2.3;7.6) 5.2(2.4;7.2) 0.174 
SM36:1 4.7(1.9;6.4) 3.9(1.9;5.5) 0.199 
SM38:1 2.4(0.8;3.3) 2.2(0.7;2.9) 0.199 
SM40:1 2.2(0.8;3.2) 2(0.8;2.9) 0.199 
SM42:1 2.1(0.6;2.7) 1.7(0.5;2.6) 0.131 
SM42:2 2.2(0.8;3.4) 1.8(0.7;2.7) 0.257 
SM42:3 0.4(0.1;0.5) 0.3(0.1;0.4) 0.059 
LPC 18:0 0.8(0.6;0.8) 0.7(0.4;0.9) 0.131 
LPC 18:1 1.7(0.6;2) 0.7(0.4;1.2) 0.002 
LPC 22:6 2.8(0.9;3.1) 1.2(0.4;2) 0.001 
PE 34:1 0.8(0.6;0.9) 0.7(0.4;0.9) 0.290 
PE 36:0 0.3(0.2;0.4) 0.3(0.2;0.4) 0.880 
PE 36:2 0.9(0.8;1.2) 0.9(0.7;1.1) 0.151 
PE 36:4 0.6(0.4;0.8) 0.6(0.4;0.8) 0.650 
PE 38:4 3.3(1.8;3.7) 2.6(1.5;3.1) 0.019 
PE 38:6 5(2.8;6.3) 4.2(2;5.1) 0.008 
PE 40:6 12.2(7.6;13.8) 10.3(5.1;11.4) 0.013 
PE 44:12 2.9(1.9;3.8) 2.3(1.1;2.7) 0.013 
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PON1 does not influence photoreceptor degeneration or RPE survival after 
light exposure 
To evaluate whether the lack of the anti-oxidative PON1 protein influences cell 
survival under oxidative stress conditions, we exposed wild type and Pon1–/– mice 
to high levels of white light (Wenzel et al., 2005). At 5 days after exposure, many 
photoreceptors were lost and large numbers of pyknotic nuclei were detected in 
the ONL of wild type and Pon1–/– mice (Fig. 5A). We also observed similar levels of 
subretinal macrophages in Pon1–/– and wild type mice, although previous reports 
suggested inhibitory effects of PON1 on monocyte transmigration (Shih et al., 
1998). At 10 days after light exposure the photoreceptor layer was further 
degenerated, with only few pyknotic nuclei left in the ONL of both Pon1–/– and wild 
type mice. Additionally, some RPE cells displayed severe morphological changes in 
both mouse lines (Fig. 5B). Enlarged RPE cells with increased cytoplasmic -catenin 
localization, as well as a global increase in cytoplasmic phalloidin (F-actin) staining 
were observed. The number of RPE cells before and after light exposure was 
comparable in wild type and Pon1–/– mice (data not shown). 
Acute LD not only induces retinal degeneration, but also activates survival 
pathways to protect retinal cells from cell death. Leukemia inhibitory factor (LIF) is 
a key cytokine regulating an endogenous rescue pathway that involves activation of 
the Janus kinase signal transducer and activator of transcription (Jak-STAT) 
signaling pathway, and expression of protective factors like endothelin-2 (Edn2) 
and fibroblast growth factor-2 (Fgf2) (Joly et al., 2008; Samardzija et al., 2006). In 
line with the comparable extent of tissue damage (Fig. 5A, B), light exposure caused 
a similar expression pattern of these genes in retinas of wild type and Pon1–/– mice, 
even though Edn2 and Fgf2 were significantly stronger induced in mice lacking 
PON1 (Fig. 5C). No differences between the two genotypes were detected in 
eyecups. Remarkably, upon exposure to the light Pon2, Sod1 and Sod2 expression 
was reduced in the retina, but not in the eyecup, while Hmox1 was up-regulated in 
both tissues (Fig. 5C; supplementary Table 2). Additionally, expression of Socs3 was 
strongly up-regulated in the eyecup, suggesting that JAK/STAT signaling was also 
induced in the RPE. Whether this was a consequence of LIF signaling or whether 
other factors led to such activation needs to be established. 
Untreated Pon1–/– mice had decreased levels of total LPCs and in particular of 
LPC 22:6 (see above). Since PON1 is an anti-oxidative enzyme, we tested whether 
its lack might impact the PL composition under oxidative stress induced by light 
exposure. At 2 hours after light exposure, PL profiles were comparable in wild type 
and in Pon1–/– retina/eyecups and showed increased levels of PE 34:1, PE 36:0 and 
PE 36:4 in both strains (Supplementary Table 3). In contrast, light exposure caused 
an increase in total LPC and LPC 22:6 in Pon1–/– but not in wild type mice (Table 3). 
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Although these differences did not remain statistically significant after Bonferroni 
correction, there was a clear trend for increased LPC in Pon1–/– compared to wild 
type mice. This suggests that PON1 protects from a raise of total LPC, especially of 
LPC 22:6 in light-induced oxidative stress. 
 
 
 
 
 
Figure 5. PON1 does not protect against damage by acute light exposure (p. 81). 
(A) Representative light micrographs of retinas of 8-week old control (WT) and Pon1–/– 
mice at 5 and 10 days after light exposure. Control mice (dark control, DC) were reared 
in normal cyclic light conditions (12 hours dark; 12 hours light) and not exposed to 
light. Arrows: pyknotic nuclei indicating photoreceptor cell death. Arrowheads: 
macrophages in the subretinal space. Shown are representative sections of N=3. Scale 
bar: 50 m. 
(B) Immunostaining of RPE flat mounts from 8-week old WT and Pon1–/– dark control 
(DC) mice and at 10 days after light exposure (10 d). Red: -catenin; green: phalloidin; 
arrowheads: diffuse -catenin staining in RPE cells of light exposed mice. Scale bar: 50 
m. 
(C) Gene expression in retinas (upper panels) and eyecups (lower panels) of 8-week 
old WT (white bars) and Pon1–/– (black bars) mice at 12 hours after light exposure (12 
h) or in dark controls (DC). Values were normalized to -actin and expressed relative 
to the levels in the retina of unexposed wt animals, which were set to 1. Shown are 
mean values ± SD of N=3. Two-way ANOVA with Bonferroni post-hoc analysis was used 
to test significance. A p-value of less than 0.05 was considered significant; *p<0.05; 
**p<0.01; ***p<0.001. Shown are significantly different expression levels between WT 
and Pon1–/– mice in DC or light exposed mice. See supplementary Table 2 for statistical 
analysis of differences in gene expression between DC and light exposed WT and DC 
and light exposed Pon1–/– mice. 
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DISCUSSION 
 
PON1 in the normal retina 
Since PON1 has been implicated in AMD (Baird et al., 2004; Baskol et al., 2006; 
Ikeda et al., 2001; Oczos et al., 2013), we assessed whether lack of PON1 would 
alter retinal physiology in young and old Pon1–/– mice. We showed that PON1 is not 
essential for development and maintenance of a normal retinal structure, 
vasculature, or function. Similarly, RPE cells were morphologically indistin-
guishable between wild type and Pon1–/– mice, even though the RPE has the highest 
level of Pon1 expression. Although PON1 has anti-oxidative activity, no signs of 
oxidative damage were detected and no compensatory increase in the expression of 
other anti-oxidative enzymes was observed. Lack of PON1 did also not influence the 
susceptibility of retina and RPE to light damage.  
However, retina/eyecup samples of Pon1–/– mice showed decreased levels of 
LPCs in general and of LPC 22:6 in particular. LPCs are molecular species produced 
by the hydrolysis of PCs through enzymes of the phospholipase A2 (PLA2) 
superfamily. Previous studies have shown that PON1 has a PLA2-like activity 
leading to the formation and release of LPCs from macrophages (Rosenblat et al., 
2006; Rosenblat et al., 2005). In wild type mice, PON1 may thus increase LPC 
production and modulate the content of phospholipids in the retina/RPE. In 
analogy to the stimulatory effect of PON1-generated LPCs on cholesterol efflux 
from macrophages (Hara et al., 1997; Rosenblat et al., 2006), LPCs might stimulate 
reverse lipid transport from RPE regulating lipid content in this cell layer (Ishida et 
al., 2006). 
Since PON1 is a secreted protein that retains its hydrophobic signal peptide 
(James and Deakin, 2004), it may remain in the membrane of PON1 producing cells, 
or may reach membranes of neighboring cells. Thus, PON1 synthesized in the RPE 
might affect photoreceptors as well. The immunohistochemical detection of PON1 
in the region of photoreceptor inner segments (and other nonnucleated areas of the 
retina) (Marsillach et al., 2008) and our observation that LPC 22:6, which was 
reduced in Pon1–/– mice, was very abundant in the retina but almost absent from 
the eyecup (data not shown) supports a role for a PLA2-like activity of PON1 in the 
neuronal retina.  
We detected a general age-related decrease in the expression of anti-oxidative 
genes in retinas and especially eyecups of wild type mice. Pon1 was among the 
affected genes and down-regulated about 65%. Remarkably, also levels of total 
LPCs and of LPC 22:6 were decreased in 1-year old wild type mice, by 63% and 
75%, respectively (Table 3). This suggests a correlation between Pon1 expression 
and LPC levels and indicates that reduced expression of Pon1 resulted in reduced 
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PON1-related PLA2 activity and thus in a diminished PON1-mediated hydrolysis of 
PCs. Furthermore, increased lipid peroxidation and glycation in the aged eyes 
might have additionally compromised PON1 activity as it has been observed in 
metabolic syndrome and type II diabetes in humans (Garin et al., 2005; Mackness et 
al., 2000a; Mastorikou et al., 2008).  
 
PON1 in the light-exposed retina  
Even though PON1 has anti-oxidative and anti-inflammatory activities, Pon1–/– and 
wild type mice were similarly affected by light exposure: photoreceptors were 
equally susceptible to light induced degeneration; changes in RPE morphology after 
light exposure were comparable; expression of genes involved in anti-oxidative 
defense or the LIF-controlled cell survival pathway was similar; and levels of PE 
34:1, PE 36:0 and PE 36:4 increased to the same extent. However, levels of total 
LPC and LPC 22:6 increased only in Pon1–/– but not in wild type mice after light 
exposure suggesting that presence of PON1 prevents generation of LPC upon light 
exposure. Whether this is a direct effect of PON1 or whether a differential 
activation of phospholipases A2 in the two mouse strains influences LPC 
production remains to be explored. 
Several possible mechanisms may explain the lack of striking differences in 
response to light damage between Pon1–/– and wild type mice. Previous studies 
showed that PON1 may be inactivated by its own substrates such as oxidized lipids 
(Aviram et al., 1999). Thus, generation of a large amount of oxidized molecules by 
light exposure may substantially reduce PON1 activity in wild type mice. 
Alternatively, PON1 may “neutralize” only a subset of oxidized species produced in 
LD, such as oxidized PUFAs (Draganov et al., 2005). Other light-induced oxidation 
products may remain toxic and participate in the induction of cell death. It may also 
be of importance that PON1 is a secreted protein (James and Deakin, 2004) that 
may not be able to detoxify intracellular molecules that have been generated by 
light exposure and that are involved in the degenerative process.  
 
PON1 in AMD  
AMD is a complex, multifactorial disease. Most existing mouse models for AMD 
combine advanced age, which is the major risk factor to develop AMD, with genetic 
defects in key genes involved in AMD pathogenesis. Considering the complex 
nature of the disease, it may not be surprising that some models require the 
combination of more than two environmental or genetic risk factors to cause a 
pathological phenotype. An excellent example is a murine model that combines 
three known AMD risk factors: advanced age, high fat and cholesterol-rich diet, and 
mutations in ApoE (Malek et al., 2005). Importantly, neither age nor the diet alone 
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was sufficient to elicit changes that mimic human AMD pathology in the transgenic 
ApoE4 mice.  
The absence of an AMD-like phenotype in eyes of aged Pon1–/– mice suggests 
that even long-lasting absence of PON1 is not sufficient to cause detectable 
pathological changes like thickening of Bruch’s membrane or sub-RPE deposits 
typical for AMD. Noteworthy, despite the well-established anti-atherogenic 
properties of PON1, Pon1–/– mice developed significantly larger atherosclerotic 
lesions than wild type controls only when raised on a high-fat/high-cholesterol but 
not on a regular diet (Rozenberg et al., 2003; Shih et al., 1998). This suggests that 
additional factors/stimuli may be needed to provoke phenotypes of complex 
diseases like atherosclerosis or AMD in Pon1–/– mice. This hypothesis is also 
supported by the observation that pathological processes in ApoE–/– mice were 
slowed in the presence of a human PON1 transgene (Tward et al., 2002), but 
accelerated by PON1 deficiency (Rozenberg et al., 2003; Shih et al., 2000). 
These studies provide evidence that a co-existing chronic metabolic burden 
may be needed to reveal the role of PON1 in development and or progression of a 
complex disease. A long-lasting exposure to low levels of light (in contrast to the 
short-term exposure to high light levels used in present study), a high-fat diet or 
the inclusion of the ApoE-null genetic background might provide such an additional 
chronic stress to provoke AMD-like lesions in Pon1–/– mice.  
We postulate that PON1 could be involved in AMD as a modulatory protein 
and that direct or indirect interactions with additional factors may influence its 
contribution to disease development and/or progression. Presence or absence of 
such factors may determine the association of PON1 with AMD in particular 
populations and may help to explain contradictory results regarding the 
implication of PON1 in AMD pathology. Nevertheless, the controversy on the role of 
PON1 in AMD still remains and there is a clear need for further studies to identify 
the precise function of PON1 in ocular tissues such as RPE and neuronal retina. 
Knowledge of these functions seems a prerequisite to understand how the anti-
oxidative and anti-inflammatory properties of PON1 may influence AMD. 
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SUPPLEMENTARY MATERIAL 
 
Supplementary Methods 
Analysis of retina and eyecup lipidome: LC-MS instrumentation and chroma-
tographic conditions 
The liquid chromatography-mass spectrometry (LC-MS) method combining HPLC 
separation on normal phase column with multiple parent-ion or neutral loss scans 
on a triple quadrupole mass spectrometer is capable of the analysis of six different 
phospholipid (PL) classes: phosphatidylcholines (PC), sphingomyelins (SM), 
phosphatidylglycerols (PG), phosphatidyl-ethanolamines (PE), phosphatidic acids 
(PA) and ceramide/hexosylceramides (Cer/HexCer). 
For PL analysis, 40 µg of total proteins from tissue homogenates were 
supplemented with 200 ng of internal standards (IS) and extracted by using the 
method by Bligh and Dyer (Bligh and Dyer, 1959). The mixture of ISs contained 
non-naturally occurring lipids: PG 17:0/17:0, PA 14:0/14:0, PE 14:0/14:0, 
PC14:0/14:0, PC24:0/24:0, LPC 17:0, SM d18:1/12:0 and Cer d18:1/17:0 (Avanti 
Polar Lipids, Alabaster, AL, USA).  
For an adequate quantification, each series of measurements included 
calibration solutions of seven PL standards at six different concentrations in the 
range from 0.625 µg/ml to 12 µg/ml or from 0.8 µmol/l to 24.2 µmol/l, which were 
spiked with 200 ng of IS. Calibration solutions were composed of commercially 
available standards of PC 16:0/18:2, SM d18:1/16:0, LPC 16:0, PE 18:0/18:0, Cer 
d18:1/14:0, PG 16:0/16:16 and PA 14:0/14:0 (Avanti Polar Lipids, Alabaster, AL, 
USA). Two quality controls of a low and of a high concentration (2 µg/ml and            
6 µg/ml for PC 16:0/18:2 and SM d18:1/16:0 versus 4 µg/ml and 12 µg/ml for LPC 
16:0, PE 18:0/18:0, Cer d18:1/14:0, PG 16:0/16:16 and PA 14:0/14:0) were 
evaluated at the beginning and at the end of each samples series. Carry-over control 
was done by analyzing blank samples. The samples were prepared by adding 
methanol (DB) and IS (B) to 20 µl of water.  
At first retina/eyecup samples were mixed with 375 µl of methanol/ 
chloroform (2:1, v/v) and vortexed. After that, 100 µl of water and 125 µl of 
chloroform were added. The mixture was shaken for 15 min and centrifuged at 
16100g for 5 min at 25°C. The lower phase was collected and an additional 250 µl 
of chloroform was added. The mixture was agitated for 15 min and centrifuged at 
16100g for 5 min at 25°C. All lower phases were combined and evaporated to 
dryness under a stream of nitrogen. The dried material was reconstituted in 200 µl 
of a mixture of mobile phases A (80%; hexane/isopropanol/water (70:30:2, v/v) 
containing 15 mM ammonium formate) and B (20%; isopropanol/water (50:2, v/v) 
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containing 15 mM ammonium formate). 10 µl of sample was injected into the LC-
MS system for PL analysis. 
The LC-MS system contained of a Rheos 2200 HPLC pump (Flux 
Instruments, Reinach, Switzerland), an HTC PAL autosampler (CTC Analytics, 
Zwingen, Switzerland) and a TSQ Quantum Access triple quadrupole mass analyzer 
(Thermo Fisher Scientific, Waltham, MA, USA). Separation of PLs was achieved by 
using a diol silica-based column (QS Uptisphere 6 OH, 150 × 2.1 mm, 5 µm) from 
Interchim (Montluçon, France). Gradient elution started with 80% mobile phase A 
and 20% of B and lasted for 7.0 min. Mobile phase B was increased to 40% within 
1.0 min and kept constant for 2 min then mobile phase B was increased to 60% 
within 1 min and kept constant for 12 min. After that the column was re-
equilibrated with 80% mobile phase A and 20% of B for 5.0 min. The solvent flow 
was 0.35 ml/min and the column was maintained at 30°C.  
The MS parameters were set as follows: 4500 V spray voltage, skimmer 
voltage was constantly changing in range from 2 to 14 V depending on scan mode, 
250°C capillary temperature, and 10 and 6 (arbitrary units) sheath and auxiliary N2 
gas, respectively. Tube lens voltages were tuned using a standard mixture of LPC 
17:0, PC 14:0/14:0, PC 20:0/20:0 and PC 24:0/24:0, covering a wide molecular 
mass range. Both Q1 and Q3 resolution were set at 0.7 peak-width (at full-width 
half-maximum). Molecular masses provided by a neutral loss and precursor scans 
were used to selectively detect specific phospholipids. Multiple parent-ion and 
neutral loss scan events were performed in positive ionization mode by using 0.7 
mTorr collision gas.  A neutral loss of masses m/z 115 and 189 from [M+NH4]+ ions 
were used for analysis of PA and PG lipids, respectively. A precursor ion scan of 
m/z 184 specific for phosphocholine containing lipids was used for PC, SM and LPC. 
A neutral loss scan of m/z 141 was used for PE and a precursor scanning of m/z 
264 was applied for screening of Cer and HexCer. Acquired data was analyzed using 
the Xcalibur software (version 2.0.6) from Thermo Scientific. 
The identification of the molecular species was based on the molecular mass 
provided by MS, the structure of the head group was determined from the type of 
MS/MS scanning. From each scan segment, a mass-peak list containing parent-ion 
masses (m/z) and their intensities was generated by Xcalibur. The mass-peak list 
was entered into the lipid mass spectrum analysis software LIMSA (The 
Somerharju Lipid Group, Helsinki, Finland; Haimi et al., 2006) and lipid species 
were identified by using a mass tolerance of ±0.7 Da and list of theoretical PL 
species library prepared in our laboratory. Corrections were applied to the data for 
isotopic overlap in the species with mass difference ∆ m/z of two Da. As a result all 
lipids were assigned to the individual lipid class and species with a defined total 
number of carbon atoms and double bounds in O-linked fatty acids. Identification of 
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SM resulted in the total number of carbon atoms in sphingoid base and N-linked 
fatty acid. Quantification was achieved by using the linear regression of the 
calibration curve of the related lipid class. 
Lower limit of quantification (LLOQ) was defined as concentration of the 
first calibrator in standard curve. LLOQ was set at concentration levels of               
0.8 µmol/L for PC, 0.9 µmol/L for SM, 2.45 µmol/L for Cer, 2.5 µmol/L for LPC,     
2.0 µmol/L for PA, 1.7 µmol/L and 2.0 µmol/L for PG and PE, respectively. Intra- 
and inter-day accuracy (n=5) of LLOQ indicating difference between the mean 
result and expected value was within 20% of the expected value. Furthermore, 
intra- and inter-day precision (n=5) of the LLOQ measurements resulted in CV% 
better than 20%. Intra- and inter-day study (n=5) of quality controls at a low and a 
high concentration resulted in accuracy and precision within 15% for all lipid 
species. Extraction recovery of ISs from plasma varied from highest of 103% for PC 
to the lowest 68% for PA. 
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Supplementary Tables 
 
Supplementary Table S1. Expression of PON1-related genes in retinas and eyecups of 
Pon1–/– and wild type (WT) mice at 8 weeks (8w) and one year (1y) of age (page 89). 
Expression of genes related to PON1 function was determined by semi-quantitative real-
time PCR. Shown are mean values ± SD of N=3. Values were normalized to -actin and 
expressed relative to levels in the retina of WT mice at 8 weeks of age, which were set to 1. 
Two-way ANOVA with Bonferroni post-hoc analysis was used to test the statistical 
significance. A p-value of less than 0.05 was considered significant; ns, not significant. Pon1, 
paraoxonase 1; Pon2, paraoxonase 2; Pon3, paraoxonase 3; Abca1, ATP-binding cassette, 
sub-family A (ABC1), member 1; Scarb1, scavenger receptor class B, member 1; Hmox1, 
heme oxygenase 1; Sod1, superoxide dismutase 1; Sod2, superoxide dismutase 2, Mct3, 
monocarboxylate transporter, member 3 (marker for RPE); Gnat1, guanine nucleotide 
binding protein, alpha transducing activity polypeptide (marker for the neuronal retina). 
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Supplementary Table S2. Gene expression in retinas and eyecups of Pon1–/– and wild 
type (WT) mice after light damage (LD), page 91. 
Gene expression was examined by semi-quantitative real-time PCR in retinas and eyecups 
of wild type and Pon1–/– mice, which either were (light damage, LD) or were not (dark 
control, DC) exposed to damaging light. Analysis was at 12 h after light exposure (12h). 
Values were normalized to -actin and expressed relative to levels in retinas of dark 
control WT mice, which were set to 1. Shown are mean values ± SD of N=3. Two-way 
ANOVA with Bonferroni post-hoc analysis was used to test the statistical significance.          
A p-value of less than 0.05 was considered significant. Lif, leukemia inhibitory factor; Edn2, 
endothelin 2; Fgf2, fibroblast growth factor 2; Stat3, signal transducer and activator of 
transcription 3; Socs3, suppressor of cytokine signaling 3; Hmox1, heme oxygenase 1; Sod1, 
superoxide dismutase 1; Sod2, superoxide dismutase 2; Abca1, ATP-binding cassette, sub-
family A (ABC1), member 1; Scarb1, scavenger receptor class B, member 1; Mct3, 
monocarboxylate transporter, member 3 (marker for RPE); Gnat1, guanine nucleotide 
binding protein, alpha transducing activity polypeptide (marker for the neuronal retina). 
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Supplementary Table S3. Phospholipid composition of the retina/eyecup samples 
from WT and Pon1–/– mice at the age of 8 weeks (8w) and 1 year (1y), and from mice 
exposed to light (page 93 and 94). 
Phospholipid (PL) analysis was performed by LC-MS. Content of PL, phosphatidylcholines 
(PC), phosphatidylethanolamines (PE), sphingomyelins (SM) and lysophosphatidylcholines 
(LPC), ceramides/hexosylceramides (Cer/HexCer), phosphatidylglycerols (PG) and 
phosphotungstic acids (PA) was calculated as nmol/ mg of retina and eyecup protein. Total 
phospholipids represent sum of molecular species of a given class. The median and ranges 
are given from N=10 for WT (8w), N=10 for Pon1–/– (8w), N=5 for WT (1y), N=6 for Pon1–/– 
(1y), N=10 for WT (LD), N=10 for Pon1–/– (LD). Total concentration is shown for PC, SM, 
LPC, PE, Cer/HexCer, PG, PA lipids. Man-Whitney U test was applied since data were not 
normally distributed. After Bonferroni correction for 37 tests a p-value of 0.00135 
corresponds to a significance level of 0.05. Bold letters indicate statistically significant 
levels. An assignment of PL species includes number of carbon atoms and double bonds in 
both acyl chains (for example, PC 34:1 consist of 34 carbon atoms and one double bond and 
can correspond to the following species PC 16:0/18:1 or PC 18:0/16:1, etc.). 
Sphingomyelin assignment comprises number of carbon atoms and double bonds in both 
sphingoid base and in N-linked fatty acid. 
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3.3.2 Revealing the role of PON1 in RPE cell cultures in vitro 
 
Unpublished data 
 
Contributors 
Jadwiga Oczos1 and Christian Grimm1  
1 Lab for Retinal Cell Biology, Department of Ophthalmology, University of Zurich, Zurich, 
Switzerland 
 
Personal contribution 
Isolation, culture and experiments on mouse RPE cells, culture and experiments on 
ARPE19 cell line, light microscopy, RNA preparation and analysis of gene expre-
ssion 
 
PURPOSE 
We detected high levels of PON1 transcripts in the RPE, a cellular layer strongly 
affected in AMD. To further characterize function of PON1 in the RPE and its 
contribution to AMD, we established primary mouse RPE cultures in vitro. 
 
 
METHODS 
Isolation and culture of mouse RPE (mRPE) cells 
RPE cell cultures were established from mouse at 6-8 weeks of age. Intact eye balls 
were isolated and placed in ice cold PBS, pH 7.4 (PAA Laboratories GmbH, Pasching, 
Austria). Each eye ball was opened by a round cut below the ora serata, and the 
cornea, lens and vitreous were removed. Remaining tissue (choroid, RPE, and 
retina) was incubated in 1 mM PBS-EDTA buffer, pH 7.4 (0.5 M EDTA, pH 8.0; Gibco, 
Paisley, UK) for 20 min at 37°C to let the retina dissociate from the RPE. After 
gentle removal of the retina, the remaining eye cup underwent protease treatment 
for 23 min at 37°C (1U papain (Roche Diagnostics GmbH, Mannheim, Germany) per     
1 ml of dissociation buffer (1 mM PBS-EDTA containing 3 mM L-cystein (Sigma-
Aldrich, St. Louis, MO, USA) and 1 mg/ml BSA (PAA Laboratories GmbH)). Protease 
digestion was stopped by the addition of culturing media containing 10% FBS 
(DMEM/Ham’s F-12 (Sigma-Aldrich) containing 2.5 mM L-glutamine, 15 mM 
HEPES, 0.5 mM sodium pyruvate, 1.05 mM calcium chloride, and 1.2 g/L sodium 
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bicarbonate, additionally supplemented with 2% FBS-Gold (PAA Laboratories 
GmbH), 1% penicillin-streptomycin (PAA Laboratories GmbH), 500 l/L insulin-
transferrin-selenium (Gibco), and 10 ml/L non-essential amino acids (PAA 
Laboratories GmbH)) and RPE cells were immediately released by gentle pipetting. 
Culturing medium containing RPE cells was centrifuged (300 rcf, 3 min). The 
resulting pellet of RPE cells was resuspended in 50 l of fresh culturing medium. 
Cells were seeded in a drop in culture dishes of various size (TPP, Trasadingen, 
Switzerland) and cultivated at 37°C in a humidified atmosphere of 95% air and 5% 
CO2. After 2 days 1 ml of medium was added. Culturing medium was changed every 
3 to 4 days. For passaging, mRPE cultures were incubated in trypsin-EDTA solution 
(PAA Laboratories GmbH) for 5 min at 37°C, and released by gentle pipetting. 
 
Culture of human ARPE19 cell line 
Human ARPE19 cells at passage 19 were purchased from the American Type 
Culture Collection (ATCC, Manassas, VA, USA; product ATCC-CRL-2302), and 
handled according to the provider’s instructions. Cells were cultivated in culturing 
medium DMEM/Ham’s F-12 (Sigma-Aldrich) containing 2.5 mM L-glutamine,         
15 mM HEPES, 0.5 mM sodium pyruvate, 1.05 mM calcium chloride, and 1.2 g/L 
sodium bicarbonate, additionally supplemented with 10% FBS-Gold (PAA 
Laboratories GmbH) and 1% penicillin-streptomycin (PAA Laboratories GmbH) at 
37°C in 5% CO2 in air. Passaging of ARPE19 cultures was performed by incubation 
in trypsin-EDTA solution (PAA Laboratories GmbH) for 7 min at 37°C.    
 
Light microscopy 
Living mRPE and ARPE19 cells in culture dishes were observed using an inverted 
microscope (Axiovert 25, Zeiss, Feldbach, Switzerland).  
 
Restoration of PON1 expression in ARPE19 cells 
ARPE19 cells at passage 24-26 were seeded in 12-well culture dishes (TPP) at a 
density of 105/well (24h incubation time) or 7104/well (48h incubation time) in 
culturing medium. Various compounds (Table 5) were added in an attempt to 
restore PON1 expression in ARPE19 cells. Light microscopy served to monitor 
eventual toxic effects of each chemical. After 24h or 48h incubation time cells were 
washed and lysed with RLT buffer (Qiagen, Hilden, Germany) and RNA was 
extracted for analysis of gene expression (see below).   
For a long-term culture ARPE19 cells were seeded in 12-well culture dishes 
(TPP) at a density of 105/well. Cells were maintained for 60 days in culturing 
medium containing reduced amount of FBS (2%). Medium was exchanged every 3 
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to 4 days. At day 60 DMEM/Ham’s F-12 was replaced by the culturing medium 
additionally containing compounds listed in table 5, and cells were further cultured 
for 24h prior to the lysis and RNA extraction. 
 
Compound Solvent Final concentration 
Gallic acid 
culturing medium 
absolute ethanol 
10 M, 20 M, 50 M 
Resveratrol absolute ethanol 10 M, 20 M 
Quercetin DMSO 50 M 
Aspirin (400 mg acetylsalicylacid 
pro tablet)  
absolute ethanol 
0.25 mM, 0.5 mM, 1 mM of 
acetylsalicylacid 
All-trans retinoic acid 
DMSO 
chloroform 
20 M, 50 M, 100 M 
22(R)-hydroxycholesterol DMSO 20 M, 50 M, 100 M 
Human HDL crude —— 25 g/ml, 50 g/ml 
Human HDL dialyzed —— 25 g/ml, 50 g/ml 
Table 5. List of compounds used to attempt to restore expression of PON1 in ARPE19 
cells. 
Gallic acid, resveratrol, quercetin, all-trans retinoic acid, and 22(R)-hydroxycholesterol 
were purchased from Sigma-Aldrich; aspirin was from Bayer Schweiz (Zürich, Switzer-
land). Human HDL was prepared by sequential ultracentrifugation from normolipidemic 
human plasma (blood bank of Kantonsspital Schaffhausen, Switzerland) at the Institute of 
Clinical Chemistry, UniversitätsSpital Zürich, Switzerland, according to the protocol 
described by Tong et al., 1998. 
 
RNA preparation and analysis of gene expression 
Total RNA was prepared with an RNA isolation kit including a DNase treatment to 
digest residual genomic DNA. For primary mRPE cells the RNeasy Micro kit 
(Qiagen) and for ARPE19 cultures the RNeasy Mini kit (Qiagen) were used. cDNA 
was synthesized by means of random hexamer primers (High-Capacity cDNA 
Reverse Transcription Kit; Applied Biosystems, Foster City, CA, USA) or oligo(dT) 
and M-MLV reverse transcriptase (Promega, Madison, WI, USA) for primary mRPE 
and ARPE19 cultures, respectively. 
Gene expression was analyzed either by agarose gel electrophoresis of the 
PCR products or by semi-quantitative real-time PCR. Conventional PCR reaction 
consisted of an initial denaturation step (95°C, 5 minutes), 35 amplification cycles 
(denaturation: 95°C, 45 seconds; annealing: specific temperatures for each primer 
pair listed in table 4, 30 seconds; extension: 72°C, 30 seconds), and a final extension 
step (72°C, 10 minutes). Real-time PCR was performed using specific primer pairs 
(Table 6), a polymerase ready mix (LightCycler 480 SYBR Green I Master Mix; 
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Roche Diagnostics, Basel, Switzerland), and a thermocycler (LightCycler480, Roche 
Diagnostics). Signals were normalized to -actin and relative gene expression was 
calculated using the Ct method. 
For ARPE19 line experiments human liver cDNA served as a positive control. 
 
Gene Forward 5’ → 3’ Reverse 5’ → 3’ AT 
(°C) 
Product 
(bp) 
Pon1 GAGCCAGCAGTGTCAGAGTT GACGAGGAGTCTGGATGGTT 60 137 
Pon2 CAGAGGCTCTTCGTGTACCA ATGTTCTGAATGCGGAGGAC 60 88 
Pon3 TTGACCGTTGATCCAGCCAC GAAGCACAGAGCCGTTGTTC 62 175 
Mct3 GGCTCAACCCTAAATCCAGA CTTCGGAGTTTCCTCACCAG 58 75 
Rpe65 ATGACTGAGAAGAGGATTGTC CTGCTTTCAGTGGAGGGATC 60 366 
Rlbp1 CCTTTCCAGTCGGGACAAGTATG GGGTTTCCTCATTTTCCAGCAG 60 140 
Rdh5 GGCTACTGTGTCTCCAAGTT CTGGTCACCTTCGTTAGTTC 62 278 
Pde6a GGCTGAGATCCTGCAAGGAG ATCTGGATGCCGCACTTCAC 62 114 
Pde6c GGCCATATTGAAGGAGGACT GCATTTAACCAACTCGTGCT 62 100 
Gfap CCACCAAACTGGCTGATGTCTAC TTCTCTCCAAATCCACACGAGC 62 240 
Actb CAACGGCTCCGGCATGTGC CTCTTGCTCTGGGCCTCG 62 153 
PON1 GACTGGCACTCTTCAGGAAC GGCAGTATCTCCAAGTCTTCA 62 139 
PON2 CGAGAGGCTTCTGGCACTCA GTGCAAAGCTGTGGAGTCCTG 62 182 
PON3 TCTCAGCAGACCAGAAGTATG CAGGTTATCCACTAAGGTGC 62 131 
RPE65 ACAAGGCTGACACAGGCAAG CAAGCCAAGTCCATACGCAT 62 194 
ACTB CCTGGCACCCAGCACAAT GGGCCGGACTCGTCATAC 62 144 
Table 6. Primers and conditions for conventional and for real-time PCR. 
Human genes are written in uppercase letters. In mouse genes only first letter is uppercase 
and the rest is lowercase. AT, annealing temperature. 
 
RESULTS 
Characterization of the primary mRPE cultures 
Isolation procedures and culture conditions are known to alter the morphological 
and functional features of the primary cells. In order to study RPE cell behaviour 
under the conditions resembling an in vivo situation, there is a need to evaluate and 
adopt isolation and culture protocols to obtain in vitro RPE cultures that retain the 
native RPE structure and characteristics.  
Morphology of primary mRPE cultures was evaluated by light microscopy. 
Figure 14A illustrates a typical appearance of a cell culture 8 days after the 
isolation. RPE cells formed a monolayer of highly pigmented, polygonal cells. 
Proliferating cells, which were found only on the outskirts of the culture (cells 
seeded in a drop), displayed a decrease in the pigment density and an elongated 
form. After the first passage numerous RPE cells were less pigmented and lost their 
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polygonal shape. Cells were dividing more dynamically and mitotic doublets were 
present throughout the culture (Fig. 14B). After the second passage fibroblast-like 
morphology became more striking (Fig. 14C). Although many dividing cells were 
observed, the number of living cells suggested reduced proliferation after passage 
2. Cultures obtained from two mouse eyes gave on average 6.4104 RPE cells at 
passage 1, 1.5105 cells at passage 2, and only 6.2104 cells at passage 3, indicating 
approximately 2.4-fold increase in proliferation after passage 1 and comparable 
decrease in proliferation after passage 2. Number of RPE cells directly after 
isolation could not be assessed because of the high content of the RPE sheets and 
fragments of other cells (e.g. photoreceptor outer segments) in the extract.  
 
 
Figure 14. Morphology of primary mRPE cultures 
(A) 8 days after isolation of mRPE, cells formed a monolayer of highly pigmented, regularly 
shaped cells. (B) After passage one, highly pigmented polygonal cells were grouped in 
islands surrounded by less pigmented elongated cells. Dividing cells were present through-
out the culture (red arrowheads). (C) After passage two, the majority of cells lost pigmen-
tation and displayed fibroblast-like morphology. (D) Confluent culture of undifferentiated 
ARPE19 cells at passage 24. Scale bar = 50 m. 
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An important step in characterisation of the primary RPE cultures is 
monitoring of the expression of specific RPE markers. Monocarboxylate transporter 
3 (MCT3) is known to be expressed in the basolateral membrane of the RPE and to 
be unique to this monolayer among the other retinal cells (Philp et al., 1998; Yoon 
et al., 1997). In the cultured RPE cells the level of MCT3 mRNA depends on the 
degree of cell differentiation (Philp et al., 2003). Our RPE extracts (fresh mRPE) 
showed high expression of Mct3 (Fig. 15A), which was massively down-regulated 
after one day in culture and completely lost after 8 days in culture (Fig. 15A, C). 
Although it has been reported that RPE cells cultured for 60 days are highly 
differentiated and therefore express Mct3 (Philp et al., 2003), we could not detect 
any Mct3 mRNA in such cultures (Fig. 15C). Nevertheless, all RPE cultures that were 
not passaged formed a monolayer of highly pigmented, polygonal cells, indicative 
for RPE. 
One of the main functions of the RPE in vivo is recycling of the chromophore 
11-cis-retinal. Expression of the various enzymes and binding proteins involved in 
this process by cultured RPE cells can be indicative of their state of differentiation 
(Pfeffer, 1991). We did not detect any transcripts encoding the isomerase RPE65 or 
CRALBP (Rlbp1) in RPE cells after 8 days and 4 weeks in culture, even though they 
were present in freshly isolated RPE (Fig. 15A). In contrast, RPE-specific retinol 
dehydrogenase (RDH5) mRNA was found in all analysed RPE samples.  
To test whether the RPE extracts and cultures were contaminated with 
adjacent photoreceptor cells we tested mRNA expression of a rod and cone cGMP-
specific 3',5'-cyclic phosphodiesterase subunit (Pde6a and Pde6c, respectively; Fig. 
15A). Presence of those transcripts in freshly isolated RPE, but not in cultured RPE 
cells suggests that RPE extracts contained some photoreceptor cells (or cellular 
debris), which did not survive in culture. Additionally, we checked expression of 
Gfap (glial fibrillary acidic protein), a marker for Müller cells (Fig. 15A). Presence of 
Gfap mRNA in one freshly isolated RPE sample indicated its contamination with 
glial cells, and suggested that Rlbp1 transcripts detected in this sample originated 
both from the RPE and Müller cells. It is important to notice differences in 
contamination with rods, cones and glial cells between RPE isolations.  
We tried to modify the basic composition of culturing media according to 
several reports in order to obtain differentiated RPE monolayers expressing RPE 
markers. Reduction of serum to 1%, supplementation with all-trans-retinoic acid 
(Pfeffer, 1991) or with mouse retinal extracts (Hu, 2000; Pfeffer et al., 1986) did 
not improve characteristics of primary mRPE cultures (data not shown). 
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Figure 15. Expression of RPE markers and paraoxonases in primary mRPE cultures. 
(A) RNA was prepared from freshly isolated mouse RPE and primary mRPE cells cultured 
for 8 days or 4 weeks (mRPE, 4w.), which were obtained from 129S6/SvEvTac (129S6) or 
C57Bl/6 (B6) wild type mice. Expression of various genes was analysed by agarose gel 
electrophoresis of PCR products amplified from cDNA with the use of specific primer pairs 
(Table 6). All tested RPE-specific genes were expressed in fresh RPE, but only Rdh5 was 
detected in primary mRPE cultures. Fresh RPE showed variable contamination with photo-
receptors (Pde6a, Pde6c as marker) or Müller cells (Gfap as marker), whereas mRPE 
cultures were free of contamination. Eye cup or retinal cDNA were used as a positive 
control (PC) for RPE-specific genes and contamination controls, respectively. -actin (Actb) 
served as a control for RNA integrity. NC, negative control; Mct3, monocarboxylate 
transporter 3; Rpe65, retinal pigment epithelium 65kDa protein; Rlbp1, cellular 
retinaldehyde binding protein; Rdh5, retinol dehydrogenase 5; Pde6a, rod cGMP-specific 
3',5'-cyclic phosphodiesterase subunit alpha; Pde6c, cone cGMP-specific 3',5'-cyclic 
phosphodiesterase subunit alpha; Gfap, glial fibrillary acidic protein.  
(B, C) Expression of paraoxonases and Mct3 gene was determined by semi-quantitative 
real-time PCR in fresh mRPE and primary mRPE cells cultured for 1 day (1d), 8 days (8d), 
or 60 days (60d), which were obtained from 129S6 wild type mice. Shown are mean values 
± SD of N = 3. Values were normalized to -actin, and levels in fresh mRPE were set to 1. 
Pon1 was rapidly down-regulated in culture and followed the expression pattern of Mct3. 
PON2 and PON3 mRNA levels were lower in one and eight day old cultures, compared to 
fresh RPE, but prolonged cultivation caused slight increase in their abundance. 
RESULTS and DISCUSSION 
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Expression of paraoxonases in primary mRPE cultures 
The main aim of establishing primary mouse RPE cultures was to set up cultures 
either expressing PON1 (wild type 129S6 mice) or lacking PON1 protein (Pon1–/– 
mice), to test their behaviour upon oxidative stress (H2O2, oxLDL), and thus reveal 
if and how PON1 is involved in a potential response to such conditions. Therefore 
in the first place we characterized expression of Pon1 gene in mRPE cultures 
obtained from wild type animals. As shown in figure 15B, RPE cells in culture were 
rapidly losing Pon1 mRNA expression, and one day after isolation contained only 
about 1% of the transcripts present in fresh RPE. After 8 days in culture no Pon1 
mRNA could be detected. Interestingly, decay of Pon1 expression in RPE cultures 
was strikingly similar to the down-regulation of Mct3 (Fig. 15C). Additionally, we 
found decreased levels of Pon2 and Pon3 mRNA in 1- and 8-day old cultures, 
compared to the freshly isolated RPE. But, in contrast to Pon1, the Pon2 and Pon3 
transcripts were present in RPE cells cultured for 60 days at slightly increased 
levels compared to the 8-day old cultures. Application of modified media did not 
lead to up-regulation of Pon1 expression in primary mRPE cultures.  
Noticeably, the ARPE19 cells expressed PON2 mRNA at levels comparable 
with human liver, whereas neither PON1 nor PON3 transcripts could be detected 
(data not shown). 
 
Restoration of PON1 expression in ARPE19 cells  
The observed complete loss of PON1 mRNA in primary mRPE cultures would 
disable the execution of our planed experiments on Pon1+/+ and Pon1–/– RPE cells. 
Therefore, we conducted extensive trials to restore PON1 expression in cultured 
cells by applying molecules previously reported to up-regulate PON1 expression in 
vitro. Because of the limited supply in primary mouse RPE cells, we performed all 
experiments on the ARPE19 cell line, which also does not express PON1 (data not 
shown). Importantly, primary mRPE and ARPE19 cells display a similar expression 
pattern of the nuclear receptors involved in regulation of the PON1 gene (Dwyer et 
al., 2011). We supplemented culture medium with various concentrations of 
resveratrol, quercetin and aspirin that are known to induce PON1 expression via 
interaction with aryl hydrocarbon receptor (AhR) (Gouedard et al., 2004a, b; 
Jaichander et al., 2008); with gallic acid, an activator of PPAR nuclear receptor 
(Khateeb et al., 2010); and with 22(R)-hydroxycholesterol, which up-regulates 
PON1 expression via liver X receptor (LXR) (Gouedard et al., 2003). Although all-
trans retinoic acid (ATRA) has not been reported to regulate expression of PON1 
gene, we tested its influence on PON1 transcript level in ARPE19 culture. We 
hypothesized that presence of ATRA could improve differentiation state and 
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polarity of the cells and therefore affect expression of PON1. Additionally, we tested 
if presence of human HDL in medium restored PON1 expression.  
We measured PON1 gene expression both in undifferentiated and in 60 
days old ARPE19 cells cultured in presence of the above substances, but we could 
not detect any PON1 transcripts in any of the analyzed cultures (data not shown). 
 
DISCUSSION 
Our initial experiments demonstrated that primary mRPE cells were rapidly losing 
Pon1 expression in culture. Since this phenomenon was accompanied by the loss of 
Mct3, Rpe65 and Rlbp1 expression, we concluded that expression of Pon1, in 
contrast to Pon2 and Pon3, is dependent on the state of differentiation and 
polarization of RPE cells. Such assumption was confirmed by the detection of Pon1 
mRNA in highly polarized mouse RPE cultures by our collaborators (personal 
communication with Rosario Fernández Godino, Ocular Genomics Institute, 
Harvard Medical School, Boston, MA, USA). Additional supplementation of the 
culturing medium with substances known to promote differentiation of RPE cells 
(Pfeffer, 1991) neither improved characteristics of cultures established in our 
laboratory, nor induced Pon1 expression. Another possible modification of the 
culture procedure would be an application of culture dishes with Transwell filters 
that were successfully used by several groups to establish a polarized RPE cell 
culture (Sonoda et al., 2009). 
The in vitro cultures of polarized primary mRPE cells on Transwell filters 
would serve to answer several questions. Analysis of the apical and basal culture 
medium by western blot or by paraoxonase activity assays would reveal whether 
PON1 is retained in the RPE cell membranes, or whether it is secreted basally or 
apically. Survival of Pon1–/– and Pon1+/+ RPE cells and production of MDA upon 
treatment with oxLDL could be examined to test a protective function of RPE-
derived PON1 against lipid peroxides (Aviram et al., 1998; Besler et al., 2011; Kim 
et al., 2012; Yin et al., 2012). Study of the lipid efflux from Pon1–/– and Pon1+/+ RPE 
cells would help to establish the function of PON1 in this process (Duncan et al., 
2009; Ishida et al., 2006). 
Alternatively, the experiments proposed above might be performed in the 
ARPE19 cell line expressing the human PON1 gene from an expression vector. 
However, since originally described ARPE19 cultures displayed pronounced 
heterogeneity resulting in a low transepithelial resistance (Dunn et al., 1996), their 
application for more complex studies, such as polarized secretion of proteins, might 
be limited. 
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IV. CONCLUDING DISCUSSION 
 
In the final discussion I will not focus on specific aspects of each project, since they 
were discussed in detail in the previous sections of this dissertation, but rather try 
to present a general picture on the role of PON1 in the retina and in AMD that 
emerged from current analyses and previous reports.  
Our case-control study showed for the first time association between the 
upstream regulatory region of PON1 and neovascular AMD. We found four SNPs 
(rs705379, rs705381, rs854573, rs757158) and two 7-SNP haplotypes (TGGCCTC 
and CGATGCT) significantly associated with the disease. Inclusion of haplotype 
analysis increased power of the association and provided insight into the cis-
interaction between the analyzed loci (Liu et al., 2008). Nevertheless, our study did 
not clarify the involvement of PON1 genotypes at the early or intermediate stage of 
the disease, or in geographic atrophy. Since genetic association may change with 
the form of AMD (Adams et al., 2012), additional association studies between the 
PON1 gene and early, intermediate, or nonexudative AMD would complement our 
analysis.  
In a functional assay in vitro we showed that protective and risk PON1 5’UTR 
haplotypes affect gene expression differently. The TGG haplotype, which appeared 
to be protective against AMD in association study, yielded the lowest level of 
luciferase activity in both ARPE19 and Caco-2 cells. Also protective alleles -107T 
and -162G (our association study) decreased PON1 expression (present and 
previous studies (Brophy et al., 2001a; Brophy et al., 2001b; Leviev and James, 
2000; Suehiro et al., 2000)). Thus, it may be difficult to understand, how lower 
levels of an anti-oxidant and anti-inflammatory PON1 protein can be associated 
with a decreased risk for AMD. One possible explanation is that the -107T and           
-162G alleles are in linkage disequilibrium with the p.55M coding variant (Aviram 
et al., 1998; Leviev and James, 2000) that was shown to affect PON1 activity 
towards lipid peroxides, with the MM genotype being more effective than the LL 
genotype (Mackness et al., 1998). As a consequence, lower levels of PON1 may be 
linked to its higher activity against lipid peroxides and therefore confer protection 
against AMD by decreasing serum oxLDL levels (Ikeda et al., 2001). Another 
important notion is that in a pathological situation PON1 serum content and its 
paraoxonase and arylesterase activity show inverse trend. For example, in CAD 
higher serum PON1 levels are accompanied by decreased enzymatic activities 
(Besler et al., 2011). Similar scenario might happen in AMD, since affected 
individuals display lower serum PON1 activity in comparison to controls (Ates et 
al., 2009; Baskol et al., 2006).  
CONCLUDING DISCUSSION 
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PON1 enzymatic activity in human tissue, which is relevant for its protective 
function against AMD, depends on several factors: (i) among genetic factors PON1 
polymorphisms within upstream regulatory region influence PON1 activity by 
regulating gene expression (the more molecules of protein synthesized, the more 
acting molecules and the higher measurable enzymatic activity), PON1 coding 
polymorphisms affect conformation of the protein and therefore catalytic activity of 
PON1; (ii) among environmental factors smoking (Isik et al., 2007; Solak et al., 
2005), age (Marchegiani et al., 2008), and disease status (e.g. CAD, AMD (Deakin 
and James, 2004; Ng et al., 2005)) reduce PON1 enzymatic activity in serum. The 
interaction between all these factors is not fully understood. It is not clear yet, how 
PON1 levels and activity in serum and/or ocular tissue affect the onset and 
progression of AMD. Alternatively, how PON1 function is affected by the disease. 
Further studies are required to better understand this interaction.  
Our analyses of Pon1+/+ and Pon1–/– retina/eyecup revealed a specific 
function for PON1 in modulating the composition of retinal phospholipids, in 
particular, in increasing the lysophosphatidylcholines (LPC) content. Since LPC 
stimulate cholesterol efflux from macrophages (Hara et al., 1997; Rosenblat et al., 
2006; Rosenblat et al., 2005), PON1-mediated release of LPC might control this 
process in the retina or RPE as well. Further studies on primary RPE cultures would 
help to understand the potential role of PON1 in the lipid efflux from RPE. 
Strikingly, besides the decreased levels of LPC, retinas of Pon1–/– mice seemed not 
to be affected by the absence of PON1 under any tested conditions, suggesting that 
this protein is not essential for normal development, function, defense against light 
damage and aging of the mouse retina and RPE.  
In mouse models of atherosclerosis PON1 was protective against the 
formation of atherosclerotic plaque (Rozenberg et al., 2003; Shih et al., 1998; Shih 
et al., 2000; Tward et al., 2002). However, lack of PON1 together with advanced age 
were insufficient to promote formation of atherosclerotic lesions in mice 
(Rozenberg et al., 2003), implicating that PON1 does not act as a “switch” from a 
healthy to a pathological condition, but rather as a modulatory factor that slows 
down progression of a pathology. Considering parallels in etiology of 
atherosclerosis and AMD, I would expect a similar protective role of PON1 in the 
formation of drusen in the eye. This protective role might become prominent in 
mice already bearing some drusen-like lipid deposits, e.g. in aged transgenic ApoE 
mice on a high fat diet (Malek et al., 2005). Drusenogenesis in mice progresses 
differently than in human (Mishima and Hasebe, 1978; Ramkumar et al., 2010), 
therefore no mouse model can truly mimic AMD. Nevertheless, because of the 
limitation in the availability of human ocular tissue for analyses and the lack of 
other, more convincing model organism to study AMD, the mouse would still be my 
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model organism of choice to further investigate a potential protective role of PON1 
in drusenogenesis.  
Taken together, findings presented in this thesis advance our understanding 
of the function of PON1 in the eye and its contribution to AMD. Association found 
between PON1 gene and neovascular AMD confirms involvement of PON1 at the 
end stage of the disease, which might be related to altered levels of PON1 protein in 
serum and ocular tissue. Our studies on Pon1–/– mice together with previous 
reports suggest that PON1 may be involved in AMD as a modulatory protein and 
that interplay with additional factors could influence its role in disease 
development and/or progression. 
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ABBREVIATIONS 
 
 
A2E Bis-retinoid N-retinylidene-N-retinylethanolamine 
ABCA ATP-binding cassette transporter, sub-family A 
ACS Acute coronary syndrome 
AGE Advanced glycation end product 
AhR Aryl hydrocarbon receptor 
AMD Age-related macular degeneration 
ApoE Apolipoprotein E 
ARPE19 Retinal pigment epithelium-derived cell line 
BRB Blood-retinal barrier 
BrM Bruch’s membrane 
Caco-2 Colon carcinoma-derived cell line 
CAD Coronary artery disease 
CC Choriocapillaris 
Ccl2 Chemokine (C-C motif) ligand 2 
Ccr2 Chemokine (C-C motif) receptor 2 
CEP Carboxyethyl pyrrole 
CEPT Cholesterylester transfer protein 
CFH Complement factor H 
CFI Complement factor I 
cGMP Cyclic guanosine monophosphate 
CH Choroid 
CNV Choroidal neovascularization 
CRALBP Cellular retinaldehyde binding protein 
CRBP Cellular retinol-binding protein 
Cx3cr1 Chemokine (C-X3-C motif) receptor 1 
DAMP Damage-associated molecular patterns 
DMEM Dulbecco's Modified Eagle Medium 
DMSO Dimethyl sulfoxide 
EDTA Ethylenediaminetetraacetic acid 
ELOVL4 Elongation of very long chain fatty acids protein 4 
ER Endoplasmic reticulum 
ERG Electroretinogram 
ABBREVIATIONS 
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FBS  Fetal bovine serum 
GA Geographic atrophy 
GCL Ganglion cell layer 
GDP Guanosine diphosphate 
GFAP Glial fibrillary acidic protein 
GTP Guanosine triphosphate 
GWAS Genome-wide association scans 
HDL High-density lipoprotein 
HEK293 Human embryonic kidney-derived cell line 
INL Inner nuclear layer 
INL Inner plexiform layer 
IRBP Interphotoreceptor retinoid-binding protein 
LCA Leber congenital amaurosis 
LD Light damage 
LDL Low-density lipoprotein 
LIPC Hepatic lipase 
LPC Lysophosphatidylcholine 
LPL Lipoprotein lipase 
LRAT Lecithin:retinol acyltransferase 
LXR Liver X receptor 
MAF Minor allele frequency 
MCT3 Monocarboxylate transporter 3 
MDA Malondialdehyde 
mRNA Messenger ribonucleic acid 
NLRP3 NLR family, pyrin domain containing 3 
Nrf2 Nuclear factor-like 2 
ONL Outer nuclear layer 
OPL Outer plexiform layer 
OR Odds ratio 
oxLDL Oxidized low-density lipoprotein 
PBS Phosphate buffer saline 
PDE Phosphodiesterase 
Pde6a Rod cGMP-specific 3',5'-cyclic phosphodiesterase subunit alpha 
Pde6c Cone cGMP-specific 3',5'-cyclic phosphodiesterase subunit alpha 
PEDF Pigment epithelial derived factor 
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PIS Photoreceptor inner segments 
PON Paraoxonase 
POS Photoreceptor outer segments 
PPAR Peroxisome proliferator-activated receptor gamma 
PRR Pattern recognition receptors 
PUFA Polyunsaturated fatty acid 
RAL All-trans-retinal 
RBP Retinol-binding protein 
RDH Retinol dehydrogenase 
REs Retinyl esters 
ROL All-trans-retinol 
ROS Rod outer segments 
ROS Reactive oxygen species 
RP Retinitis pigmentosa 
RPE Retinal pigment epithelium 
RPE65 Retinal pigment epithelium 65kDa protein 
SAM Senescence-Accelerated Mouse 
SD Standard deviation 
siRNA Small interference ribonucleic acid 
SNP Single nucleotide polymorphism 
Sod Superoxide dismutase 
TIMP3 Tissue metalloproteinase inhibitor 3 
TLR Toll-like receptor 
UTR Untranslated region 
UUR Upstream untranscribed region 
VEGF Vascular endothelial growth factor 
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